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ABSTRACT 
 
Stephanie B. Wheeler 
A CLOSER LOOK:  HEALTH SERVICES STRUCTURE AND ORGANIZATION, HEALTH 
DISPARITIES, AND RECEIPT OF HIGH QUALITY BREAST CANCER TREATMENT 
(Under the direction of Andrea K. Biddle, PhD) 
 
Racial/ethnic disparities in breast cancer outcomes have been well documented; 
however, the reasons why certain groups have widely different health experiences are not 
well understood.  Recognizing that variation in quality of cancer care may correlate with 
socio-demographic and health system characteristics, the overall objectives of this 
dissertation were (1) to investigate the relationships between race/ethnicity and 
structural/organizational aspects of health services in terms of post-operative receipt and 
timing of initiation of radiation therapy and adjuvant chemotherapy, and (2) to determine 
whether timing of adjuvant therapy initiation affects mortality.  This dissertation used 
population-based SEER-Medicare data to examine these issues in female Medicare 
beneficiaries ages 65 and older diagnosed with primary breast cancer in the years 1994 to 
2002.  Structural/organizational variables examined included characteristics of the surgical 
facility (i.e., type/ownership, teaching status, size, institutional affiliations, and presence of 
on-site radiation services), distance traveled to surgical facilities, distance to nearest 
radiation therapy provider, and distance to nearest chemotherapy provider.  Racial/ethnic 
groups examined included non-Hispanic white, non-Hispanic black, and Hispanic patients.  
We found significant racial/ethnic disparities in terms of receipt and timing of initiation of 
radiation therapy, as well as all-cause and breast cancer specific mortality, whereas we 
found no evidence of racial/ethnic disparities in adjuvant chemotherapy.  We also found 
evidence that certain health services characteristics, including type/ownership and size of 
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surgical facility, presence of on-site radiation at surgical facility, and distance from patient 
residence to adjuvant therapy providers, were associated with quality of care received, 
suggesting that health care systems or policies may be designed in such a way to improve 
outcomes for all breast cancer patients, and particularly, among minority women at risk for 
undertreatment.  Finally, we found evidence that earlier initiation of radiation therapy and 
adjuvant chemotherapy may correspond to better health outcomes.  This study documents 
the important role that health services characteristics may play in determining quality of 
care.  Additionally, considering that black women are more likely to be diagnosed with 
aggressive, advanced stage cancers and more likely to die from breast cancer, this study 
suggests that earlier initiation of treatment may help minimize racial disparities in breast 
cancer mortality.  
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CHAPTER 1:  INTRODUCTION 
 
Variation in cancer treatment and outcomes has been widely documented across 
providers and geographic regions within the United States, but until recently, there was 
weak consensus on quality metrics for cancer treatment. With increasing national pressure 
to improve health care quality in the cancer domain (Bowles et al., 2008), the American 
Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) 
released in July 2008 three revised quality metrics for breast cancer based on expert review 
of existing clinical guidelines (Desch et al., 2008).  These metrics included (1) receipt of 
radiation therapy (RT) after breast conserving surgery (BCS) within one year of diagnosis for 
stage I-III tumors, (2) receipt of adjuvant chemotherapy within 120 days of diagnosis for 
hormone receptor negative, stage II-III tumors, and (3) receipt of tamoxifen or aromatase 
inhibitor within one year of diagnosis for hormone receptor positive, stage I-III tumors 
greater than 1 cm.  Due to insufficient accumulation of clinical trial evidence about the 
effects of radiation and chemotherapy in older women, quality metrics for these two 
therapies were limited to women younger than 70.  These measures were selected for their 
potential to improve disease-free and overall survival at the population level, as well as the 
feasibility of data collection and quality monitoring (Desch et al., 2008). 
Although ensuring high quality cancer care in the general population is of critical 
importance, we should be especially concerned about disparities in quality within vulnerable 
sub-populations.  If the quality of cancer care improves over time in the general population, 
but differences in quality across sub-populations persist or worsen over time, inequities in 
treatment that lead to disparate health outcomes may have been essentially ignored.  A 
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bevy of previous research has shown that health disparities in breast cancer, particularly 
between white and black patients, persist in terms of timeliness of diagnosis, receipt of 
treatment, and long-term health outcomes (Bickell et al., 2005; Bickell et al., 2006; Bigby 
and Holmes, 2005; Bowen et al., 2006; Freedman et al., 2009; Gerend and Pai, 2008; Lund 
et al., 2008; Masi and Olopade, 2005; Shavers and Brown, 2002; Tammemagi, 2007).  
However, explanatory, rather than descriptive, cancer disparities research is limited.  
Possible explanations for enduring racial and ethnic disparities include differences in tumor 
behavior, patient-level psychosocial or behavioral factors, socioeconomic status, access to 
care, and treatment (Bickell, 2002; Blackman and Masi, 2006; Bowen et al., 2006; Chen et 
al., 1994; Demicheli et al., 2007; Gerend and Pai, 2008; Lund et al., 2009; Magai et al., 
2008; Newman et al., 2003; Williams and Mohammed, 2009). 
Organization and structure of health services are closely related to diffusion and 
implementation of high quality, evidence-based practices.  Organizational theory and 
diffusion of innovations theory suggest that substantially different institutional cultures exist 
within different types of health organizations (Greenhalgh et al., 2004).  Characteristics of 
local communities, including population density, local resource capacity, and neighborhood 
racial/ethnic composition, may affect the types of organizations that locate in particular 
settings.  In addition, patient-level socio-demographic characteristics may be related to 
choice of residence, utilization of services with certain organizational characteristics, and 
access to well-trained health professionals (Birkmeyer et al., 2003; Coughlin et al, 2008).  It 
is unclear exactly how structural/organizational features and functions of the health care 
system correlate with race/ethnicity and other patient-level characteristics.  If differences in 
access to or availability of health services exist among vulnerable sub-populations, 
disparities in treatment or outcomes may result.  Further, innovative treatments and care 
processes may diffuse more slowly within certain sub-populations over time.    
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The impetus for developing quality metrics for breast cancer was motivated by, and 
based upon, the existence of well-established clinical guidelines, such as those published by 
ASCO/NCCN.  Accordingly, this dissertation examined the relationships between patient 
demographics (focusing on race/ethnicity) and structural/organizational aspects of health 
services in terms of receipt and diffusion of high quality care, as defined by two of the three 
breast cancer quality metrics developed by ASCO/NCCN (Desch et al., 2008).  Specific 
aims included: 
1. Examine receipt of radiation therapy after BCS within one year of diagnosis for stage 
I-III breast cancers: 
a. Characterize diffusion of RT after BCS using diffusion curves across sub-
groups (e.g., by race/ethnicity, age group [< / ≥ 70 years])  
b. Examine the independent and interactive effects of race/ethnicity and 
structural/organizational factors on timing of receipt of RT after BCS 
2. Examine receipt of adjuvant chemotherapy within four months of diagnosis for stage 
II and III, hormone receptor negative breast cancers: 
a. Characterize diffusion of adjuvant chemotherapy using diffusion curves 
across sub-groups (e.g., by race/ethnicity, age group [< / ≥ 70 years]) 
b. Examine the independent and interactive effects of race/ethnicity and 
structural/organizational factors on timing of receipt of adjuvant 
chemotherapy  
3. Examine the effect of timing of guideline-prescribed, clinically appropriate radiation 
therapy and/or chemotherapy on health outcomes, specifically all-cause and breast 
cancer-specific mortality, across diverse patient sub-groups: 
a. Examine mortality five years after diagnosis as a function of timing of 
radiation therapy after BCS among stage I-III breast cancers 
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b. Examine mortality five years after diagnosis as a function of timing of 
adjuvant chemotherapy among stage II-III, hormone receptor negative breast 
cancers 
Information about women with breast cancer was obtained from registry data linked 
to claims data.  Surveillance, Epidemiology and End Results (SEER) registry data from 
incident breast cancer cases, linked to Medicare claims data, were used to examine aims 1-
3 among women ages 65 years and older.   
We know little about diffusion of evidence-based guidelines across vulnerable sub-
populations of breast cancer patients.  To assess diffusion of high quality, evidence-based 
treatment over time within sub-populations, aims 1a and 2a were examined descriptively 
using SEER-Medicare data.  Primary breast cancer cases diagnosed in 1994-2002, with 
claims data through 2003, were included.  Diffusion curves based upon population-level 
proportions of eligible patients receiving RT after BCS within one year of diagnosis (aim 1a) 
and adjuvant chemotherapy within four months of diagnosis (aim 2a) were constructed for 
different sub-populations using Medicare claims data.  Diffusion curves comparing 
proportions of patients receiving each therapy by race/ethnicity, age group, rural- versus 
urban-dwelling, SEER registry, and low income status, were contrasted using chi-squared 
tests, by year.  To examine reliability between the registry and claims reporting sources, 
SEER data were compared to Medicare claims data for receipt of RT after BCS within the 
first four months post-diagnosis. 
It is unclear whether structural and organizational differences in health services 
available to women can explain some of the racial/ethnic disparity in breast cancer 
treatment and outcomes.  It is also unclear whether racial/ethnic differences in timing of 
treatment exist and whether timing of treatment is related to structural/organizational 
characteristics of health services.  Using SEER-Medicare data, timing of initial receipt of 
radiation therapy (RT) (aim 1b) was examined as a binary variable indicating whether the 
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patient received a first course of RT within the specified time interval.  Primary breast cancer 
cases diagnosed in 1994-2002, with claims through 2003, were included.  Importantly, the 
ASCO/NCCN metric specifies that the patient must begin RT within one year of diagnosis; 
completion of a recommended course of RT is not included in the metric, however.  
Although adherence to or persistence in receiving the full treatment is clearly important, 
clinically appropriate variation across patients in dosage, timing of cycles, and administration 
makes assessment of therapy completion difficult.  Additionally, the quality metric “deadline” 
of one year is considered by some clinicians and researchers to be lenient, in light of studies 
that have shown improved outcomes with earlier initiation of radiation therapy.  The 
ASCO/NCCN panels relaxed the timing component of the denominator to allow for potential 
delays in administration and sequencing of multiple anticancer treatments (e.g., patients 
receiving surgery, chemotherapy, and RT) (Desch et al., 2008).  Given the controversy over 
the optimal timing of initiation of RT, time intervals for receipt of RT at 1 to 6 months also 
were examined.  As well, aim 3 helps to address the lack of consensus about the benefits of 
early initiation of radiation therapy by exploring the effects of timing of initiation of RT on 
health outcomes. 
The SEER-Medicare linked data also were used to examine aim 2b in women ages 
65 and older diagnosed with breast cancer in 1994-2002.  Time to initiation of post-operative 
adjuvant chemotherapy was examined as a binary indicator of receipt during the specified 
time period.  Notably, the ASCO/NCCN metric specifies that patients with stage II-III, 
hormone receptor negative breast cancer must begin adjuvant chemotherapy within four 
months of diagnosis, but completion of a full recommended course is not part of the metric.  
Although incomplete use of chemotherapy may have implications for treatment efficacy, 
chemotherapeutic regimens used may vary across patients, leading to clinically appropriate 
variation in dosage, timing of cycles, and administration.  Until more detailed information is 
included in cancer registries, adherence to recommended chemotherapy schedules over 
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time cannot be assessed easily.  The 120-day time allowance specified in the metric was 
intended to provide sufficient time for surgery and medical consultation, but may be overly 
lenient.  As such, additional time intervals (1 to 3 months) were examined as binary 
dependent variables to detect differences in timing of receipt of clinically appropriate care.  
Finally, because the proliferation of hormone receptor testing and anticancer hormone 
therapies occurred during the time period of interest, thereby changing practice patterns and 
guidelines according to hormone receptor positivity, we also examined patterns in initiation 
of adjuvant chemotherapy over time in hormone receptor positive patients.  Women who 
received preoperative or neoadjuvant chemotherapy were excluded.   
The main independent variables for aims 1b and 2b included race/ethnicity (limited to 
non-Hispanic white, non-Hispanic black, and Hispanic) and structural/organizational 
characteristics of oncologic health services, including surgical facility type/ownership, bed 
size, teaching status, National Cancer Institute (NCI) Comprehensive Cancer Center 
designation, American College of Surgeons Oncology Group (ACoSOG) affiliation, NCI 
Radiation Therapy Oncology Group (RTOG) membership (aim 1b only), and presence of on-
site radiation services (aim 1b only); and distance to oncology service providers. Control 
variables for aims 1b and 2b included age at diagnosis, rural/urban residence, zip code level 
income, education, and area racial composition; tumor stage, histologic grade, and ER/PR 
status (aim 1b only); receipt of chemotherapy prior to RT (aim 1b only); co-morbidity score; 
year of diagnosis; low income status (measured by State-Buy-In months); and marital status 
at diagnosis.   
Aims 1b and 2b were analyzed using stratified multivariable logistic regression.  
Strata were constructed according to age-group (<70, 70 and older) and for aim 2b, 
hormone receptor positivity.  Briefly, stratified models were used because of substantial 
differences in breast cancer guidelines and quality metrics (and presumably, practice 
patterns) based upon age and hormone receptor status.  With respect to age, the lack of 
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inclusion of women older than 70 in clinical trials has translated to a lack of evidence for 
guideline and quality metric development within older age groups (Ballard-Barbash et al., 
1996; Silliman et al., 1993; Wildiers and Brain, 2005).  However, some studies have shown 
similar benefits of radiation therapy and chemotherapy in older women compared to younger 
women (<70 years old) (Owusu et al., 2007; Smith et al., 2006).  As a result, conceivably, 
omission of older women from guidelines and denial of life-prolonging treatment could 
constitute age discrimination (Passage and McCarthy, 2007; Wildiers and Brain, 2005).  As 
such, both younger (<70) and older (70 and older) women were studied in the current 
analysis; determining whether any differences in treatment exist by age group is an 
important and timely contribution to the literature. 
Given the controversy over the significance of timing of treatment and whether timing 
is relevant in terms of clinical outcomes, aims 3a and 3b assessed the effect of timing of 
radiation therapy and chemotherapy on five-year mortality.  Aims 3a and 3b were analyzed 
using SEER-Medicare from 1994-2002 diagnoses, to allow five-year follow-up of vital status 
for all patients through 2007.  Fully adjusted logistic models were employed, stratified by 
age group (<70, 70 and older) and receipt of another anticancer therapeutic regimen, 
excluding hormone therapy for which information is not readily available in SEER-Medicare.  
All-cause mortality and disease-specific mortality at five years were outcomes of interest.  
The key independent variables, timing of radiation therapy and timing of chemotherapy, 
were specified as categorical variables using the time intervals described in aims 1b and 2b, 
primarily because timing of radiation therapy and chemotherapy are controversial issues in 
the literature, particularly among older women (>/= 70 years).  Race/ethnicity also was a key 
independent variable of interest.  Control variables for aims 3a and 3b were similar to aims 
1b and 2b. 
Structural/organizational and geographic characteristics of the health system may 
independently influence receipt of high quality care, and also may be correlated with 
 8
racial/ethnic group.  To date, the breast cancer literature has not explicitly considered the 
role of multiple health services organization measures on racial/ethnic disparities in 
treatment and outcomes.  The research presented in this dissertation reveals that 
differences in organizational health services characteristics can help to explain a portion of 
the racial and ethnic disparities in breast cancer, particularly in receipt of RT after BCS, but 
differences in treatment remain even after controlling for structural/organizational 
characteristics of health services.  Vulnerable sub-populations (for example, poor, black, 
rural-dwelling women) who ultimately receive poorer quality care are likely to have worse 
health outcomes.  Considering that elimination of health disparities was a key component of 
the United States Department of Health and Human Services’ Healthy People 2010 report 
(US DHHS, 2000) and the Institute of Medicine’s (IOM) Unequal Treatment report (IOM, 
2002), this dissertation suggests that pinpointing system-level factors that may contribute to 
persistent disparities can help policymakers focus efforts to equalize health care access and 
quality across diverse user populations.   
Sections of the dissertation are organized as follows:  Chapter 2 details the current 
literature on breast cancer disparities, quality of cancer care, and structural/organizational 
characteristics that may affect treatment, as well as the limitations of existing studies.  
Chapter 2 is intended to provide background and justification for the dissertation study and 
to provide the reader with an understanding of the complexity of breast cancer treatment 
and the array of patient-level and system-level factors that may affect quality of care 
received.  Chapter 3 provides an overview of the methods used, including a discussion of 
the study design, data sources, study hypotheses, and analytical approach used.  Chapters 
4 through 6 are individual manuscripts corresponding to aims 1-3, respectively, and are 
intended for submission for peer-reviewed publication.  Chapter 7 summarizes the strengths 
and limitations of this work, policy relevance, and future research plans.  References are 
provided in a generalized bibliography at the end of the dissertation. 
CHAPTER 2:  LITERATURE REVIEW 
 
Overview 
The problem of health disparities in cancer care and outcomes is multifaceted and 
complex.  Organizational, structural, economic, and sociopolitical dynamics of the American 
health system likely contribute to racial/ethnic, socioeconomic, age-related, and geographic 
health disparities and may not be amenable to rapid change.  In the Healthy People 2010 
report, the United States Department of Health and Human Services (DHHS) made it clear 
that elimination of health disparities was one of its main priorities (DHHS, 2000).  However, 
interim assessments of breast cancer epidemiological endpoints suggest that differences in 
outcomes by race/ethnicity persist.  For example, although use of screening mammography 
is now nearly equivalent nationally among black and white women (Mayberry, Mili, and Ofili, 
2002), mortality rates in the years 2000-2004 remained higher among black women, despite 
the fact that breast cancer is diagnosed more often in white women (American Cancer 
Society [ACS], 2008).   
Differences by race/ethnicity in diagnosis, receipt of appropriate care, and mortality 
have been well-documented in the literature (Banerjee et al., 2007; Bickell, 2002; Bickell et 
al., 2006; Bigby and Holmes, 2005; Bowen et al., 2006; Chen et al., 2008; Freedman et al., 
2009; Gerend and Pai, 2008; Haggstrom et al., 2005; Lund et al., 2008; Masi and Olopade, 
2005; Shavers and Brown, 2002; Tammemagi, 2007).  Possible explanations for enduring 
racial and ethnic disparities include biological differences in tumor behavior and morphology 
(Bowen et al., 2006; Carey et al., 2006; Chlebowski et al., 2005; Demicheli et al., 2007; 
Lund et al., 2009; Porter et al., 2004), pharmacogenetic differences in response to therapy 
(Flockhart, 2008; Goetz, 2005), patient-level psychosocial or behavioral factors 
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(Magai et al., 2008; O’Malley et al., 2004), socioeconomic status and access to care 
(Gerend and Pai, 2008; Maloney et al., 2006), and treatment differences (Blackman and 
Masi, 2006; Freedman et al., 2009; Lund et al., 2008).  Clearly, race-specific genetic 
susceptibility to more aggressive cancers may not be affected by public health efforts; 
however, recognizing that there are racial differences in tumor biology may suggest the 
need for more focused screening or help identify environment-gene interactions that lead to 
strategies for cancer prevention.  Additionally, societal-level correlates of race/ethnicity, such 
as access to insurance coverage and poor socioeconomic status may be slow to change 
over time.  If, however, access to care and socioeconomic status are held constant, there is 
no good reason why an African American woman should be offered lower quality treatment 
than a white woman with the same clinical disease.   
The decision to undergo certain treatment regimens is complex.  Treatment 
decisions leading to differential quality of care may arise from patient-level, provider-level, or 
facility-level characteristics (Ballard-Barbash et al., 1996).  Improving patient-level 
psychosocial or behavioral correlates of treatment disparities, such as health-seeking 
behavior and trust in the health care system, likely will require creative and sensitive 
interventions, given the complex historical experiences of American minority groups (Gerend 
and Pai, 2008; Shavers and Shavers, 2006).  Provider-level and facility-level correlates of 
treatment decision-making, however, should be relatively similar across patients.  For 
example, provider experience, access to specialists, and access to facilities capable of 
providing innovative procedures (such as sentinel lymph node biopsy [SLNB]) should be 
equally available to black, Hispanic, and non-Hispanic white patients, but this may not be 
true in reality.  Of course, individuals can choose to forego guideline-recommended therapy, 
but as a rule, treatment options should be made equally available and accessible to all 
breast cancer patients with clinically similar tumors.   
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In epidemiologic terms, racial and ethnic differences in breast cancer-related 
morbidity and mortality can be thought of as being produced by multiple complementary 
causes (including patient-level psycho-social or behavioral factors, institutional racism, 
genetic predisposition to more aggressive tumors, etc. [Gerend and Pai, 2008; Tammemagi, 
2007]), none of which is sufficiently explanatory alone.  Although much research has been 
published in the areas of genetic/biological tumor variation and socioeconomic status as 
these relate to race/ethnicity-related breast cancer disparities, it remains largely unknown 
whether characteristics of the health system itself, including provider- and facility-level 
factors, are correlated with race/ethnicity or whether these factors mediate the effect of 
race/ethnicity on receipt of appropriate treatment for breast cancer.  As such, the current 
study addresses this gap in the breast cancer literature by assessing the potential of 
structural/organizational health system characteristics to explain racial/ethnic variation in 
timely receipt of radiation therapy and adjuvant chemotherapy, when clinically indicated.  
Furthermore, this study examined trends in diffusion of high quality care over time, within 
vulnerable sub-populations, to determine whether guideline-recommended radiation therapy 
and chemotherapy have been uniformly received by all groups.  Finally, this study 
contributes to the existing comparative effectiveness literature in cancer by examining 
treatment effects of radiation therapy and chemotherapy in different age groups at different 
times.  In terms of policy relevance, results from this analysis can be used to (1) develop 
age-specific, place-specific, and culturally-specific interventions that target breast cancer 
patients who may be especially at risk for receiving poor quality care, (2) inform clinicians, 
policymakers, patient advocacy groups, and health care navigators about the current status 
and correlates of health disparities in breast cancer, and (3) provide additional evidence of 
radiation and chemotherapy treatment effectiveness and optimal timing of treatment for 
clinical guideline development. 
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Epidemiology of breast cancer and natural history of disease 
With nearly 200,000 incident cases diagnosed annually in the United States, breast 
cancer is the most common non-skin cancer afflicting women (ACS, 2008; Ries et al., 2006).  
Based on data from 2001 to 2003, the American Cancer Society estimates the lifetime risk 
of developing breast cancer among women to be 12.7%, or 1 out of 8, if current trends 
continue (Ries et al., 2006).  Although trend analyses of incidence rates show that incidence 
of breast cancer increased from 1980 to 2002 (Edwards et al., 2005), between 2001 and 
2004, incidence rates decreased approximately 3.5% annually (ACS, 2008).  This decrease 
may have resulted from more timely detection and treatment of early stage tumors, 
population saturation of screening mammography, or decreased used of hormone 
replacement therapy corresponding with release of the Women’s Health Initiative (WHI) trial 
results in 2002 (ACS, 2008; Jemal et al., 2007).  Worldwide, the greatest age-standardized 
incidence of breast cancer occurs in the United States and Northern Europe (Parkin et al., 
2001). 
Surpassed only by lung cancer mortality, breast cancer is the second most fatal 
cancer among women; an estimated 41,000 breast cancer deaths were anticipated in 2008 
(ACS, 2008).  Breast cancer survival is closely related to staging of disease.  Staging is 
usually based on the American Joint Committee on Cancer (AJCC) Tumor, Node, 
Metastasis (TNM) staging system (Table 1) and may be determined clinically through the 
use of physical exam, biopsy, and imaging studies or pathologically after surgery.  
Pathologic staging is generally considered to be more accurate.  Although prognosis is 
generally good for breast cancers diagnosed early (85-100% of stage I and II patients are 
alive after 5 years of follow-up), 5-year survival for patients with stage III and IV disease is 
only 58% and 19%, respectively (Gloeckler Ries et al., 2003).  These statistics demonstrate 
the importance of early detection and treatment of invasive breast cancer.  Recent 
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reductions in overall breast cancer mortality likely reflect development and uptake of more 
effective screening interventions and treatment options. 
Table 1: American Joint Committee on Cancer (AJCC) Breast Cancer Staging Definitions 
modified with permission from Springer from Edge et al., (eds). Breast. In: AJCC Cancer 
Staing Manual, 7th edition. New York, NY, Springer, 345-376, 2010  
In Situ Breast Cancer 
Stage 0 Non-invasive (e.g., Ductal Carcinoma in Situ [DCIS] and Lobular Carcinoma in Situ 
[LCIS]) and has not spread to lymph nodes 
Early-stage Invasive Breast Cancer 
Stage IA Tumor measures 2 cm or less and has not spread to lymph nodes 
Stage IB Small tumor; exclusively micrometastases in lymph nodes 
Stage IIA No evidence of a tumor but cancer has spread to lymph nodes under arm; OR 
Tumor is <=2 cm and has spread to lymph nodes under arm but no other nodes; OR 
Tumor is between 2-5 cm and has not spread to any lymph nodes 
Stage IIB Tumor measures between 2-5 cm and has spread to only lymph nodes under the arm 
on the same side as the cancer; OR 
Tumor is >5 cm but has not spread to any lymph nodes 
Advanced-stage Invasive Breast Cancer 
Stage IIIA Tumor is any size and cancer has spread to lymph nodes under arm and possibly other 
lymph nodes as well 
Stage IIIB Tumor is any size, has spread to breast skin or chest wall and possibly lymph nodes 
Stage IIIC Tumor is any size, may have spread to lymph nodes, but not elsewhere 
Metastatic Breast Cancer 
Stage IV Tumor is any size and has spread to other parts of body; OR 
Tumor has spread locally to skin and lymph nodes inside the neck, near collarbone 
 
Risk of developing breast cancer is related to a number of factors, including age, 
gender, race/ethnicity, familial history of breast cancer, cumulative endogenous and 
exogenous hormone exposure, inherited mutations in the BRCA1 and BRCA2 and other 
genes, high breast density, radiation exposure, nutritional intake and alcohol use, exercise, 
and post-menopausal obesity (ACS, 2008; Colditz, Baer, and Tamimi, 2006; Vogel, 2008).  
Endogenous hormone exposure is particularly related to the cumulative effects of estrogen 
in breast epithelium.  Reproductive factors, including age at menarche, parity, age at first full 
time pregnancy, lactation, and menopause, are closely related to circulating estrogen levels 
(Colditz, Baer, and Tamimi, 2006).  With regard to exogenous hormone exposure, elevated 
risks of breast cancer have been observed with current and recent oral contraceptive use 
and peri- and post-menopausal use of hormone replacement therapy (Colditz, Baer, and 
Tamimi, 2006).  Additionally, it is believed that post-menopausal obesity and weight gain are 
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associated with increased relative risk for breast cancer due to the role of fat tissues in 
storing estrogens (Eliassen et al., 2006).  Interestingly, pre-menopausal excess weight may 
be a protective factor against breast cancer, due to irregular menstrual cycling and 
increased anovulatory infertility among heavier, reproductive-age women (Rich-Edwards et 
al., 1994).   
Age and breast cancer are closely and meaningfully correlated (Vogel, 2008).  The 
majority of breast cancer diagnoses occur in women older than 60, and the median age at 
breast cancer diagnosis is 62 years. Breast cancer incidence rises dramatically and non-
linearly with age and levels off around the time of menopause (for most women, between 45 
and 55 years of age) (Figure 1).  This striking trend is biologically explained by the important 
role of reproductive factors and ovarian estrogens in breast cancer etiology (Colditz, Baer, 
and Tamimi, 2006).  Further, behavioral and morphologic characteristics of the cancer itself 
differ by age.  Younger women diagnosed with breast cancer tend to have more aggressive 
tumors and worse prognosis, whereas older women typically have more indolent disease 
(i.e., slower growing tumors) with better prognosis (Vogel, 2008; Wildiers and Brain, 2005).  
Younger women are more likely to have triple-negative breast cancers; that is, the tumor 
itself tests negative for estrogen receptors (ER), progesterone receptors (PR), and 
HER2/neu protein expression (Peppercorn et al., 2008).  Certain targeted therapies, such as 
hormonal treatment with tamoxifen, are ineffective for triple negative and ER/PR-negative 
cancers.  Understanding the characterization and clinical behavior of cancers with different 
biological characteristics has become increasingly important in recent years (Anders and 
Carey, 2008; Peppercorn et al., 2008).  Indeed, many clinicians and researchers would 
argue that the various biological subtypes of breast cancer are so strikingly different from 
one another that they represent entirely different diseases and must be treated as such 
(Carey et al., 2006; Fejerman and Ziv, 2008; Kang, Martel, and Harris, 2008; Livasy et al., 
2007; Millikan et al., 2008; Peppercorn et al., 2008).   
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As previously noted, important differences in breast cancer exist between minority 
racial/ethnic groups and white groups.  As can be seen in Figures 1 and 2, although breast 
cancer is diagnosed more often in white women, mortality from breast cancer is more 
pronounced in black women, suggesting that racial disparities may play an important role in 
health outcomes (Bach et al., 2002).  As well, important age-specific racial/ethnic trends in 
breast cancer incidence and mortality are observed (graphs not shown) (Vogel, 2008).  
Specifically, young black women (<50 years old) have a higher incidence of breast cancer 
compared to young white women, but around the time of menopause, a crossover occurs 
and incidence rates among older white women surpass rates of older black women (Colditz, 
Baer, and Tamimi, 2006).  Notably, mortality rates have been higher in black women, 
regardless of age, for years (NCI, 2005a).   
Both biological and social factors are believed to contribute to racial/ethnic 
differences observed in breast cancer mortality.  Biomarkers, histological features, and 
tumor behavior of breast cancers vary by race/ethnicity (Bowen, Stebbing, and Jones, 2006; 
Figure 2.  Breast cancer mortality, by age at 
death and race/ethnicity, 1990-2005 
Figure 1.  Breast cancer incidence, by age at 
diagnosis and race/ethnicity, 1973-2005 
Notes: Includes invasive breast cancers only (stages I-IV) and represents all age groups; mortality 
source: US Mortality Files, National Center for Health Statistics (NCHS), CDC; incidence source: 
Surveillance Epidemiology and End Results (SEER)* Stat database; mortality and incidence graphs 
created using National Cancer Institute (NCI) interactive database (URL:  http://www.seer.cancer.gov) 
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Demicheli et al., 2007; Morris and Mitchell, 2008; Porter et al., 2004).  For example, African 
American women are more likely to be diagnosed with triple negative tumors (Lund et al., 
2009).  In another study, Chen and colleagues (1994) found that after adjusting for age, 
stage, socioeconomic status body mass index, reproductive history, insurance status, and 
location, black women with invasive breast cancer were more likely to have high grade 
nuclear atypia, high grade tumors, and more necrosis compared to white women (1994).  
Furthermore, black women were less likely to have ER-positive cancers (Chen et al., 1994).  
Bauer and colleagues (2007) have substantiated these findings in a California population.  
In a review of the literature on tumor aggressiveness in black women, Morris and Mitchell 
(2008) report that in addition to differences in pathologically-defined subtypes and BRCA 
mutations, African American women also are more likely to have over-expression of cell-
cycle regulators, such as Cyclin E, p16, and p53, and polymorphisms in nucleotide excision 
repair genes.  All of these results provide strong argument for biological differences between 
black and white women in breast cancer.   
Despite the accumulating evidence for genetic and molecular biologic explanations 
for cancer aggressiveness, even after controlling for ER, PR, and HER2/neu status and 
BRCA1 and BRCA2 mutations, black women still have worse outcomes.  Much of this 
difference historically was attributed to screening practices, specifically underuse of 
screening mammography or lack of diagnostic follow-up after an abnormal mammogram 
result, poor insurance coverage, or late stage at diagnosis (Bickell, 2002; Bowen, Stebbing, 
and Jones, 2006).  However, use of screening mammography has been nearly equivalent 
among racial/ethnic groups for a decade (Bickell, 2002; Breen et al., 2001), and even when 
controlling for stage at diagnosis and insurance status, differences in mortality persist 
(Figure 3).   
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Moreover, although secular trends in disease-specific mortality have shown 
improvements in the past 30 years, the relative difference between black women’s mortality 
rate and non-Hispanic white women’s mortality rate has not changed.  Rather, the gap 
appears to be widening (Figure 4).  It is clear from the literature that biological factors and 
access to care explain part of this racial/ethnic disparity in morbidity and mortality (Bickell et 
al., 2002; Bigby and Holmes, 2005; Carey et al., 2006).  It is also clear that the African 
American sub-population is not the only group at risk for worse health outcomes.  Elderly, 
rural-dwelling, less educated, poor, disabled, and Hispanic and/or non-English speaking 
women also experience significant disparities in breast cancer detection and survival after 
diagnosis (Bigby and Holmes, 2005; DeMichele et al., 2003; Freedman et al., 2009; 
Haggstrom et al., 2005).  Interactions between these patient-level factors may have an 
additive or multiplicative negative effect on health outcomes, but little is known about 
whether and how these patient-level characteristics interrelate.  Indeed, a poor, rural-
dwelling, black woman may have more to worry about than triple-negative breast cancer; 
 
Notes: from National Cancer Institute (NCI) interactive database (URL:  http://www.seer.cancer.gov) 
Figure 3: 5-year relative survival of female invasive breast cancer patients diagnosed 1973-
2005 in SEER registries, all ages, by stage and race (Blacks on left; Whites on right) 
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she may also experience a triple burden in terms of health disparities in access to and 
receipt of high quality breast cancer care related to income/wealth, location, and race. 
Mammography use and timely detection of early stage breast cancer have been 
widely studied, and both have been the target of many public health interventions and 
advocacy campaigns.  Differences in treatment are now the focus of many studies 
examining health disparities in breast cancer (Bigby and Holmes, 2005).   In the absence of 
confounding by socioeconomic status, insurance coverage, stage at diagnosis, and patient-
level tumor characteristics, if certain sub-populations receive less-than-standard treatment 
(i.e., treatment appropriate for the genetic or molecular features of the cancer), we might 
expect to see continuing differences in outcomes.  In other words, although we have come a 
long way in improving race/ethnic relations and equality in this country, persistent health 
disparities such as those seen in breast cancer, are an indicator that we still have a long 
way to go (Bradley, Given, and Roberts, 2001; Vainshtein, 2008).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Citation:  Fast Stats, 2010.  Notes: Includes invasive breast cancers only (stages I-IV) and represents 
all age groups.  Mortality source: US Mortality Files, National Center for Health Statistics (NCHS), 
CDC; rates are per 100,000 and age-adjusted to the 2000 US standard population; created using 
National Cancer Institute (NCI) interactive database (URL:  http://www.seer.cancer.gov) 
Figure 4: Age-adjusted US female breast cancer-specific mortality rates, by race, 1975-2005 
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Economic burden of disease 
Costs of breast cancer care can be quite high because surgery, radiation therapy, 
and chemotherapy often require considerable technical skill, resource capacity at the facility 
level, and patient follow-up.  National estimates of expenditures in 1996 for breast cancer 
were on the order of $5.3 billion (Brown et al., 2002); in 2004, the national cost of treating 
breast cancer jumped to $8.1 billion.  Using the Surveillance Epidemiology, and End Results 
(SEER)-Medicare linked dataset, Warren and colleagues (2008) estimated average 
Medicare fee-for-service payments for initial treatment to be $20,964 per breast cancer 
patient diagnosed in 2002.  Long-term costs associated with cancer care can be staggering 
as well; in a systematic review published in PharmacoEconomics in 2009, lifetime costs of 
breast cancer care ranged from $20,000 to more than $100,000, depending on the 
perspective used, population studies, base-cost year (1984-2003), and duration of follow-up 
(Campbell and Ramsey, 2009).  In another study of cumulative health care costs among 
fee-for-service Medicare beneficiaries diagnosed with early stage breast cancer, Warren and 
colleagues (2002a) estimated the average 25-year cost of health care to be nearly $73,000 
in 1998 US dollars.  Cancer-related treatments accounted for $27,697, or more than one-
third, of that figure (Warren et al., 2002a).   A one-year cost of trastuzumab alone, a key 
component of adjuvant therapy for approximately 25% of women with early breast cancer, 
costs approximately $50,000 (Kurian, 2007).  For patients with metastatic breast cancer, use 
of the drug bevacizumab, approved as first line therapy with median duration of response of 
approximately one year, costs $55,000 in addition to other costs of chemotherapy and 
supportive care (Lee and Emanuel, 2008). 
Uninsured or under-insured cancer patients are especially sensitive to high costs of 
care.  Regardless of insurance status, hidden costs of cancer care, such as transportation to 
treatment centers; loss of income due to diminished productivity or loss of work days; and 
out-of-pocket premiums, deductibles, and co-payments can be especially burdensome to 
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the cancer patient (Wagner and Lacey, 2004).  Indeed, in one national survey of cancer 
patients and families conducted by Kaiser Family Foundation, USA Today, and the Harvard 
School of Public Health (2006), nearly one in four privately insured patients said she 
exhausted all or most of her personal savings to pay for cancer-related care, and 13% of 
cancer patients reported being contacted by a collection agency demanding payment for 
cancer treatment.  Costs of cancer care are not likely to decline substantially anytime soon.  
As treatment options become more sophisticated and prognosis continues to improve, 
survivorship and surveillance will become increasingly important issues to consider in 
estimating the financial burden of cancer.  Nearly 2.5 million women alive on January 1, 
2005, had a history of breast cancer (Ries et al., 2008).  An increase in the surviving breast 
cancer patient population, coupled with a demographic shift in the US general population 
consistent with aging and fertility trends, may lead to significant demands for health 
resources both from the user/patient and system/provider perspectives.   
 
Treatment guidelines 
Treatment options for women with breast cancer vary by stage of disease, suitability 
of the patient to undergo treatment, insurance status, and patient and physician 
preferences.  In short, women and their doctors choose among surgery, radiation therapy, 
chemotherapy, hormone therapy, and biological therapy, and generally, a combination of 
two or more of these are used to combat the cancer (NCI, 2005b).  Local therapies include 
surgery and radiation therapy (RT) and are used for local control of the cancer.  By contrast, 
systemic therapies are administered orally or intravenously and attack and destroy cancer 
cells throughout the body; these include chemotherapy, hormone therapy, and biologic 
therapy (NCI, 2005b).  Surgical removal of the tumor involving removal of part (breast 
conserving surgery) or all (mastectomy) of the surrounding breast tissue is often the first line 
of defense against cancer, among women with operable cancers, though increasingly, 
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locally advanced tumors may be treated with pre-operative systemic therapy or 
“neoadjuvant” therapy.  Generally, local and/or systemic therapies also are used to eliminate 
further spread of cancerous cells, but the combination, sequence, and duration of available 
radiation therapy, hormone therapy, biologic therapy, and chemotherapy depend primarily 
on stage and molecular or genetic features of the tumor (NCCN, 2008).  A brief summary of 
historic clinical guidelines for breast cancer treatment is provided in Table 2.   
As evidence has accumulated over time, clinical guidelines have evolved 
accordingly.  Major advances in the past 15-20 years in breast cancer treatment approaches 
have included:  (1) recommendation of breast conserving surgery plus RT over radical 
mastectomy, which preserves patient breast tissue and improves surgery-related side effect 
profiles; (2) widespread use of ER, PR, and HER2/neu testing to inform disease 
management and optimal use of hormonal, biologic, and chemotherapy treatment regimens; 
(3) proliferation of sentinel lymph node biopsy and use of immunohistochemistry for 
pathologic staging of disease; and (4) use of neoadjuvant chemotherapy to shrink tumors 
prior to surgical intervention (Andre and Pusztai, 2006; Cance et al., 2002; NCCN, 2008).   
Table 2: Summary of changes in selected US breast cancer treatment guidelines over time 
Organization Year Patient population Treatment recommendation Citation 
National Institutes 
of Health (NIH) 
1990 Patients with stage I-II 
breast cancer 
Should receive breast conserving 
treatment (BCS plus RT) over 
mastectomy and axillary dissection 
because it provides survival 
equivalence and preserves tissue 
NIH, 
1990 
National Institutes 
of Health (NIH) 
1990 Patients with node-
negative disease who 
received BCT or 
mastectomy 
Are considered cured, but in light of 
evidence of the benefits of 
chemotherapy and tamoxifen in 
reducing recurrence, should 
consider adjuvant treatment 
NIH, 
1990 
National Cancer 
Comprehensive 
Network (NCCN) 
1996 Patients with DCIS, 
LCIS, stages I, or 
node-negative stage 
IIa tumors 
Should receive BCS plus RT, or 
mastectomy without lymph node 
dissection (plus reconstruction), 
unless patient refuses 
Carlson 
et al., 
1996 
National Cancer 
Comprehensive 
Network (NCCN) 
1996 Patients with DCIS 
and negative margins, 
and all women with 
BCS or mastectomy 
with >/=T3 status 
Should have radiation of standard 
fractionated doses totaling 40-
60Gy, unless contraindicated or 
patient refuses 
Carlson 
et al., 
1996 
National Cancer 
Comprehensive 
1996 All patients with node 
positive disease and/or 
Should receive multicycle adjuvant 
cytotoxic poly-chemotherapy, 
Carlson 
et al., 
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Organization Year Patient population Treatment recommendation Citation 
Network (NCCN) tumor >1cm, except 
for DCIS and LCIS 
unless patient refuses 1996 
National Cancer 
Comprehensive 
Network (NCCN) 
1996 Patients with positive 
ER and/or PR status, 
regardless of 
diagnosis or stage 
Should receive non-steroidal, anti-
estrogen therapy, unless 
contraindicated or the patient 
refuses 
Carlson 
et al., 
1996 
National Cancer 
Comprehensive 
Network (NCCN) 
1996 Patients with stage 
IIIa, IIIb, or IV disease 
Should receive modified radical 
mastectomy plus reconstruction, 
radiation, poly-chemotherapy, and 
tamoxifen if ER and/or PR-positive, 
unless the patient refuses 
Carlson 
et al., 
1996 
American Society 
for Clinical 
Oncology (ASCO) 
1996 Every primary breast 
cancer patient 
Should have ER/PR status testing 
and upon determination of 
hormone receptor positivity, should 
be offered endocrine therapy 
ASCO, 
1996 
American Society 
for Clinical 
Oncology (ASCO) 
2000 Every primary breast 
cancer patient 
Should be evaluated for over-
expression of c-erbB-2 (HER2/neu) 
at time of diagnosis or recurrence, 
and status should inform disease 
management decisions (e.g., use 
of Herceptin) 
Bast et 
al., 2001 
National Institutes 
of Health (NIH)  
2000 Patients  <70 whose 
tumors express 
hormone receptor 
protein 
Should receive adjuvant hormonal 
therapy, unless patient refuses 
NIH, 
2000 
National Institutes 
of Health (NIH)  
2000 Patients <70 with 
localized cancers 
>1cm, any nodal, 
menopausal, or ER/PR 
status 
Should receive adjuvant poly-
chemotherapy, unless patient 
refuses 
NIH, 
2000 
National Institutes 
of Health (NIH)  
2000 Patients who received 
mastectomy and have 
four or more positive 
lymph nodes or 
advanced primary 
cancer (>5cm) 
Should receive postoperative 
radiation therapy within 6 months 
of mastectomy (but not 
concurrently with anthracycline 
chemotherapy), unless patient 
refuses 
NIH, 
2000 
National Institutes 
of Health (NIH)  
2000 Patients who received 
mastectomy and have 
1-3 positive lymph 
nodes 
Inconclusive evidence for post-
operative RT 
NIH, 
2000 
National Cancer 
Comprehensive 
Network (NCCN) 
2008 Patients with stage I 
and II breast cancers 
receiving breast 
conserving surgery 
Should receive whole breast 
irradiation.  Evidence insufficient to 
support partial breast irradiation at 
this time 
NCCN, 
2008 
National Cancer 
Comprehensive 
Network (NCCN) 
2008 All patients with early 
breast cancer 
Should receive sentinel lymph 
node biopsy as the preferred 
pathologic assessment method 
NCCN, 
2008 
National Cancer 
Comprehensive 
Network (NCCN) 
2008 All patients with 
primary breast cancer 
Should be evaluated for hormone 
receptor and HER2-neu status, 
anatomic and pathologic tumor 
characteristics to determine the 
optimal systemic adjuvant therapy 
to reduce recurrence and improve 
survival 
NCCN, 
2008 
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More than anything, the nature of these improvements suggests that breast cancer is 
a highly complicated disease.  Indeed, given the diversity in tumor characteristics (as 
determined by presence of biomarkers, pathologic features, and behavior), it could easily be 
argued that different types of breast cancers are actually different diseases (Andre and 
Pusztai, 2006; Munoz et al., 2008; Peppercorn et al., 2008).  
Despite gains in our understanding of breast cancer, as evidenced by changes in 
treatment guidelines over time (Table 2), many nagging questions remain regarding optimal 
treatment strategies.  Among these are questions about the utility of gene expression 
profiles in directing patient-centered care (Benowitz, 2008), appropriate management of 
elderly breast cancer patients (Passage and McCarthy, 2007; Wildiers and Brain, 2005), use 
of partial breast irradiation (Buchholz, Kuerer, and Strom, 2005); sequencing and 
compatibility of multiple systemic adjuvant therapies (Bartelink, 2007; Gradishar and 
O’Regan, 2003), use of in vivo intraoperative radiotherapy (IORT) (Stitzenberg et al., 
2007a), and impact of delays in receipt of radiotherapy and chemotherapy on recurrence 
and survival (Hartsell et al., 1995; Hebert-Croteau et al., 2002; Lohrisch et al., 2006).  As 
new treatment innovations emerge and new guidelines are developed, it will be increasingly 
important to monitor uptake and to ensure that vulnerable sub-populations have equal 
access to these evidence-based advances in care. 
 
Quality improvement in cancer 
Translating research findings into practice is not always as straightforward as it 
would seem (Davis et al., 2003; Gold and Taylor, 2007; Shiffman et al., 2004; Waitman and 
Miller, 2004).  Indeed, there are many barriers to adoption of evidence-based guidelines, 
including poor dissemination systems, provider resistance or lack of awareness of new 
evidence, the fragmented nature of the health care financing system, lack of effective 
monitoring, and lack of incentives to change practices (Davis et al., 2003; Grol, 2001; 
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McGlynn et al., 2003).  Older studies in diffusion of innovation from the 1970s and 1980s 
suggest that there is a considerable time delay, possibly as much as 10 or 15 years, 
between the production of technical evidence and full implementation (Dobbins et al., 2002).  
In recent years, the gap between research and practice has likely narrowed.  After the 
Institute of Medicine (IOM) report in 2000, To Err is Human, concerns about quality and 
safety in medicine rose to fever pitch level.  Physician adherence to clinical guidelines had 
perhaps been previously assumed and safety of medical care had been taken for granted; 
these assumptions were shattered with this report.  Additionally, the proliferation of 
institutional and external quality monitoring programs, improved patient access to quality 
performance information, and electronic medical systems helped to spur providers to 
practice better medicine (Bowles et al., 2008; Neuss et al., 2005).   
Cancer care has lagged somewhat in the national move towards quality 
improvement, but is quickly gaining ground.  In 1999, the National Cancer Policy Board, part 
of the IOM, produced a report entitled Ensuring Quality Cancer Care, which summarized 
cancer treatment patterns in the US in one word:  “inconsistent” (Hewitt and Simone, 1999).  
Since then, although everyone seems to agree that measurement of cancer care quality is 
important, there has been much debate about how to do it (Bickell, et al., 2005; Bowles et 
al., 2008; Cornfeld et al., 2001; Smith and Hillner, 2001; Zapka et al., 2003).  Building upon 
the IOM report Crossing the Quality Chasm, which proposed that high quality care should be 
effective, safe, timely, efficient, equitable, and patient-centered, Bowles and colleagues 
(2008) interviewed professional experts in cancer care to describe barriers and facilitators to 
quality improvement in cancer. They concluded that the most important hindrances to high 
quality cancer care were: (1) unnecessary variation (lack of standardization and lack of 
adherence to guidelines), (2) inadequate coordination and communication among 
multidisciplinary care teams, (3) lack of patient awareness and empowerment, (4) delays 
during provider transitions, (5) inappropriate financial incentives within a fragmented 
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financing system, and (6) lack of interoperable electronic medical records (2008).  Zapka 
and colleagues (2003) add that the complex nature of cancer care, which requires 
numerous transitions and handoffs among multiple providers and facilities, further 
complicates adherence to guidelines and quality monitoring.  Despite these barriers, 
ensuring high quality practice in cancer care is possible, and diverse stakeholders are 
interested in this endeavor (Cornfeld et al., 2001; Hewitt and Simone, 1999; Schneider et al., 
2004; Smith and Hillner, 2001).  For instance, Medicare has demonstrated a strong 
commitment to quality improvement in cancer (Etheredge, 2009). 
In response to the national demand for quality metrics, NCCN and ASCO nominated 
content and methodology experts in the cancer domain to develop national quality 
monitoring measures (Desch et al., 2008).  This effort was coordinated with a similar 
process begun by the National Quality Forum in 2004.  The criteria for evaluating whether 
an evidence-based guideline should become a metric included determining perceived 
impact on population survival, potential for improvement based on pilot data, and feasibility 
of data collection and reporting (Desch et al., 2008; Hassett et al., 2008).  A metric is 
defined by a count numerator and an appropriate denominator indicating the eligible patient 
population that should receive the treatment or procedure (Hassett et al., 2008).  Defining 
the denominator also requires specificity in timing; over what period should care be 
considered adherent if the treatment/procedure is received?  Based upon these criteria and 
the potential for quality improvement in the breast cancer patient population, NCCN/ASCO 
released in July, 2008, three breast cancer quality metrics:  (1) receipt of radiation therapy 
after breast conserving surgery within one year of diagnosis for stage I-III breast cancers, (2) 
receipt of post-operative adjuvant chemotherapy within 120 days of diagnosis for hormone 
receptor (ER and PR) negative, stage II-III cancers, and (3) receipt of tamoxifen or 
aromatase inhibitor within one year of diagnosis for hormone receptor positive tumors 
greater than 1 cm (Desch et al., 2008).  These were refined from a much broader set of 
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metrics originally released by NCCN/ASCO in 2006 (Malin et al., 2006).  Due to insufficient 
accumulation of clinical trial evidence about the effects of radiation and chemotherapy in 
older women, these metrics were limited to women younger than 70, but many experts 
agree that such an age-specification sets a low bar for quality, given observational evidence 
showing that older women benefit as much as younger women from these therapies 
(Wildiers and Brain, 2005).  Moreover, a randomized trial published recently showed that 
women older than 70 treated less aggressively with chemotherapy fared worse (Muss, 
2009).   
Using data from five metropolitan areas, in 2006, a National Initiative for Cancer 
Care Quality (NICCQ) study reported high adherence to similar measures (96% for radiation 
therapy, 60-91% for chemotherapy, and 85-95% for hormonal therapy) (Malin et al., 2006).  
However, their results are likely unrepresentative of national norms because the study 
included only a small number of metropolitan districts and patients within institutions closely 
affiliated with a national quality monitoring organization (Desch et al., 2008; Malin et al., 
2006).  Patients from rural areas and hospitals unaffiliated with NICCQ may receive less 
adherent care.  Other studies have shown substantial variation in guideline adherence.  
Using data from Philadelphia region oncology specialty practices, Bloom and colleagues 
(2004) reported that for stage I or IIA node-negative disease, 45-60% of women received 
adequate treatment according to NCCN guidelines, whereas for stage IIa or IIb node-
positive disease, only 15% of women received guideline-recommended treatment.  Among 
women with stages IIIa, IIIb, or IV disease, only 12% received guideline-appropriate care 
(Bloom et al., 2004).  Eighty-two percent of women received hormone receptor testing (ER 
and PR status) as recommended by NCCN, but only 2% received HER2/neu oncogene 
testing.  This finding could be explained by the fact that HER2/neu was a fairly new 
diagnostic test at the time of data collection.  In a review article by Smith and Hillner (2001), 
participation in the development of quality monitoring programs had no demonstrable effects 
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on practice patterns.  In another study in Virginia employing “report cards” based upon NIH 
guidelines, adherence to guidelines was generally low, but particularly disturbing were low 
rates of referral to medical oncologists to discuss adjuvant therapy after surgery (56%) and 
low rates of referral to plastic surgeons to discuss reconstructive options after mastectomy 
(27%) (Hillner et al., 1997). 
 
Previous studies in health disparities and breast cancer treatment 
Health disparities are profoundly apparent in post-diagnosis breast cancer treatment, 
particularly for black women, elderly women, and poor women.  Whereas poor women 
mainly suffer problems of access to care due to lack of insurance, inability to afford out-of-
pocket deductibles and co-payments, and/or lack of reliable or free transportation, the 
issues of race/ethnicity and age are more complex.  Age-related disparities in cancer 
treatment are well-documented in the literature, but the implications of such disparities are 
muddied by poor representation of elderly breast cancer patients in clinical trials.  These 
issues are discussed in detail elsewhere (Ballard-Barbash et al., 1996; Chagpar et al., 2007; 
DiMichele et al., 2003; Heflin et al., 2006; Hershman et al., 2008; Gorin et al., 2005; Kosiak, 
Sangl, and Correa-de-Araujo, 2006; Passage and McCarthy, 2007; Wildiers and Brain, 
2005). 
Previous studies have demonstrated that black women, more often than other 
women with the same stage disease, fail to receive mammography, timely diagnosis, and 
recommended treatment for breast cancer (Bradley, Given, and Roberts, 2001; O’Malley et 
al., 2001; Shavers and Brown, 2002).  In abstracting inpatient and outpatient medical 
records from six New York City hospitals in 1999 and 2000, Bickell and colleagues (2006) 
found that 34% of black women and 23% of Hispanic women, compared to 16% of white 
women, failed to receive appropriate adjuvant therapy for early stage breast cancer.  Non-
optimal adjuvant treatment was defined as omissions of radiation therapy after BCS, 
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adjuvant chemotherapy after definitive surgery in hormone receptor negative tumors greater 
than or equal to 1cm in size, or hormonal therapy for hormone receptor positive tumors 
greater than or equal to 1cm in size (Bickell et al., 2006).  Underuse was significantly 
associated with black or Hispanic racial/ethnic status, lack of medical oncologic referral, 
more co-morbid conditions, and lack of insurance.  Black and Hispanic women were more 
than twice as likely to receive poorer care, after controlling for clinical tumor features, age, 
insurance status, and medical oncologist consultation.  Consulting with a medical oncologist 
reduced the racial disparity somewhat, but not entirely; no other provider or health system 
factors were taken into account in this analysis (Bickell et al., 2006). 
In a recent study by Freedman and colleagues (2009), SEER data from 1988 to 2004 
were used to assess definitive local treatment (i.e., mastectomy or BCS with RT) for early 
stage cancers.  Over time, rates of mastectomy decreased as BCS with RT diffused into 
practice; however, in adjusted models, rates of any definitive treatment remained lower for 
black and Hispanic women compared to white women, and no reduction of this disparity was 
observed over time (Freedman et al., 2009).  Additionally, persistent age-related disparities 
in receipt of definitive treatment were observed for women younger than 60 years old and 
older than 70 years old.  The lack of definitive treatment among women older than 70 years 
was consistent with findings from other studies and likely explained by the absence of 
sufficient clinical trial evidence on treatment for older women with breast cancer.  The 
reasons for under-treatment of women younger than 60 were less clear, but may have been 
related to employment and insurance status.  This analysis lacked information about 
employment, insurance status, and co-morbidities and did not control for possible 
organizational confounders.  Control variables were limited to biologic features of the tumor, 
year of diagnosis, and region (Freedman et al., 2009). 
Lund and colleagues examined first course of treatment among women diagnosed in 
2000-2001 with invasive breast cancer in five Atlanta SEER counties (2008).  They 
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described differences in treatment delay, cancer-directed surgery, and receipt of radiation, 
hormonal, and chemotherapy, focusing on racial differences between black and white 
women.  In this analysis, black women were four to five times more likely to experience 
treatment delays longer than 60 days (p<0.001).  Black women also were less likely to 
receive cancer-directed surgery, radiation therapy after BCS, and hormonal therapy, among 
women with hormone receptor positive tumors, controlling for age, tumor size, stage, lymph 
node involvement, and ER/PR status (Lund et al., 2008).  This study was limited by the fact 
that the SEER registry collects treatment information only for the four-month time window 
after diagnosis, so later cancer-directed treatments may have been missed.  Linking to 
Medicare data could have provided more detailed information about treatment for the portion 
of women covered by Medicare.  This study also was limited by the inability to capture 
HER2/neu status, possible under-reporting of chemotherapy, lack of information about 
health status and co-morbidities, and lack of information about provider and system-level 
characteristics (Lund et al., 2008). 
In a study employing SEER-Medicare data from 1992-1999, differences in processes 
of care were evaluated, focusing on BCS with RT, documentation of ER status, surveillance 
mammography during remission, and a combined measure of adequate care (Haggstrom, 
Quale, and Smith-Bindeman, 2005).  In adjusted comparisons, Hispanic women were 33% 
less likely to receive adequate care, and black women were 23% less likely to receive 
adequate care, compared to white women.  Black/white disparities actually worsened over 
time, as evidenced by a secondary analysis limited to 1997-1999 breast cancer diagnoses 
(adjusted odds ratio: 0.63; 95% CI: 0.50-0.79).  Additionally, older women, and women from 
rural areas were significantly less likely to receive standard quality care.  Interactions 
between race/ethnicity and age, and race/ethnicity and area income were tested, but not 
included in final models.  Adjusted models controlled for median area income, year of 
diagnosis, SEER region, Charlson co-morbidity index, tumor size, and stage, but no 
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structural/organizational variables were assessed.  This analysis was further limited by the 
exclusion of young women (i.e., younger than 65 years), women with stages III or IV cancer, 
women with larger tumors (>5cm), women with health maintenance organization (HMO) or 
private insurance coverage, and the lack of consideration of other therapies, including 
chemotherapy, biologic, and hormonal treatments (Haggstrom, Quale, and Smith-Bindeman, 
2005). 
Banerjee and colleagues (2007) assessed receipt of BCS, radiation, tamoxifen, and 
chemotherapy by conducting comprehensive medical record reviews of women diagnosed 
with breast cancer in 1990-1996 in Detroit at the Karmanos Cancer Institute and found that 
for local stage disease, white and black women received equivalent care across treatment 
paradigms, but for regional disease, black women were less likely to receive guideline-
recommended hormonal therapy and chemotherapy.  Interestingly, they also found that 
women enrolled in government insurance plans were less likely to receive BCS plus 
radiation; rather, government-insured patients tended to get the more invasive mastectomy 
procedure.  Additionally, they found that married women with regional disease were more 
likely to receive guideline-recommended chemotherapy, compared to non-married women 
with regional disease, suggesting, as other authors have, that social support plays a role in 
treatment decision-making (Banerjee et al., 2007).  Banerjee and colleagues (2007) also 
found that African American women had far more co-morbid conditions than white women, 
which implied a need to control for additional illnesses in future analyses to avoid potential 
confounding.  Because this study was limited to one institution in the Detroit area, 
institutional, structural, and geographic factors were ignored in the analysis.  Furthermore, 
the breast cancer patient population in the Detroit metropolitan region is mainly composed of 
older, insured, black women with low socioeconomic status; thus, variations in rural/urban 
residence, income and education, neighborhood racial composition, insurance status, and 
ethnic identity could not be easily assessed in the study. 
 31 
We also know that black women enroll in clinical trials much less often than white 
women and thus may have poorer access to life prolonging treatment offered by many 
cancer trials (Advani et al., 2003; Movsas et al., 2007; Murthy, Krumholz, and Gross, 2004; 
Newman and Martin, 2007; Simon et al., 1999; Sateren et al., 2002; Tejeda et al., 1996).  As 
a result, diffusion of research-related innovations may be disproportionately benefiting 
certain women as compared to others.  As one example of an innovation that has perhaps 
diffused differently within sub-populations, some evidence suggests that black women are 
less likely to receive sentinel lymph node biopsy (SLNB) and that this disparity cannot be 
explained by differences in clinical factors, insurance status, type of hospital, teaching status 
of hospital, or age (Chen et al., 2008).  Despite overall higher levels of uptake of SLNB 
between 1998 and 2005, racial/ethnic gaps in receipt of SLNB remained largely the same 
over time (Chen et al., 2008).  In addition, Mitchell and colleagues (2009) found that few 
breast cancer randomized trials report or analyzed outcomes based on race/ethnicity, 
indicating a failure to report data that may help evaluate and overcome health disparities. 
Additional review articles by Tammemagi (2007) and Shavers and Brown (2002) 
overwhelmingly echo the findings of specific empirical studies highlighted above.  Shavers 
and Brown (2002) also reported on several other treatment disparities between racial/ethnic 
groups, including differences in receipt of biomarker testing, follow-up after diagnosis and 
initial treatment, and surveillance mammography.  In their reviews of the literature, both 
Tammemagi (2007) and Blackman and Masi (2006) concluded that disparities in treatment 
were the result of patient/tumor-related, provider-related, and health system-related 
differences, but that these factors were rarely explicitly considered in empirical studies as 
acting in conjunction.  Additionally, Tammemagi (2007) discussed the post-surgical 
experiences of black and Hispanic women and concluded, as previous authors have, that 
black and Hispanic women are more likely than white women to experience inadequate pain 
management and serious side effects of treatment (Bigby and Holmes, 2005; Payne, 
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Medina, and Hampton, 2003).  Tammemagi also discussed the role of co-morbidities in 
explaining the survival disparity between white and black women; the co-morbidity issue is 
an important one and should not be overlooked (2007).  Beyond the role of co-morbidities in 
survival, higher co-morbidity burden among blacks could lead to competing priorities in 
health care seeking-behavior.  If, for example, a woman with uncontrolled diabetes and/or a 
serious disability has limited time and resources to attend health care appointments, she 
may prioritize certain health visits over others.  Furthermore, if her functional status or 
mental health status is compromised by co-morbid condition(s), these may additionally 
inhibit, rather than promote, health-seeking behaviors for her cancer diagnosis, particularly if 
she feels she is at low risk for metastasis or death (i.e., she has early-stage cancer). 
Beyond co-morbid conditions and biological tumor characteristics, both of which 
affect treatment options and health outcomes, several other patient-level factors may help 
explain why different patients receive different treatments, including health literacy and 
personal preferences (Polacek, Ramos, and Ferrer, 2007); insurance and socioeconomic 
status (Blackman and Masi, 2006; Bradley et al., 2005); cognitive and social network 
correlates (Magai et al., 2008); experience with/trust of the health care system; and fatalistic 
beliefs and health-seeking behavior (Blackman and Masi, 2006; Talcott et al., 2007).  One 
example of an intervention that has successfully improved patient awareness, 
empowerment, and trust in the health care system is the introduction of patient navigation 
programs (Vargas et al., 2008).   
Evidence suggests that when women across racial/ethnic groups receive equal 
treatment, equal outcomes follow (Dignam et al., 1997; Roach et al., 1997; Yood et al., 
1999).  Black patients are at no greater risk for chemotherapy-related hematologic toxicity 
than white patients (Smith et al., 2005), and clinical trial results suggest that patterns of 
response to local and systemic therapy are similar for black and white women with clinically 
equivalent disease (Newman et al., 2003).  In light of this evidence, it is critically important 
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that the health system itself is designed in such a way that all women have access to life-
prolonging cancer treatments, regardless of race, age, or socioeconomic status. 
 
Organization of health services and cancer care 
Organizational and structural factors affect diffusion of innovation and 
implementation of high quality, evidence-based practice (Greenhalgh et al., 2004).  
Generally, elements of the health care system are described in terms of physician-level 
factors (e.g., provider specialty, age, race/ethnicity, board certification), facility-level factors 
(e.g., type, size, profit status, procedural volume, teaching status), and system-level or 
structural factors (e.g., location, dispersion, and availability of health services, health care 
financing, technology investment, existence of quality monitoring systems).  Several studies 
have investigated the effects of these factors on guideline-concordant practices in cancer 
care, but rarely are racial/ethnic (and other patient-level) variables considered in the context 
of the design and operation of the health system.  Facility and physician characteristics of 
health services that have been associated with adherence (or lack thereof) to cancer clinical 
guidelines include: 
• Geographic location (Chagpar et al., 2007 ; Engelman et al., 2004 ; Punglia et 
al., 2006a) ;  
• Existence of cancer-directed programs or affiliation with cancer care 
organizations (Birkmeyer et al., 2005; Punglia et al., 2008; Stitzenberg, Thomas, 
and Ollila, 2007);  
• Teaching status or academic affiliation of surgical hospital (Chagpar et al., 2007; 
Hebert-Croteau et al., 2005; Goldzweig et al., 2004; Gort et al., 2007; Jerome-
D’Emilia and Begun, 2005; Lee-Feldstein, Anton-Culver, and Feldstein, 1994);  
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• Surgical, procedural, or cancer case volume (Allgood and Bachmann, 2006; 
Begg et al., 1998; Billingsley et al., 2007; Birkmeyer et al., 2003; Birkmeyer et al., 
2006; Birkmeyer et al., 2007; Chagpar et al., 2007; Finlayson et al., 2003; 
Gilligan et al., 2007b; Gort et al., 2007; Hillner, Smith, and Desch, 2000; Jerome-
D’Emilia and Begun, 2005; Neuner et al., 2004; Schrag et al., 2003; Wilt et al., 
2008); 
• Specialist consultation and primary physician training/specialization (Allgood and 
Bachmann, 2006; Hillner, Smith, and Desch, 2000; Stitzenberg, Thomas, and 
Ollila, 2007; Zork et al., 2008); 
• On-site radiotherapy at surgical hospital (Hebert-Croteau et al., 2005); 
• Research activity (Hebert-Croteau et al., 2005);  
• Caseload severity (Hebert-Croteau et al., 2005; Schrag et al., 2006) ;  
• Distance to care (Jones et al., 2008; Punglia et al., 2006; Shea et al., 2008; 
Stitzenberg et al., 2007b; Voti et al., 2006) ; 
• Quality and procedural notification/reminder systems (Goins et al., 2003); 
• Frequency of specialist/generalist collaboration (Goldzweig et al., 2004); 
• Stated organizational commitment to quality improvement (Goldzweig et al., 
2004);  
• Incentive-based systems in place (Goins et al., 2003; Goldzweig et al., 2004); 
• Gender, age, race/ethnicity, and education of physician/surgeon (Gilligan et al., 
2007a; Hershman et al., 2008; Neuner et al., 2004; Waljee et al., 2006); and 
• Facility type, practice setting, profit status, and size (Chaudhry, Goel, and Sawka, 
2001; Gort et al., 2007; Himmelstein et al., 1999; Lee-Feldstein, Anton-Culver, 
and Feldstein, 1994; Stitzenberg, Thomas, and Ollila, 2007). 
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These physician- and facility-level factors have varying degrees of influence on 
quality of cancer care received.  Several may be more or less problematic for particular 
patient sub-populations.  For example, the issue of distance to care has been found to be 
more problematic for older women, perhaps not surprising, given the transportation and 
mobility difficulties some elderly women may face (Punglia et al., 2006).  Bao and 
colleagues (2007) also have discussed the importance of distinguishing “within” physician 
differences from “between” physician differences, suggesting that the problem of one 
physician practicing poorly across all his/her patients is quite different from the problem of 
one physician providing worse quality care to certain patients, while providing better quality 
care to others. 
In addition, health system-level factors play a role in high quality cancer care.  Extent 
of interagency collaboration, local socioeconomic environment and resource capacity, 
supply of radiation oncologists, ratio of specialists to generalists, and investment in 
technology all may affect receipt of appropriate care (Jerome-D’Emilia and Begun, 2005). 
 
Race/ethnicity and health services organization 
Although many organizational and structural health services characteristics, such as 
facility location and profit status, are fixed over time, preference for and utilization of certain 
health services are not.  Race, ethnicity, age, rural residence, and socioeconomic status 
may be correlated with health-seeking behavior and use of health services with certain 
structural/organizational characteristics.  As an example, some ethnic groups may prefer 
hospitals which recognize and address language barriers by hiring translators; health 
facilities that can afford to do so are likely different in terms of organizational setup and size 
from those facilities that do not offer bilingual services.   
In addition, membership in racial and ethnic groups may correlate with community 
residence, and type and location of health facilities may be related to socio-demographic 
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makeup of the local user population.  As a result, access to medical innovations and new 
technology may be distributed unequally.  If distribution and diffusion of evidence-based 
innovations are disproportionately benefiting certain women as compared to others, 
differential quality of care may be observed across socio-demographic groups.   
Finally, patient socio-demographics could be associated with the types and quality of 
providers and health facilities that are available to the local user population.  In terms of 
access to well-trained health professionals, one study showed that black cancer patients 
were more likely than white patients to be treated by physicians who lacked board 
certification, experience, and technical resources (Bach et al., 2004).  Moreover, physicians 
treating black patients more often reported that they were unable to provide high quality care 
to their patients (Bach et al., 2004). 
Despite strong evidence for racial/ethnic disparities in breast cancer outcomes, few 
empirical studies have explicitly considered the modifying or confounding potential of health 
services organization on race/ethnicity.  Analyses that have included health system 
variables as covariates in addition to race/ethnicity have generally highlighted the 
importance of a few structural/organizational variables as confounders only, such as one 
publication by Jerome-D’Emilia and Begun (2005) using information from National Cancer 
Database (NCDB).  In this study of diffusion of BCS, Jerome-D’Emilia and Begun highlighted 
the importance of hospital teaching status, regional supply of radiation oncologists, surgical 
volume, and ratio of specialists to generalists in predicting receipt of BCS over time; 
race/ethnicity was statistically non-significant.  Other studies of screening mammography 
have found that black women more often than white women cite lack of physician referral or 
recommendation for mammography as the reason they failed to receive the test (Tropman-
Hawley et al., 2000; Vernon et al., 1992). 
The interactive effects of structural/organizational variables and race/ethnicity have 
been explored to a greater degree in literatures of other cancers.  For example, in a two-
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step analysis of rectal cancer patients, Morris and colleagues (2008) examined associations 
between race and specialist consultation and subsequent receipt of adjuvant therapy and 
found that blacks were equally likely to consult either a medical or radiation oncologist, but 
were less likely than whites to consult with both a medical and radiation oncologist (49.2% 
vs. 58.8%, p=0.03).  Among patients who consulted with any oncologist, black patients 
remained less likely to receive chemotherapy and/or radiation therapy, suggesting that 
specialist consultation does not explain racial/ethnic disparities in receipt of adjuvant therapy 
in rectal cancers (Morris et al., 2008).   
In another study of prostate cancer screening in North Carolina, researchers found 
that black men were at no greater distance to medical care, but that they had worse access 
to health facilities, less continuity in medical care (lack of a “medical home”), and poorer 
insurance coverage overall (Talcott et al., 2007).  In examining racial disparities in survival 
after rectal cancer treatment, Morris et al. (2006) demonstrated that African Americans more 
often were treated by low-volume physicians and were less likely to receive adjuvant 
therapy.  Importantly, after adjusting for provider variables, the effect of race became 
statistically non-significant, suggesting that provider-level differences in treatment explain a 
portion of racial disparities in health outcomes (Morris et al., 2006).  In another study by 
Gooden and colleagues, black men with prostate cancer were more likely to receive surgery 
at high volume hospitals and at NCI-designated Cancer Centers, but were more likely to be 
treated by low volume surgeons, regardless of hospital surgical volume (2008).  In spite of 
these differences in volume by race, the authors found that racial differences in prostate 
cancer recurrence-free survival persisted, even after stratifying by hospital and surgical 
volume.  Finally, in a study by Earle and colleagues (2002) of advanced lung cancer 
patients, African Americans, particularly of lower socioeconomic statuses, were less likely to 
see an oncology specialist and subsequently, less likely to receive clinically-recommended 
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chemotherapy, after controlling for age, sex, year of diagnosis, region, hospital teaching 
status, and co-morbidities.   
 
Significance and contribution 
Cancer outcomes are a function of not only innate biological factors, but also 
modifiable characteristics of individual behavior and decision-making, characteristics of the 
patient-health system interaction, and characteristics of the health system itself.  Disparities 
in cancer care have been well documented; however, the reasons why certain groups have 
widely different health experiences are not well understood.  Attempts to explain persistent 
racial/ethnic disparities have mostly been limited to discussion of differences in insurance 
coverage, socioeconomic status, stage at diagnosis, co-morbidity, and molecular subtype of 
the tumor.  In the current study, access to insurance coverage was effectively controlled by 
limiting the study to Medicare beneficiaries.  Socioeconomic status and resource availability, 
as measured by State-Buy-In months (a proxy for low income status) and census-tract 
median income and education level, also were included in analytic models.  Finally, stage at 
diagnosis and ER and PR status of the primary tumor were included as covariates.  This 
study adds to the evidence by examining racial/ethnic disparities in treatment in light of 
structural/organizational characteristics of health services, controlling for each of the other 
important “complementary” causes of disparities that have been discussed in the literature.  
Because breast cancer care requires a high degree of multidisciplinary team collaboration, 
structural/organizational features of care are important.  Exploring the interaction between 
race/ethnicity and health services organization in terms of receipt of high quality breast 
cancer care is therefore an important contribution to the health services literature.   
Recognizing that variation in quality of cancer care received may be correlated with 
socio-demographic and health system characteristics may assist policymakers in identifying 
strategies to distribute more equally clinical expertise and health infrastructure across 
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multiple user populations.  Rather than simply describing health disparities in cancer, this 
study goes one step further towards pinpointing policy levers in health services organization 
that may be modified to improve health outcomes for underserved breast cancer patients.
CHAPTER 3:  STUDY DESIGN AND METHODS 
 
Overview and study design 
This study was a secondary analysis of data collected for ongoing cancer 
surveillance and control efforts and administrative insurance billing (from government-based 
insurance claims). The study employed a retrospective design using linked SEER-Medicare 
data to identify women diagnosed with clinically-defined primary breast cancers.  The binary 
dependent variables of interest were timing of receipt of radiation therapy, timing of receipt 
of adjuvant chemotherapy, and all-cause and breast cancer-specific mortality.  Independent 
variables of interest included race/ethnicity, and structural/organizational characteristics of 
oncologic services, including surgical hospital type, size, teaching status, NCI Cancer 
Center designation, ACoSOG affiliation, RTOG affiliation, availability of on-site radiation 
services; and distance to providers. 
 
Conceptual framework:  the Chronic Care Model and Diffusion Theory 
The conceptual framework for this study was informed by two models or theories of 
patient interactions with health systems.  The first is the Chronic Care Model (CCM), initially 
conceived by Wagner, Austin, and Von Korff (1996a) and revised in 2002 (Bodenheimer, 
Wagner, and Grumbach, 2002a; Bodenheimer, Wagner, and Grumbach, 2002b).  These 
authors recognized that adequate management of long-term illnesses required coordinated 
efforts on the parts of patients, providers, the health system, and the environment that 
extended beyond traditional self-management.  These authors argued that focusing only on 
patient self-management would be an insufficient and potentially overtly passive approach to 
controlling serious diseases - arguably, a hands-off approach.  With ever-increasing costs of 
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health care, aging of the American population, and national emphasis on improving and 
monitoring quality of care in the 1990s, “disease management” became a popular catch 
phrase in American health care, but it was Wagner and colleagues who, drawing upon 
disease management activities across the nation, most clearly delineated critical interacting 
components of high-quality chronic illness care.  Their model for effective chronic illness 
care posits that high quality care requires a coordinated and appropriately organized health 
care system existing within and cognizant of the context of local community resources and 
policies (Wagner et al., 2002).  Appropriately organized health care systems are composed 
of six essential elements:  community resources and policies, health services organization, 
decision support, self-management support, delivery system design, and clinical information 
systems (Bodenheimer, Wagner, and Grumbach, 2002a; Bodenheimer, Wagner, and 
Grumbach, 2002b).  According to the authors, a well-designed system should lead to more 
productive interactions between informed, activated patients and prepared, proactive 
professional health care providers (Figure 5). 
Positive clinical outcomes, then, are a product of a coordinated care experience, 
involving: (1) an expert, informed, easily accessible, health system with continuing provider 
education, decision support, prevention programs, and patient self-management support; (2) 
community resources and policies to ensure equity in access to health services; (3) 
informed, activated patients; and (4) proactive, well-trained providers.  Although the CCM 
traditionally has been discussed in the management of diseases such as diabetes, 
congestive heart failure, and chronic obstructive pulmonary disease, cancer care also fits 
nicely within this framework for several reasons (Goins et al., 2003; Zapka et al., 2003).  
First, medical management of the condition requires harmonization of many moving clinical 
parts.  Multiple medications, specialists, visits, and procedures must be coordinated to 
ensure optimal effectiveness of treatment regimens.  Second, self-management is required 
in juggling multiple health visits, making treatment decisions, and dealing with side-effects 
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and toxicities of treatment.  Changes in lifestyle and quality of life frequently accompany 
cancer treatments, and patients must adjust their lives accordingly.  Moreover, continued 
self-surveillance through screening is critically important as survivors are generally at a 
greater risk for recurrent cancers.  Third, from the perspective of the health system, 
monitoring and following patients closely can improve performance/quality measures, 
ensure a more efficient system, and eliminate costly redundancies (Zapka et al., 2003).   
 
 
 
 
 
 
 
 
 
 
 
In addition to the CCM, Rogers’ theory of Diffusion of Innovations provides insight to 
the process by which health care innovations and technologies are adopted over time.  First 
introduced in 1962, Rogers theorized that innovations moved through communities following 
an “S” curve until reaching a saturation point.  In 1995, Rogers further adapted this model to 
demonstrate how health decision-making occurred in the context of a new innovation being 
introduced.  In other words, Rogers described the research-to-practice paradigm.  
Specifically, knowledge and information lead to persuasion, based upon perceived 
Figure 5: A model for effective chronic illness care, adapted with permission from Elsevier 
from Wagner et al., Journal of Nursing Care Quality, 16(2):67-80, 2002. 
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characteristics of the innovation, such as relative or competitive advantage, compatibility, 
complexity, trialability, and observability (1995a).  Through persuasion of key stakeholders 
and decision-makers about the merits of the innovation, a decision is made to either adopt 
or reject the innovation.  After this decision, implementation or scale-up occurs, during which 
time, continued evaluation of the effectiveness and value of the innovation may either 
confirm its usefulness in practice or lead to its discontinuation (Dobbins et al., 2002).  
Factors in decision-making are the usefulness or value of the innovation, the influence of 
key individuals who are stakeholders in the decision, and the influence and readiness of the 
system itself (Bowen and Zwi, 2005).  This decision-making process is negotiated through 
communication channels existing between patients, providers, health plans, researchers, 
and policymakers.  Diffusion of innovations theory fits nicely with the coordinated nature of 
the CCM, but provides a more linear or chronologic perspective to adoption of evidence-
based, high quality care over time.   
The conceptual framework guiding the current study is depicted in Figure 6 (adapted 
from Bickell et al., 2005).  Here, quality of care received and subsequent clinical outcomes 
are shown as a product of interacting patient-level, provider-level, and health system-level 
factors.  Previous analyses too often have assumed that these factors affect health care via 
direct pathways only.  That is, patient-level factors such as race and socioeconomic status 
are independently related to health care received, but indirect and/or mediating pathways 
are often ignored.  Given that race/ethnicity and socioeconomic status are historically-
embedded, socially-rooted constructs, it is plausible that provider and health system 
characteristics may differ across patients and that these differences could lead to differential 
care experiences.  On the one hand, race/ethnicity may affect community residence, which 
may be correlated with types, availability, and quality of local health services.  On the other 
hand, organizational theory suggests that characteristics of the local community, including 
population density, local resource capacity, and neighborhood racial/ethnic composition, 
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may affect the types of organizations that locate in a particular setting.  Organizational and 
structural characteristics of the health system independently may influence receipt of high 
quality care, but also may be correlated with racial/ethnic group, age, and/or socioeconomic 
status, potentially explaining a portion of perceived disparities.  The conceptual framework 
depicted here encompasses the interconnectedness of various units within the health 
system, which exists within the context of the larger community and society.   
 
Research questions and hypotheses 
Research question 1a:  Are diffusion curves similar across sub-populations for 
evidence-based practices in breast cancer care, specifically receipt of RT after BCS within 
one year of diagnosis for stage I-III cancers? 
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Figure 6:  Conceptual framework, adapted with permission from Elsevier from Bickell et al., Surgical 
Oncology Clinics of North America, 14(1), page 106, vi, 2005.  
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H1a:  Diffusion curves over time for receipt of RT after BCS will be significantly 
different across sub-populations of interest and specifically, diffusion will be slower within 
black, Hispanic, and older sub-populations. 
Research question 1b:  What effects do race/ethnicity and structural/organizational 
factors have on timing of receipt of radiation therapy (RT) after breast conserving surgery 
(BCS) for stage I-III breast cancers, controlling for known covariates?  
H1b:  Structural/organizational factors (including surgical hospital type, size, teaching 
status, NCI Cancer Center designation, American College of Surgeons Oncology Group 
(ACoSOG) affiliation, and presence of on-site radiation services; distance traveled to 
surgery; and distance to nearest radiation providers) will predict timing of initiation of RT 
after BCS, and structural/organizational factors will confound the effect of race/ethnicity.  
Research question 2a:  Are diffusion curves similar across sub-populations for 
evidence-based practices in breast cancer care, specifically receipt of adjuvant 
chemotherapy within four months of diagnosis for stage II and III, hormone receptor 
negative cancers? 
H2a:  Diffusion curves over time for receipt of adjuvant chemotherapy will be 
significantly different across sub-populations of interest and specifically, diffusion will be 
slower within black, Hispanic, and older sub-populations. 
Research question 2b:  What effects do race/ethnicity and structural/organizational 
factors have on timing of receipt of adjuvant chemotherapy for stage II and III, hormone 
receptor negative breast cancers, controlling for known covariates? 
H2b:  Structural/organizational factors (including surgical hospital type, size, teaching 
status, NCI Cancer Center designation, and ACoSOG affiliation; distance traveled to 
surgery; and distance to nearest chemotherapy providers) will independently predict timing 
of initiation of adjuvant chemotherapy and will confound the effect of race/ethnicity. 
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Research question 3a:  What is the effect of timing of radiation therapy on health 
outcomes, specifically five-year, all-cause and disease-specific mortality across sub-
populations? 
H3a:  Late timing of RT after BCS, relative to the shortest time period between 
diagnosis and receipt of initial RT treatment, will be positively associated with mortality, and 
black patients will experience greater all-cause and disease-specific mortality. 
Research question 3b:  What is the effect of timing of adjuvant chemotherapy on 
health outcomes, specifically five-year all-cause and disease-specific mortality across sub-
populations? 
H3b:  Late timing of adjuvant chemotherapy, relative to the shortest time period 
between diagnosis and receipt of initial adjuvant chemotherapy, will be positively associated 
with mortality, and black patients will experience greater all-cause and disease-specific 
mortality. 
 
Data  
Specific aims 1-3 employed linked SEER-Medicare data from 1994-2003, with vital 
status follow-up through 2007.  SEER-13 registries, excluding the Alaska Native Tumor 
Registry since it is limited to Native Americans, were used for construction of the descriptive 
diffusion curves (aims 1a and 2a), due to the fact that the SEER registry system expanded 
over time, and diffusion curves needed to reflect patterns of care within registries that 
existed during the entire time period; registries with insufficient numbers of minority breast 
cancer patients were excluded.  SEER-17 registries, excluding the Alaska Native Tumor 
Registry, were used for multivariate analyses (aims 1b, 2b, 3a, and 3b).  Due to low 
numbers of minority breast cancer patients in some registries by year, additional sensitivity 
analyses explored the effect of excluding registries with low minority representation.  The 
SEER program was originally designed by NCI to be an epidemiologic surveillance system 
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for incident cancers (Warren et al., 2002c).  The SEER program publishes data from 
population-based registries across the country, representing approximately 26% of the US 
population.  Registrars in SEER areas report information about each newly diagnosed 
cancer, including patient demographic characteristics; date of diagnosis; tumor histology; 
stage, grade, and size; type of surgical treatment; radiation therapy and chemotherapy 
provided in the first four months after diagnosis; vital status; and cause of death, when 
applicable (Warren et al., 2002c).  The SEER program has existed since 1973 and has 
grown to encompass diverse geographic areas across the country (Figure 7) and is 
considered to be largely representative of the US general population.  SEER registry data 
have been linked to Medicare claims data by social security number, name, sex, and age for 
the population of individuals eligible for and enrolled in Medicare (Warren et al., 2002c).  
Eligibility for Medicare is based on age (65 and older), disability, and/or disease (end stage 
renal disease).  Medicare is the primary insurance provider for the vast majority of the older 
US population, covering 97% of Americans ages 65 
years and older.  Part A (inpatient care, 
skilled nursing facilities, home health, and 
hospice care) and Part B (outpatient care, 
durable medical equipment, and physician 
services) claims have been linked to 
individuals with cancer picked up by the 
SEER system.  Medicare Part D pharmacy 
claims are not yet linked to the SEER data.   
Within the SEER-Medicare linked data, there are several types of files.  The Patient 
entitlement and diagnosis summary file (PEDSF) contains all of the SEER registry data, 
Medicare HMO and entitlement information, initial treatment information up to four months 
post-diagnosis, and area socioeconomic information, derived from linked census data.  The 
NCI, 2009; http://seer.cancer.gov/registries/  
Figure 7: SEER regions and funding 
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Medicare analysis and procedure file (MEDPAR) contains claims and billing data from any 
inpatient hospitalizations (Part A services).  The Medicare outpatient file contains claims and 
billing data from outpatient services rendered (Part B services).  The carrier claims 
(physician/supplier) file contains all bills from physicians and other health professionals, 
which can occur in hospital or office settings.  The durable medical equipment file contains 
claims processed by the Durable Medical Equipment Regional Carriers (DMERCs) and may 
include claims for some cancer-related therapies, such as oral equivalents of IV 
chemotherapies (NCI, 2009).  Limited information about providers and facilities may be 
obtained from the NCI hospital file, which collects facility-level data from the Center for 
Medicare and Medicaid Services (CMS) Healthcare Cost Report (HCRIS) and the Provider 
of Service (POS) survey.  Additional hospital and physician data may be obtained by linking 
the SEER-Medicare data to the American Medical Association (AMA) provider database or 
to American Hospital Association (AHA) database (Warren et al., 2002c).  Table 3 provides 
a summary of the data files which were used in this study. 
Table 3: SEER-Medicare data files used 
Requested cancer site PEDSF Site recode number 
Breast cancer (female only) 46 (female only) 
Requested data file name Years  
Patient Entitlement and Diagnosis Summary File (PEDSF) 
Medicare Provider Analysis and Review (MEDPAR) file 
Carrier Claims file (NCH) 
Outpatient Claims file 
Durable Medical Equipment (DME) file 
NCI Hospital file 
1994-2007 
1994-2003 
1994-2003 
1994-2003 
1994-2003 
All possible 
 
 
Study population and inclusion/exclusion criteria 
The population of interest was female, Medicare beneficiaries aged 65 and older who 
lived in SEER regions and who had been diagnosed with primary cancer of the breast.  Due 
to the lack of claims information in Medicare from beneficiaries enrolled in HMOs, only 
continuously enrolled, fee-for-service enrollees were included in this analysis.  Continuous 
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enrollment was defined as continuous enrollment during the one year period prior to 
diagnosis and at least one year post-diagnosis, or until death, whichever occurred first.  
Approximately 15-20% of Medicare beneficiaries are enrolled in HMOs.  Men with breast 
cancer were excluded, as were women younger than 65 and women whose eligibility for 
Medicare was due to end stage renal disease (ESRD).  Table 4 provides a summary of 
inclusion and exclusion criteria for the study. 
Table 4: Inclusion and exclusion criteria for study 
 Inclusion Criteria Exclusion Criteria 
Sex Women Men 
Cancer 
diagnosis 
Incident in situ, Stage I (T1N0), II (T1N1, T2N0, 
T2N1, and T3N0), and III (T1N2, T2N2, T3N1, 
T3N2, T4N0, T4N1, T4N2, T1N3, T2N3, T3N3, 
and T4N3), primary breast cancers (site code 46) 
Unclassified or unknown tumor or 
node status 
Secondary breast cancers 
(metastasized to breast) 
Prior breast cancer diagnosis 
Cancers diagnosed at autopsy 
Insurance Continuously enrolled in Medicare Parts A and B, 
Fee-For-Service  
Enrolled in Medicare Advantage 
(HMO) at any time during study 
period 
Non-continuously enrolled 
Surgical 
Treatment 
Primary surgery received as 1st definitive 
treatment, defined as:  Breast conserving surgery 
(BCS) includes segmental mastectomy, 
lumpectomy, quadrantectomy, tylectomy, wedge 
resection, nipple resection, excisional biopsy, or 
partial mastectomy; Non-BCS includes total 
simple, modified radical, radical, extended 
radical, or subcutaneous mastectomy 
First definitive treatment is not 
surgery, i.e., received neoadjuvant 
chemotherapy prior to surgery or 
did not receive tumor removal 
surgery first 
Notes: BCS: Breast conserving Surgery; HMO: Health Maintenance Organization; T: tumor, N: node, 
of the American Joint Committee on Cancer (AJCC) Tumor Node Metastasis (TNM) staging 
 
For analytic models, only invasive, non-metastasized breast cancers were examined; 
therefore, in situ and metastatic (stage IV) cases were excluded.  Secondary breast cancers 
(metastases from other sites) were excluded.  Additionally, only women who received 
primary surgery as the first definitive treatment were included; as such, patients receiving 
neoadjuvant chemotherapy prior to surgery were excluded from analytic models.  Because 
care-seeking behavior may be different among people previously diagnosed with breast 
cancer, women with prior histories of breast cancer were excluded.  Finally, in cases of 
multiple primary tumors, to eliminate any confusion about which cancer-directed treatments 
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were targeted to which cancer, women with additional cancer diagnoses within one year of 
the index breast cancer diagnosis were excluded.  
 
Sample size 
SEER-Medicare data were used to examine receipt of radiation therapy and 
chemotherapy descriptively and analytically.  SEER-Medicare data from breast cancer 
patients diagnosed in 1994-2002 with claims through 2003 and vital status follow-up through 
2007 were used.  From previous studies employing SEER-Medicare data, we knew that 
approximately 2,500-3,500 female Medicare beneficiaries living in SEER regions were 
diagnosed annually with stages I and II breast cancer (Haggstrom et al., 2005; Hershman et 
al., 2008).  From 1992-1999, 22,701 new diagnoses of early stage breast cancer occurred 
among women in the SEER-Medicare dataset (ages 66-79) (Haggstrom et al., 2005).  
Another study of women with stage I or II breast cancer using SEER-Medicare data reported 
that 29,760 women were newly diagnosed in the years 1991-2002 (Hershman et al., 2008).  
Examining all invasive breast cancers (i.e., excluding only in situ cancers) diagnosed in the 
SEER-Medicare dataset from 1993-1999, Keating and colleagues (2005) found that 
approximately 5,700 to 6,100 incident breast cancer diagnoses occurred each year.  Based 
on these figures, we estimated that approximately 4,000-5,000 incident stage I, II, or III 
breast cancer diagnoses per year would be included in the sample; over a 9-year period 
(i.e., 1994-2002), we expected 36,000-45,000 women would have been newly diagnosed 
with stages I-III, primary breast cancer.   
Of these cases, we estimated that 3-5% would be missing data for race/ethnicity or 
date of diagnosis (i.e., month and year) (Gilligan et al., 2007b).  Another 10-15% would likely 
be excluded because they were not eligible for Medicare Parts A and/or B or because they 
were enrolled in a Medicare HMO (Gilligan et al., 2007b).  We estimated that another 2-5% 
would not receive surgery (i.e., either BCS or mastectomy) as the first definitive treatment 
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post-diagnosis.  Based upon these numbers, approximately 15-25% of the total sample 
diagnosed between 1994 and 2002 would be expected to be excluded from analyses.  As 
such, the analytic SEER-Medicare sample was expected to include approximately 27,000-
38,250 women with non-metastatic, primary breast cancer.  Given that the earlier analyses 
using SEER-Medicare data upon which these estimations were based included fewer 
registries, it was believed that this expected sample size was a conservative estimate.   
For aims related to receipt of radiation therapy after BCS (1a, 1b, and 3a), we know 
that approximately 40-60% of women with stage I and II breast cancer received breast 
conserving surgery in 1994-1996 (Gilligan et al., 2007b; Jerome-D-Emilia and Begun, 2005; 
Neuner et al., 2004).  This proportion likely has increased over time, as it may have taken 
several years for BCS plus RT, which has been the preferred standard of care since 1990, 
to diffuse into practice (Jerome-D’Emilia and Begun, 2005).  Assuming that 70% of women 
diagnosed with breast cancer in 1996-2002 received BCS over mastectomy, the expected 
analytic sample size for aim 1b was approximately 18,900-26,775. 
For aims related to receipt of adjuvant chemotherapy (2a, 2b, and 3b), the 
NCCN/ASCO metric is specific to stage II and III, hormone receptor negative cancers.  
Desch and colleagues (2008) estimated the annual denominator for this metric (i.e., number 
of eligible patients) in the entire United States to be 38,000; however, this number reflects 
only women younger than 70 years old.  As a very rough calculation of the sub-sample of 
women with hormone receptor negative status in SEER-Medicare, we used this number and 
assumed that 40% of breast cancer diagnoses (or about 25,300 diagnoses) occur in women 
older than age 65 (Vogel, 2008; NCI, 2009), 97% of the US population older than 65 years is 
enrolled in Medicare (Warren et al., 2002c), SEER registries capture cancer diagnoses in 
approximately 26% of the US population (NCI, 2009), and ER/PR-negativity is distributed 
equally across age groups, leaving about 6,300 women per year in the SEER-Medicare 
dataset who should be eligible to receive adjuvant chemotherapy (Warren et al., 2002c).  
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This number seems high, given the number of incident cases estimated annually.  In a study 
of women with stage I or II breast cancer using SEER-Medicare data from 1991-2002, 
approximately 10% of women had both ER-negative and PR-negative tumors (Hershman et 
al., 2008).  This proportion applied to the number of women who met inclusion criteria and 
were stage II-III was expected to reflect a more realistic picture of sample size for aims 2a, 
2b, and 3b.  A schematic showing inclusion and exclusion criteria for the SEER-Medicare 
analytic sample is provided below (Figure 8). 
Figure 8: Sample size schematic based upon inclusion/exclusion criteria 
First or only primary breast cancer cases from SEER areas diagnosed in 1994+, female only, N=254,803
INCLUDED EXCLUDED
65 or older
White, black, or Hispanic
Invasive cancer (stage I-IV)
N= 128,895
Reason for entitlement is ESRD
Diagnosed at autopsy or death
Stage is in situ or missing
N= 125,908
Enrolled in Medicare HMO or 
lapse in parts A & B Medicare 
coverage
N= 44,376
No ESRD diagnosis
N= 84,242
Has ESRD
N= 277
Continuous parts A & B Medicare 
coverage 12 mos pre/post 
diagnosis
N= 84,519
No surgery
N= 1,395
Diagnosed in 1994-2002
N= 54,524
Stage IV disease
N= 5,070
Received surgery
N= 53,129
Stage I-III disease only
N= 79,172
Diagnosed in 2003 or later
N= 24,648
Additional cancer diagnosis in 1yr
N= 2,524
Cancer treatments (claims) found 
before diagnosis
N= 1,776
No additional cancer in 1yr
N= 48,829
No cancer treatments (claims) 
found before diagnosis
N= 51,353
 
Notes: ESRD: End Stage Renal Disease; HMO: Health Maintenance Organization; SEER: 
Surveillance, Epidemiology and End Results 
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Variables and measurement 
Variable constructs, dimensions, and measures of interest in this study and the 
SEER-Medicare data sources from which they were obtained are summarized in Table 5.  In 
brief, receipt and timing of initiation of breast cancer treatments and long-term health 
outcomes were the dependent variable constructs of interest, and race/ethnicity and health 
system organization and navigability were key independent variable constructs of interest.  
Based upon review of the literature, control variable constructs that were included were:  
socioeconomic status, social support, community resources and socio-cultural context, 
biological features of the tumor, competing health risks, and environmental factors.  
Appendix A contains more detailed information about variable definitions and sources. 
 
Dependent variables 
For aims 1 and 2, primary outcomes of interest were timing of receipt of radiation 
therapy after BCS for stage I-III cancers and timing of receipt of adjuvant chemotherapy 
after definitive surgery among hormone receptor negative stage II-III breast cancers.  Time 
to treatment for diffusion curves in aims 1a and 2a was considered categorically as receipt 
or non-receipt of RT after BCS within one year of diagnosis and receipt or non-receipt of 
adjuvant chemotherapy within four months, according to the ASCO/NCCN quality metrics, 
respectively.  For aims 1b and 2b, time to treatment between diagnosis and therapy was 
considered as receipt of therapy within the ASCO/NCCN specified time periods, as well as 
additional time intervals shown to be potentially clinically meaningful in the literature.  The 
primary outcomes of interest for aims 3a and 3b were all-cause and breast cancer-specific 
mortality at five years.  Mortality was used instead of survival in light of inherent problems 
with measurement, including possible lead-time bias, length-time bias, and analytic 
difficulties in teasing out competing risks of death, discussed at length by other authors 
(Earle et al., 2002; Boyle et al., 2005; Ries et al., 2006; Sant et al., 2006; Shwartz, 1980).  
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Table 5: Variable measures and data sources 
Construct Dimension Measure/Variable Source 
Dependent Variables 
Quality of breast 
cancer treatment 
Timing of receipt of 
radiation therapy (RT)  
Time in months between diagnosis 
and RT for stage I-III breast cancers 
Claims; 
PEDSF 
Timing of receipt of 
adjuvant chemotherapy  
Time in months between diagnosis 
and chemotherapy for stage II-III, 
ER/PR-negative breast cancers 
Claims; 
PEDSF 
Long-term health 
outcomes 
Mortality Breast cancer-specific mortality at 5 
yrs 
PEDSF 
All-cause mortality at 5 yrs PEDSF 
Key Independent Variables 
Patient-level 
characteristics  
Race/ethnicity Non-Hispanic white PEDSF 
Non-Hispanic black PEDSF 
Hispanic PEDSF 
Health system 
organization and 
navigability 
Facility-level factors 
(institutional experience 
at surgical hospital) 
Bed size of surgical facility NCI file 
ACoSOG and RTOG affiliation  NCI file  
Teaching status  NCI file  
On-site radiation at surgical facility NCI file  
Type/ownership NCI file 
NCI Cancer Center designation NCI file 
Relational factors Distance to nearest radiation facility  Claims; 
PEDSF 
Distance to nearest chemotherapy 
facility  
Claims; 
PEDSF 
Distance traveled for surgery  Claims; 
PEDSF 
Control Variables 
Patient-level 
characteristics 
Age Age at diagnosis PEDSF 
Residential area Rural/urban residence PEDSF 
Low income status State-buy-in months PEDSF 
Social support Marital status PEDSF 
Community resources 
and cultural context 
Area/aggregate 
socioeconomic status 
% of census tract (2000) with less 
than high school education 
PEDSF 
Median census tract (2000) income PEDSF 
Area racial/ethnic profile % Caucasian within census tract PEDSF  
% black within census tract PEDSF  
% Hispanic within census tract PEDSF  
Tumor/biological 
characteristics 
Extent of disease Stage PEDSF 
Cell differentiation Histologic grade PEDSF 
Hormone receptor status Estrogen receptor (ER) status PEDSF 
Progesterone receptor (PR) status PEDSF 
Competing health 
risks 
Co-morbid conditions Constructed NCI-combined co-
morbidity index (using claims data) 
Claims 
Temporal factors Time Year of diagnosis PEDSF 
 
 
Because women received surgery, radiation and chemotherapy from various types of 
facilities, multiple claims files were examined in order to fully capture the therapeutic 
Notes: ACoSOG: American College of Surgeons Oncology Group; NCI: National Cancer Institute; PEDSF: 
Patient Entitlement and Diagnosis Summary file; RTOG: Radiation Therapy Oncology Group; SEER: 
Surveillance Epidemiology and End Results 
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experiences of women, including the MEDPAR (inpatient), carrier claims, outpatient, and 
durable medical equipment (DME) files (Virnig et al., 2002).  Identification of breast cancer-
related therapy has been discussed at length elsewhere (Cooper et al., 2002; Lamont et al., 
2002; Virnig et al., 2002; Warren et al., 2002b); however, to ensure that all relevant codes 
for surgery, radiation therapy and chemotherapy were captured, billing and coding 
specialists and clinicians were consulted.  Relevant codes for this analysis primarily came 
from the Healthcare Common Procedure Classification System (HCPCS) and International 
Statistical Classification of Diseases and Related Health Problems, 9th revision, clinical 
modification (ICD-9-CM) (Table 6).  However, some chemotherapy claims may be identified 
by National Drug Codes (NDC) in the DME files; as such, a HCPCS/NDC crosswalk was 
created for chemotherapy drugs relevant for this analysis (available upon request).  
Table 6: Identification of breast cancer treatments in Medicare claims 
Treatment Primary means of identification 
Diagnostic codes  174.0, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9 
Other:  V10.3  
Aggressive surgery ICD9CM procedure: 85.41, 85.42, 85.43, 85.44, 85.45, 85.46, 85.47, 85.48 
CPT/HCPCS: 19180, 19182, 19200, 19220, 19240, 19260-19272, 19303-19307 
BCS ICD9CM procedure:  85.20, 85.21, 85.22, 85.23, 85.24, 85.25  
CPT/HCPCS: 19120, 19125, 19126, 19160, 19162, 19301, 19302 
Radiation therapy ICD9CM procedure: 92.21-92.29  
CPT/HCPCS: 77261-77499, 77520, 77522, 77523, 77525, 77750-77799, G0256, G0261 
Revenue Center Code: 0330, 0333, 0339 
DRG: 409 
Other: V58.0, V66.1, V67.1  
Chemotherapy ICD9CM procedure:  99.25, 285.3, 999.81 
CPT/HCPCS: 51720, 96400-96549, 99555, Q0083-Q0085 (oral), C9127, C9415, C9420, 
C9421, C9431, C8953-C8955, S9329-S9331, G0355, G0357-G0363, G9021-G9032, 
J8510, J8520, J8521, J8530-J8999 (oral), J9000-J9999 (IV)  
Revenue Center Code: 0331; 0332; 0335 
Betos: O1D 
DRG: 410; 492 
Other: V58.1, V58.11, V66.2, V67.2, V87.41, NDC codes 
Notes: Bold type indicates commonly used codes; CPT: Current Procedural Terminology; DRG: 
Diagnostic Related Group HCPCS: Healthcare Common Procedure Classification System; ICD-9-CM: 
International Statistical Classification of Diseases and Related Health Problems, 9th revision, clinical 
modification; NDC: National Drug Codes 
 
Key independent variables 
Key independent variables included race/ethnicity and structural/organizational 
characteristics of health services.  Race/ethnicity was taken from the PEDSF file, using 
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SEER-reported data instead of Medicare-reported race/ethnicity data, due to well-known 
measurement problems and inconsistencies over time in the Social Security Administration’s 
definition of racial and ethnic groups (Bach et al., 2002a).  It is believed that the SEER data, 
which uses a Spanish-surname algorithm in addition to self-reported race information, is the 
superior source for this measure (Bach et al., 2002a).  For the purposes of this analysis, 
racial/ethnic classification was limited to non-Hispanic white, non-Hispanic black, and 
Hispanic.   
Key structural/organizational variables of interest included facility-level factors 
(surgical facility bed size, NCI Cancer Center designation, ACoSOG affiliation, RTOG 
affiliation, teaching status, type/ownership, as well as presence of an on-site radiologic 
facility at the surgical hospital), and relational factors (distance to nearest radiation and 
chemotherapy facilities and distance traveled for definitive surgery).  These variables were 
obtained from the NCI hospital file, Medicare claims, and PEDSF file.  Please refer to Table 
5, Appendix A, and individual manuscripts (chapters 4, 5, and 6) for more detail about 
measurement and coding of these variables.   
In terms of relational factors (i.e., distance to care), distances were calculated by 
assigning spatial coordinates (latitudes and longitudes) to 5 digit ZIP codes and using 
spherical geometry to calculate distances between points. Nearest neighbor analysis was 
performed by executing a Cartesian product of all patients and providers, calculating, all 
distances by the above method, and selecting the minimum distance for each patient.  Data 
files from various companies with geographic information for ZIP codes have been 
purchased over the past 15 years (Healthcare Solution Series database for ZIP codes, 
Nielsen Claritas Inc., Ithaca, NY: 1998-2000; Trendline database for ZIP codes, Nielsen 
Claritas Inc., Ithaca, NY: 1995-1996; Pop-Facts database for ZIP codes, Nielsen Claritas 
Inc., Ithaca, NY: 2003-2009) and combined into an aggregate file where every ZIP code 
found in any of these files has been assigned geographic coordinates for every year.  The 
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ZIP code coordinates provided in data files are internal points to ZIP code polygons, but 
companies do not claim these points to be centers of gravity or population nor do they 
document their methods.  Some changes are just movement of borders, but ZIP codes are 
created and eliminated every year.  For the aggregate location file, if a ZIP code does not 
have data for a given year information from the last year preceding was used, when 
available.  If no information for preceding years was available, information for the soonest 
following year was used. was used for calculating distances in miles between two sets of 
geographic coordinates. This formula is necessary (as opposed to simple Pythagorean 
equation) because lines of longitude converge while traveling north, so the distance 
between varies with latitude. The Great Circle formula has been shown to be imprecise at 
distances of less than a tenth of a mile, but is reliable for distance to care calculations.  
 
Control variables 
Review of the breast cancer literature reveals that there are several potentially 
confounding variables that must be considered in any analysis of patient treatment and 
outcomes.  These include age and tumor biology, both of which affect physician prescribing 
patterns and suitability of the patient to withstand invasive therapeutic treatment.  Age is 
found within the PEDSF file and was considered categorically (i.e., in five-year age groups) 
and continuously in model specification.  Features of tumor biology, including stage of 
disease, ER status, PR status, and histologic grade are reported by SEER registrars and 
were considered categorically in analytic models.  Given evidence of regional variation in 
cancer treatment, rural/urban residence was included as a covariate when possible (too little 
variation in some cases precluded inclusion of this measure).  Rural/urban residence was 
measured categorically, with rurality/urbanicity defined as:  metropolitan (250,000 - >1 
million), urban (2,500-250,000), and (<2500 per county) from the source geographic cancer 
registry (Gorin et al., 2005). 
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Socioeconomic status was considered by including a variable for any evidence of 
State-Buy-In months (a proxy for low income status) and by including zip code-level 
socioeconomic measures (i.e., median income and proportion of residents with less than a 
high school education).  Neighborhood racial and ethnic diversity was measured by 
assessing proportions of white, black, and Hispanic residents within the zip code.  
Social/familial support has been shown to be a predictor for receipt of and adherence to 
anti-cancer therapeutic regimens (Banerjee et al., 2007).  Due to limitations in using registry-
based claims data, social/familial support could be obtained only by examining marital 
status, so a categorical indicator for marriage status was included in analytic models.  Co-
morbidities were assessed by developing an analytic index of co-morbid conditions using 
the NCI combined index (NCICI) method described by Klabunde and colleagues (2007).  
This co-morbidity index was developed for use with the SEER-Medicare data, with risk 
adjustment weights specific to each cancer site of interest (Klabunde et al., 2007).  
Compared with other co-morbidity indices, the NCICI performed better in predicting non-
cancer mortality for the population of survivors of cancer (Klabunde et al., 2007).  Models for 
receipt of radiation therapy further were adjusted by receipt of adjuvant chemotherapy 
(yes/no), to allow for possible time delays associated with treatment sequencing.  Finally, 
year of diagnosis dummy variables were included as covariates to adjust for cohort effects 
and secular changes in healthcare policies and practices over time.   
 
Statistical analyses by aim  
Descriptive statistics were run prior to running analytic models to examine 
proportions and means of patient demographics and clinical features of the cancers across 
the sample.  Descriptive statistics were stratified according to age group (i.e., younger than 
70 years versus 70 years and older) and by race/ethnicity.  Chi-square tests and t-tests were 
used, as appropriate, to determine whether differences between groups were statistically 
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significant at the 5% level of significance (Chernoff and Lehmann, 1954; Pagano and 
Gauvreau, 2000).   
Aims 1a and 2a were examined using SEER-Medicare data from years 1994-2003 in 
SEER-13 regions, excluding the Alaska Native Tumor Registry which is limited to Native 
Americans.  Diffusion curves (Rogers, 1995a) based upon proportions of the sample 
receiving clinically recommended RT within one year and receipt of chemotherapy within 
four months were constructed for different sub-populations (e.g., by race/ethnicity, age 
group).  Groups were compared using chi-square tests by year (Chernoff and Lehmann, 
1954; Pagano and Gauvreau, 2000).   
Aims 1b and 2b were examined using SEER-Medicare breast cancer cases 
diagnosed in 1994-2002 with claims through 2003 from SEER-17 regions, excluding the 
Alaska Native Tumor Registry.  Multivariate logistic regression (Berkson, 1944; Hosmer and 
Lemeshow, 2000; Rothman et al., 2008) was employed for each binary dependent variable, 
specifically, receipt of radiation within the specified time frame (aim 1b) and receipt of 
chemotherapy within the specified time frame (aim 2b).  Multivariate analyses were 
conducted employing a backwards model building strategy that included race/ethnicity, all 
structural/organizational variables, covariates, interactions of race/ethnicity and 
structural/organizational variables, and interactions of race/ethnicity and year of diagnosis in 
“full” or “saturated” versions of the logit models (Kleinbaum et al., 1998; Mickey and 
Greenland, 1989; Rothman et al., 2008).  Each variable and interaction, in turn, was 
assessed for modification or confounding potential, by removing terms one-by-one from the 
model, starting with interaction terms (i.e., to assess modification potential).  Modification 
and confounding were evaluated by examining changes in the magnitude or significance of 
the main effect of race/ethnicity (using the hazard ratio/odds ratio), changes in the likelihood 
ratio (LR) test statistic, and Wald test statistics for individual terms and interactions (Mickey 
and Greenland, 1989).  The 5% level of significance was to assess predictive power of each 
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individual term, and a change threshold of 10% was used to assess confounding and 
modification potential of covariates (Hosmer and Lemeshow, 2000; Mickey and Greenland, 
1989).  Wald tests were used to test significance of variable constructs (e.g., the group of 
dummy variables for year of diagnosis) (Wooldridge, 2006).  All logistic models were 
stratified by age-group (<70, 70 and above) (Rothman et al., 2008; Wooldridge, 2006).  Final 
estimations were adjusted for heteroskedasticity using Huber-White robust standard errors. 
Aims 3a and 3b (which focus on the effects of timing of radiation therapy and 
chemotherapy on five-year mortality) were examined using data from patients diagnosed 
with breast cancer in 1994-2002 with vital statistics through 2007, living in SEER-17 regions 
excluding the Alaska Native Tumor Registry (which is limited to Native Americans only).  
Multivariate logistic regression was used to determine likelihood of mortality at five years as 
a function of timing of first RT and/or chemotherapy, controlling for known covariates 
(Berkson, 1944; Hosmer and Lemeshow, 2000; Rothman et al., 2008).  Specification of the 
explanatory variables, timing of RT and timing of adjuvant chemotherapy, was informed by 
results from aims 1b and 2b and by consulting the clinical literature. 
Analyses were performed using Stata version 10.0 (Stata Corporation, College 
Station, Texas) and SAS version 9.2 (SAS Institute, Inc., Cary, North Carolina).   
CHAPTER 4:  EFFECT OF STRUCTURAL/ORGANIZATIONAL CHARACTERISTICS OF 
HEALTH SERVICES ON THE RELATIONSHIP BETWEEN RACE/ETHNICITY AND 
TIMELY RECEIPT OF RADIATION THERAPY IN BREAST CANCER PATIENTS 
 
Abstract 
Purpose 
Racial/ethnic health disparities in breast cancer outcomes are well documented but 
the factors contributing to disparities remain poorly understood.  Characteristics of the health 
system may affect whether and when women receive high quality breast cancer care and 
may explain in part racial/ethnic and age-related disparities in outcomes.  Given that current 
quality metrics in breast cancer were based upon well-established breast cancer treatment 
guidelines (Desch et al., 2008), this study retrospectively examined the relationships 
between race/ethnicity and health services characteristics in terms of receipt, timing of 
initiation, and diffusion of high quality cancer care, specifically radiation therapy (RT) after 
breast conserving surgery (BCS) for stage I-III cancers.   
 
Methods 
We used the linked Surveillance Epidemiology and End Results (SEER) – Medicare 
longitudinal dataset to isolate registry information and claims for women ages 65 and older 
whose first or only cancer diagnosis was primary breast cancer in 1994-2002.  To be 
included, women had to be continuously enrolled in Medicare parts A and B fee-for-service 
one year prior to and one year post-diagnosis.  Overall receipt and timing of initiation of RT, 
the primary outcomes of interest, were measured as binary variables indicating whether the 
patient ever initiated RT and whether the patient initiated RT within several time intervals 
varying from one to twelve months.  Diffusion curves were used to describe trends in 
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guideline adoption across sub-populations over time; multivariate logistic regression was 
employed to examine the confounding potential of facility-level characteristics, including 
profit status, teaching status, institutional affiliations, and distance-to-care, on the effect of 
race/ethnicity.  Covariates in multivariate analyses included age at diagnosis, marital status, 
socioeconomic status, tumor characteristics, co-morbid conditions, and year of diagnosis.   
 
Results 
Among the 38,574 women who met inclusion/exclusion criteria, 6% were non-
Hispanic black and 4% were Hispanic.  Overall, two-thirds received RT after breast 
conserving surgery, with significant variation by race/ethnicity and age.  Specifically, receipt 
of RT was significantly higher among non-Hispanic white women (p<0.001) and women 
younger than 70 years old (p<0.001).  Trends in timing of receipt of RT also varied 
significantly over time by race/ethnicity, age, and surgical provider characteristics. 
Multivariate models demonstrated that although structural/organizational variables have 
predictive power and vary by race/ethnicity, they do not eliminate disparities in treatment.  
For example, black women 70 years and older had significantly lower odds of receiving 
clinically-appropriate RT within one year of diagnosis (ORblack: 0.77; p<0.05) compared to 
white women, controlling for all covariates.  As well, black women of all ages had 
significantly lower odds of receiving RT across all time intervals examined, whereas the 
Hispanic disparity in treatment disappeared in older age groups. 
 
Conclusion 
Despite guidelines calling for RT after BCS within 1 year, a substantial minority of older 
women with breast cancer fail to receive this important therapy.  Significant disparities 
persist in receipt of RT for breast cancer after adjusting for structural/organizational 
characteristics of health services that may affect the type of care offered to vulnerable 
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groups.  Recognizing that structural/organizational characteristics of health services may be 
correlated with race/ethnicity may enable us to identify strategies targeting health 
interventions to especially vulnerable breast cancer patients; however, more creative 
approaches to improve quality in vulnerable sub-populations must be identified.  
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Introduction 
Variation in breast cancer treatment quality and outcomes has been documented 
widely across providers and geographic regions within the United States (Ballard-Barbash et 
al., 1996; Bickell et al., 2006; Bloom et al., 2004; Chaudry et al., 2001; Gilligan et al., 2007a; 
Gilligan et al., 2007b; Haggstrom et al., 2005; Hebert-Croteau et al., 2005; Hershman et al., 
2008; Jerome-D’Emilia and Begun, 2005; Keating et al., 2003; Keating et al., 2009; Laliberte 
et al., 2005; Onega et al., 2009).  Particularly at risk for poor quality breast cancer care are 
minority and elderly women (Edwards et al., 2005; Freedman et al., 2009; Haggstrom et al., 
2005).  Breast cancer trends during the past 25-30 years have shown general improvements 
in guideline adherence and mortality (Edwards et al., 2005); however, if the quality of cancer 
care improves over time in the general population but differences in quality across sub-
populations persist or worsen over time, inequities in treatment that lead to disparate health 
outcomes may not have been adequately recognized or addressed.  
Often cited reasons for racial/ethnic disparities in breast cancer are differences in 
socioeconomic status, co-morbid conditions, and biological characteristics of the tumor 
(Carey et al., 2006; Du et al., 2008; Gross et al., 2005; Lund et al., 2009; Schootman et al., 
2009).  The most commonly cited reasons for age-related differences in breast cancer 
management are differences in health status or co-morbidities and lack of guidelines for 
elder age groups (Ballard-Barbash et al., 1996; Desch et al., 2008; Passage and McCarthy, 
2007).  However, other explanations may be possible.  Specifically, organizational and 
structural characteristics of the health system, such as distance between patient residence 
and health services, may independently influence receipt of high quality care, and also may 
be correlated with racial/ethnic group and/or age, potentially explaining a portion of 
observed disparities.  As an example, in a study by Punglia and colleagues (2006a), among 
elderly women, increasing distance to the nearest radiation treatment facility significantly 
 65 
lowered the likelihood of receiving guideline-recommended radiation therapy (RT), and the 
effect of distance was more pronounced with increasing patient age.   
Previous studies have explored the role of organizational/structural factors in 
determining quality of breast cancer care and health outcomes without examining whether 
these characteristics vary by patient demographics.  For example, studies have examined 
the effects of facility caseload or volume (Gilligan et al., 2007b; Hebert-Croteau et al., 2005), 
teaching facility status (Chaudry et al., 2001; Hebert-Croteau et al., 2005; Jerome-D’Emilia 
and Begun, 2005), surgeon characteristics (Gilligan et al., 2007a), and NCI Comprehensive 
Cancer Center designation (Birkmeyer et al., 2005; Laliberte et al., 2005; Onega et al., 
2009) on treatment and outcomes.  Institutional theory and diffusion of innovations theory 
suggest that substantially different institutional cultures exist within different types of 
organizations, such as institutions that engage in cancer-directed research compared to 
those that do not (DiMaggio and Powell, 1983; Hebert-Croteau et al., 2005; Laliberte et al., 
2005; Scott et al., 2000).  Characteristics of the local community, including population 
density, local resource capacity, and neighborhood racial/ethnic composition, may affect the 
types of health organizations that locate in a particular setting.  Conversely, racial/ethnic 
identification and/or age may influence health-seeking behavior, utilization of certain types of 
providers, and choice of residence.  It is unclear exactly how multiple characteristics of the 
health care system correlate with patient demographics such as race/ethnicity and whether 
they act in conjunction to determine receipt of high quality breast cancer care.  Because 
structure and organization of health services are closely related to diffusion and 
implementation of evidence-based practices, if differences in access to or availability of 
certain types of health services exist among vulnerable sub-populations, disparities in 
treatment or outcomes may result.  Furthermore, innovative treatments and evidence-based 
guidelines may diffuse more slowly within certain sub-populations over time.    
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Accordingly, we examined the relationships between race/ethnicity and 
structural/organizational aspects of health services in terms of diffusion of guideline-
recommended care, specifically, initiation of RT within 1 year of diagnosis among women 
who received breast conserving surgery (BCS).  We also examined initiation of RT within 
additional time intervals.  BCS with subsequent RT is considered a standard option for 
women with early stage breast cancer, which may be preferable to mastectomy due to a 
similar survival benefit and improved quality of life outcomes for some patients (NIH, 1990).  
Considering the importance of age in determining receipt of RT, as demonstrated by Punglia 
and colleagues (2006a) among others, all analyses were stratified by age group (<70 versus 
70 years and older).  Although a substantial body of evidence has documented racial/ethnic 
and age-related disparities in overall receipt of RT after BCS (Bickell et al., 2006; Freedman 
et al., 2009; Haggstrom et al., 2005; Keating et al., 2009), we sought to add to this literature 
by exploring possible explanations for persistent disparities, by examining the effects of 
structural/organizational factors, including distance to care and surgical facility 
characteristics, on racial/ethnic variation in receipt of RT after BCS for stage I-III cancers.  
We also examined uptake of this guideline over time across vulnerable sub-populations and 
racial/ethnic variation in timing of initiation of RT.   
 
Methods 
Data Source and Patient Population 
Surveillance, Epidemiology, and End Results (SEER) registry data from 1994-2002 
linked to Medicare claims through 2003 were used for this study. SEER registries represent 
approximately 26% of the US population, and Medicare is the primary insurer for 97% of the 
American population ages 65 and older (Warren et al., 2002c).  Patient records from SEER-
13 regions (excluding the registry consisting of Native Americans from Alaska) were used for 
construction of the descriptive diffusion curves, due to the fact that the SEER registry 
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system expanded over time, and diffusion curves needed to reflect patterns of care within 
registries that existed during the entire time period.  Patient records from SEER-17 registries 
were used for all multivariate analyses.  
The Patient Entitlement and Diagnosis Summary File (PEDSF) was used to assess 
clinical, demographic, geographic, and census-derived aggregate socioeconomic 
information about breast cancer patients.  The Medicare analysis and procedure (MEDPAR) 
file, carrier claims file, outpatient claims file, and Durable Medical Equipment (DME) file were 
used to ascertain details about surgery and RT services provided to breast cancer patients, 
as well as distance to healthcare providers.  The National Cancer Institute (NCI) hospital file 
was used to explore organizational characteristics related to the surgical provider, including 
type/ownership; size; NCI Comprehensive Cancer Center designation; NCI Radiation 
Therapy Oncology Group (RTOG) membership; American College of Surgeons Oncology 
Group (ACoSOG) affiliation; teaching status; and presence of on-site radiation services. 
The population examined was female, Medicare beneficiaries living in SEER regions 
who were diagnosed with stage I-III primary cancer of the breast in 1994-2002 and who 
received BCS.  Due to the lack of claims information in Medicare from beneficiaries enrolled 
in managed care, only continuously enrolled (from one year prior to one year post-
diagnosis) in parts A and B fee-for-service beneficiaries were included in the analysis.  Men 
with breast cancer were excluded, as were women of racial/ethnic background other than 
non-Hispanic white, non-Hispanic black, and Hispanic, due to insufficient numbers of 
women from other racial/ethnic groups for analyses.  Hispanic ethnicity was determined by 
SEER and is considered to be more accurate than Medicare’s or the Social Security 
Administration’s classification, in part because of a Spanish surname algorithm employed by 
SEER to supplement ethnicity information (Bach et al., 2002).  Individuals with end-stage 
renal disease and those women who had an additional cancer diagnosis within one year of 
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the index diagnosis also were excluded.  Inclusion and exclusion criteria for this study and 
the corresponding effects on sample size are illustrated in Figure 9. 
Figure 9: Sample size diagram based on inclusion/exclusion criteria 
First or only primary breast cancer cases from SEER areas diagnosed in 1994+, female only, N=254,803
INCLUDED EXCLUDED
65 or older
White, black, or Hispanic
Invasive cancer (stage I-IV)
N= 128,895
Original reason for entitlement is 
ESRD; diagnosed at autopsy or 
death; stage is in situ or missing
N= 125,908
Enrolled in Medicare HMO or 
lapse in parts A & B Medicare 
coverage
N= 44,376
No current ESRD diagnosis
N= 84,242
Has current ESRD
N= 277
Continuous parts A & B Medicare 
coverage 12 mos pre/post 
diagnosis
N= 84,519
No breast conserving surgery
N= 11,786
Diagnosed in 1994-2002
N= 54,524
Stage IV disease
N= 5,070
Got breast conserving surgery
N= 42,738
Stage I-III disease only
N= 79,172
Diagnosed in 2003 or later
N= 24,648
Additional cancer diagnosis in 1yr
N= 1,927
No cancer treatments (claims) 
found before diagnosis
N= 40,501
Got mastectomy prior to BCS
N= 677
No additional cancer in 1yr
N= 38,574
No mastectomy prior to BCS
N= 42,061
Cancer treatments (claims) found 
before diagnosis
N= 1,560
 
Notes: ESRD: End Stage Renal Disease; HMO: Health Maintenance Organization 
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Dependent Variable 
Timing of initial receipt of radiation therapy (RT) was examined as a binary variable 
indicating whether the patient received a first course of RT within a specified time interval.  
Importantly, the ASCO/NCCN quality metric specifies that the patient must begin RT within 
one year of diagnosis; completion of a recommended course of RT is not included in the 
metric (Desch et al., 2008).  Although adherence to or persistence in receiving the full 
treatment is clearly important, clinically appropriate variation across patients in dosage, 
timing of cycles, and administration makes assessment of therapy completion difficult.  
Different time intervals for initiation of RT at one to twelve months post-diagnosis were also 
examined in the current study because we were interested in variation in initiation of RT.   
Identification of breast cancer-related therapy has been discussed at length 
elsewhere (Cooper et al., 2002; Virnig et al., 2002).  Relevant codes used in this analysis 
from the Healthcare Common Procedure Classification System (HCPCS) and the 
International Statistical Classification of Diseases and Related Health Problems, 9th revision, 
clinical modification (ICD-9-CM) are summarized in Table 7.   
Table 7: Identification of breast conserving surgery and radiation therapy in Medicare claims 
Treatment Primary means of identification 
Diagnostic codes  174.0, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9 
Other:  V10.3  
Breast conserving 
surgery 
ICD9CM procedure:  85.20, 85.21, 85.22, 85.23, 85.24, 85.25  
CPT/HCPCS: 19120, 19125, 19126, 19160, 19162, 19301, 19302 
Radiation therapy ICD9CM procedure: 92.21-92.29  
CPT/HCPCS: 77261-77499, 77520, 77522, 77523, 77525, 77750-77799, G0256, G0261 
Revenue Center Code: 0330, 0333, 0339 
DRG: 409 
Other: V58.0, V66.1, V67.1  
Notes: CPT: Current Procedural Terminology; DRG: Diagnostic Related Group; HCPCS: Healthcare 
Common Procedure Classification System; ICD-9-CM: International Statistical Classification of 
Diseases and Related Health Problems, 9th revision, clinical modification  
 
Independent Variables of Interest 
The main independent variables were race/ethnicity (defined as non-Hispanic white, 
non-Hispanic black, and Hispanic) and characteristics of the health system and providers, 
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including characteristics of the facility where women received surgery (i.e., type/ownership; 
size; NCI Comprehensive Cancer Center designation; NCI Radiation Therapy Oncology 
Group (RTOG) membership; American College of Surgeons Oncology Group (ACoSOG) 
affiliation; teaching status; and presence of on-site radiation) and distance to care (i.e., 
distance traveled for surgery and distance to nearest RT facility).   
Surgical facility characteristics have been shown by other researchers to be 
important predictors of subsequent breast cancer care (Keating et al., 2009), survival 
(Hebert-Croteau et al., 2005), and mortality (Birkmeyer et al., 2005).  Previous studies have 
mostly examined the effect of a single variable, such as hospital teaching status; in the 
current study, a number of surgical facility characteristics were considered in conjunction.  
The NCI Hospital File, a data resource combining provider information from the Healthcare 
Cost Report (HCRIS) and Provider of Service (POS) survey, was used in our study to 
provide information about structural and organizational features of the hospital-affiliated 
facilities where women received primary surgery, as identified in the medical claims data 
(NCI, 2009).  Data in this file were collected somewhat irregularly in 1996, 1998, and 2000-
2006; as such, we used the closest date to the claims date to determine surgical provider 
characteristics.   
Distance traveled for surgery was determined by identifying the unique provider ID 
and zip code associated with first reported incidence of a surgical claim for BCS in the 
MEDPAR, carrier claims, and/or outpatient claims files and identifying patient zip code at 
diagnosis.  Distances from patient zip code centroid and surgical provider zip code centroid 
were then calculated by assigning spatial coordinates (latitudes and longitudes) to zip codes 
and using spherical geometry and the Great Circle Distance Formula to calculate distance in 
miles between two sets of geographic coordinates.  This method has been shown to be 
more precise than simple Pythagorean equations because lines of longitude converge while 
traveling north.  We used this approach to proxy the distance in miles that patients traveled 
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for surgery; previous analyses have used a similar approach (Shea et al., 2008; Nattinger et 
al., 2001; Meden et al., 2002; Schroen et al., 2005).  To calculate distance to the nearest 
radiation facility (as a measure of patient access to radiation providers), we identified all 
Medicare beneficiaries treated for breast cancer in SEER regions from 1994-2003 and all 
providers/facilities for which radiation therapy claims were filed.  From this information, we 
created a master file of all radiation therapy providers who had treated Medicare patients 
over the study period and their associated zip codes.  Using a minimum distance algorithm 
based on Cartesian products of all latitude and longitude of zip code centroids, we 
determined shortest distance to the nearest radiation facility for each woman in the study 
sample (Phibbs and Luft, 1995).  Data files from various companies with geographic 
information for ZIP code analysis were consulted, matching the year of patient diagnosis to 
the closest year for which updated ZIP code information was available.  If a ZIP code did not 
have data for a given year, information from the last year preceding was used. If no 
information for preceding years was available, information for the soonest following year 
was used.  Previous authors have demonstrated that straight-line distances are a 
reasonable proxy for travel time and geographic access to care in the absence of patient-
level data on actual time spent traveling to health care providers (Phibbs and Luft, 1995). 
 
Control Variables 
Control variables were age at diagnosis, rural/urban residence, zip code-level 
income, education, and racial/ethnic composition, tumor characteristics (stage, grade, 
estrogen receptor [ER] status, and progesterone receptor [PR] status), receipt of 
chemotherapy prior to RT, year of diagnosis, low income status (in this case, defined as 
whether the patient had any indication of State-Buy-In during the study period) (Bach et al., 
2002a), and marital status at diagnosis.  Additionally, a measure of co-morbidity was 
included as a covariate, assessed by developing an analytic index of co-morbid conditions 
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using the NCI combined index (NCICI) method described by Klabunde and colleagues 
(2007).  This co-morbidity index was developed with risk adjustment weights specific to each 
cancer site of interest (Klabunde et al., 2007).  Compared with other co-morbidity indices, 
the NCICI is the best predictor of non-cancer mortality among cancer survivors, including 
survivors of breast cancer (Klabunde et al., 2007).   
 
Statistical Analysis 
To assess dissemination and uptake of high quality, evidence-based treatment over 
time, an overall diffusion curve was constructed based upon population-level proportions of 
eligible patients receiving RT after BCS within one year of diagnosis (Rogers, 1962; Rogers, 
1995a).  Then, diffusion curves within sub-populations comparing patients by racial/ethnic 
group, age groups, rural versus urban residence, and health services characteristics were 
constructed and contrasted using chi-squared tests (Pagano and Gauvreau, 2000; Chernoff 
and Lehmann, 1954), by year. 
Unadjusted odds ratios were first examined showing the effect of race/ethnicity on 
receipt of RT by each time endpoint (i.e., one to twelve months post-diagnosis), stratified by 
age group (under 70 versus 70 years and older) and excluding women who received a 
subsequent mastectomy during each time period of interest.  The exclusion of these women 
is critical, because many breast cancer patients undergo mastectomy following an initial 
breast conserving surgery due to positive margins or another clinically meaningful reason; 
as such, adherence to the RT guideline is no longer relevant.  Confounding potential of 
structural/organizational variables on race/ethnicity was assessed in bivariate analyses by 
constructing 2xr tables; chi-squared tests or t-tests then were used to examine differences 
by group, as appropriate (Mickey and Greenland, 1989; Pagano and Gauvreau, 2000).  
Modification potential of health services characteristics on race/ethnicity was assessed by 
running unadjusted models of race/ethnicity on receipt of RT, stratified by 
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structural/organizational variables and comparing the odds ratios (and 95% confidence 
intervals and confidence limit ratios) among strata (Mickey and Greenland, 1989; Rothman 
et al., 2008).   
Multivariate logistic regressions were specified, excluding women who received 
mastectomy subsequent to BCS within each time interval of interest and stratifying on age 
(younger than 70 versus 70 years and older).  Each variable and interaction, in turn, was 
assessed as a modifier or confounder by examining changes in the magnitude or 
significance of the main effect of race/ethnicity, changes in the likelihood ratio test (LRT) 
statistic, and Wald test statistics for individual terms and interactions (Mickey and 
Greenland, 1989; Rothman et al., 2008).  The 5% level of significance was used to assess 
predictive power of each individual term, and a change threshold of 10% was used to 
assess confounding and modification potential of covariates (Mickey and Greenland, 1989; 
Hosmer and Lemeshow, 2000).   Wald tests were used to test the joint significance of 
variable constructs (e.g., the group of dummy variables for year of diagnosis) (Wooldridge, 
2006).  Due to lack of evidence for modification of the main effect of race/ethnicity, 
interactions with structural/organizational health services characteristics were ultimately 
omitted in final model estimations.   
Additional tests were employed to determine the most appropriate variable 
specification for final analytic models.  Specifically, the functional forms of continuous 
variables, such as age, distance to care, and co-morbidity score, were tested to determine 
whether continuous or multiple categorical forms of these variables should be used.  As 
well, multicollinearity among variables was tested (Wooldridge, 2006).  Finally, Huber-White 
robust standard errors were used to correct standard errors in all final model estimations, 
due to inherent heteroskedasticity in the general equation.  Analyses were performed using 
Stata version 10.0 (Stata Corporation, College Station, Texas) and SAS version 9.2 (SAS 
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Institute, Inc., Cary, North Carolina).  The primary logistic regression model takes the 
following general form: 
 
Pr(RTi) = f(β0 + β1Race/Ethnicityi + β2Structi + β3Timei + γZi+ εi) 
 
where “RT” is receipt of radiation therapy during the time interval of interest, 
“Race/Ethnicity” is non-Hispanic white, non-Hispanic black, or Hispanic, “Struct” is a 
vector of health services structural/organizational variables, “Time” is year of 
diagnosis, “Z” is a vector of all other patient and community control variables, and “ε” 
is the error term. 
 
Results 
 Of all women in the SEER-Medicare dataset diagnosed with primary breast cancer 
during the period 1994-2002, 38,574 who underwent BCS met inclusion criteria and were 
included in the current study.  Descriptive characteristics of the full sample are summarized 
in Table 8.  Average age at diagnosis was 75.6 years, and the majority (90%; n=34,965) 
was non-Hispanic white, whereas approximately 6% of women (n=2,273) were non-Hispanic 
black and 4% of women (n=1,336) were Hispanic.  In total, about 60% of all women received 
RT at some time after BCS.  Importantly one-third of the total sample received mastectomy 
subsequent to BCS in the one-year period following diagnosis.  When subsequent 
mastectomy within one year is taken into account, the proportion of women who received 
RT in the absence of a subsequent mastectomy is elevated to 78%, whereas only 18% of 
women with a subsequent mastectomy also received radiation therapy.  The majority of 
women received first definitive surgery in the same month as diagnosis, with little variation 
by race/ethnicity or age.  In general, older women were significantly less likely to receive RT 
or chemotherapy. In terms of clinical differences in cancers by race/ethnicity, black women 
were more likely to be diagnosed with advanced stage disease (i.e., stage III), less likely to  
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Table 8: Descriptive statistics of full SEER-Medicare patient sample who received BCS 
Characteristic % or mean 
(N=38,574) 
% or 
mean 
(N=7082) 
% or 
mean 
(N=526) 
% or 
mean 
(N=349) 
% or 
mean 
(N=27,883) 
% or 
mean 
(N=1747) 
% or 
mean 
(N=987) 
 
 
 
OVERALL 
< 70 
years, 
White 
< 70 
years, 
Black 
< 70 
years, 
Hispanic 
>/= 70 
years, 
White 
>/= 70 
years, 
Black 
>/= 70 
years, 
Hispanic 
Patient/demographic characteristics 
Age (years) 75.6 67.5 67.3 67.4 77.8 77.7 76.8 
Married 43.5% 61.3% 31.7% 52.4% 40.8% 22.1% 34.7% 
Low income 16.5% 10.5% 39.9% 45.8% 14.2% 46.0% 50.7% 
Residence 
   Metro  
   Urban  
   Rural  
       
85.1% 83.2% 94.1% 88.3% 84.6% 95.0% 89.8% 
13.3% 14.9% 5.9% 11.5% 13.7% 4.8% 9.8% 
1.6% 1.9% 0.0% 0.3% 1.8% 0.2% 0.4% 
Year of diagnosis 
   1994 8.6% 9.7% 8.9% 6.6% 8.3% 8.6% 6.9% 
   1995 8.8% 9.0% 9.9% 10.0% 8.7% 8.6% 8.7% 
   1996 8.5% 8.9% 8.7% 9.5% 8.4% 8.6% 8.0% 
   1997 8.8% 8.6% 7.6% 8.3% 8.8% 8.5% 9.4% 
   1998 8.5% 8.1% 8.6% 7.2% 8.6% 8.8% 7.9% 
   1999 8.9% 8.2% 8.2% 8.0% 9.1% 7.8% 9.3% 
   2000 15.9% 15.6% 16.7% 18.6% 15.9% 18.0% 16.1% 
   2001 16.2% 15.7% 15.2% 14.3% 16.4% 15.8% 17.4% 
   2002 15.8% 16.3% 16.2% 17.5% 15.7% 15.3% 16.2% 
Clinical characteristics 
Stage I  
Stage II 
Stage III 
63.5% 
33.0% 
3.5% 
63.8% 
33.5% 
2.7% 
55.5% 
38.4% 
6.1% 
56.2% 
40.1% 
3.7% 
64.6% 
32.0% 
3.4% 
51.4% 
42.5% 
6.1% 
56.5% 
37.9% 
5.6% 
Hormone 
receptors 
   ER+ 
   PR+ 
 
 
70.7% 
58.0% 
72.1% 
59.8% 
52.3% 
39.5% 
67.0% 
56.4% 
71.7% 
58.8% 
58.2% 
46.9% 
66.0% 
53.5% 
Co-morbidity 
score 
 
0.26 0.17 0.33 0.26 0.27 0.43 0.36 
Node status 
   Positive 
   Missing 
 
19.0% 
24.2% 
22.6% 
10.2% 
27.9% 
14.8% 
25.2% 
9.2% 
17.5% 
27.7% 
22.6% 
30.5% 
22.0% 
25.6% 
Treatment 
RT after BCS 
in 4 months 
 
48.3% 54.0% 48.4% 47.6% 47.9% 36.1% 46.6% 
RT after BCS 
in 1 year 
 
56.7% 68.2% 57.6% 63.3% 54.3% 47.4% 54.8% 
Ever received 
RT after BCS 
 
57.8% 69.2% 59.2% 65.3% 55.4% 49.0% 55.9% 
Received 
surgery in 
same month 
as diagnosis 
 
 
 
70.6% 71.1% 65.0% 67.3% 70.9% 67.0% 68.9% 
Ever received 
chemotherapy 
 
20.3% 32.7% 37.3% 33.8% 16.7% 20.4% 19.4% 
Notes: Full sample included in descriptive statistics – no exclusions for subsequent mastectomy 
during the time interval of interest; BCS: breast conserving surgery; ER: estrogen receptor; PR: 
progesterone receptor; RT: radiation therapy; SEER: Surveillance Epidemiology and End Results
 76 
have hormone receptor positive tumors, and more likely to have lymph node status missing 
(Table 8).  Missing lymph node status was significantly correlated with registry (p<0.001), so 
this black/white difference potentially could be explained by differences in reporting by 
registry.  Black women also suffered greater co-morbidity.  In general, Hispanic women 
tracked between white and black women with respect to tumor characteristics and co-morbid 
conditions (Table 8).  In terms of socio-demographic differences by race/ethnicity, black and 
Hispanic women were more likely to be low income (according to the State-Buy-In variable) 
and less likely to live in a rural area (Table 8).  Black women also were much less likely to 
be married. 
 Trends in receipt of radiation therapy over time varied significantly by race/ethnicity 
and age group, as evidenced in Figure 10.  Receipt of guideline-recommended RT after 
BCS within 1 year (in the absence of a subsequent mastectomy) was significantly more 
common among non-Hispanic white women (78%) and Hispanic women (79%) compared to 
non-Hispanic black women (69%) (p<0.001); as well, women younger than 70 years were 
more likely to receive RT after BCS within 1 year (91% compared to 74%, p<0.001).  In 
examining race/ethnicity and age simultaneously, black women 70 years and older were 
least likely to receive RT within 1 year of BCS (in the absence of a subsequent mastectomy) 
compared with other groups (proportions over time ranging from 59-73% in older black 
women compared to a steady 90-92% in white women younger than 70; p<0.01) (Figure 
10).  The Hispanic trend line shows greater volatility, due to lower numbers of Hispanic 
women in the dataset, leading to a higher degree of random noise.   Figures 11 and 12 
demonstrate differences in receipt of RT after BCS among all women (including those who 
may have received a subsequent mastectomy), according to structural/organizational 
characteristics of health care providers.  In general, receipt of RT increased over time.  
Women who received primary surgery at a facility that also provided radiation therapy 
services were more likely to eventually get radiation therapy, as were women who received  
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Figure 10: Receipt of radiation therapy (RT) within 1 year, among women who received 
breast conserving surgery and no subsequent mastectomy – trends by race/ethnicity and 
age group 
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Ever received RT (among those who got breast conserving surgery), 
according to whether surgical facility offers radiation therapy services
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Figure 11: Receipt of radiation therapy (RT) at any time after breast conserving 
surgery, among all women with stage I-III cancers – trends by selected surgical 
provider characteristics 
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Ever received RT (among those who got breast conserving surgery), 
according to proximity to radiation providers
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primary surgery at a facility that was a member of the NCI-affiliated Radiation Therapy 
Oncology Group (RTOG) (Figure 11).  Women receiving surgery at government facilities, 
compared to private/for-profit and non-governmental/non-profit facilities, were less likely to 
eventually receive RT, a trend that largely dissipated over time (Figure 11).  Trends in 
Notes:  Q1: Closest to RT facility – Q4: Furthest from RT facility 
Figure 12: Receipt of radiation therapy (RT) at any time after breast conserving 
surgery, among all women with state I-III breast cancers - trends by proximity to 
health services 
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overall receipt of RT according to geographic access to health care providers, specifically 
distance to nearest radiation therapy and to surgery, varied over time (Figure 12). 
 Comparing health services characteristics by racial/ethnic group, it is clear from 
bivariate analyses that significant differences exist in the types of surgical facilities used by 
racial/ethnic groups as well as geographical access to surgery and RT providers (Table 9).  
For example, 11% of black women received surgery at an NCI-designated Comprehensive 
Cancer Center, compared with 2% of white women and 3% of Hispanic women (p<0.001), 
and black women more often received surgery an American College of Surgeons Oncology 
Group (ACoSOG)-affiliated facility (35% compared with 24% of white women and 16% of 
Hispanic women, p<0.001), a teaching/academic health center (63% compared with 47% of 
white women and 37% of Hispanic women, p<0.001), or a facility where radiation services 
were offered (85% compared with 77% of white women and 73% of Hispanic women, 
p<0.001).  Hispanic women, on the other hand, were more likely to attend for-profit/private 
health care facilities (15% compared with 7% of white women and 8% of black women, 
p<0.001) and least likely to receive care from a teaching/academic health center (38% 
compared with 47% of white women and 63% of white women, p<0.001) (Table 9).  Among 
women who received surgery and radiation therapy, white women traveled the furthest on 
average to surgical facilities and radiation therapy facilities, respectively (Table 9).  
 Comparison of race/ethnicity-specific plots for timing of initiation of RT after BCS 
(Figure 13) reveals that black women were significantly less likely than white women to 
receive guideline-appropriate care and that when appropriate care was received it was 
initiated later in time.  Similar relationships were observed for Hispanic women, although by 
4 months follow-up, the differences were no longer statistically significant.    
 In multivariate models including all women in the sample (i.e., unstratified), black 
women had significantly lower odds of initiating RT at every time interval examined, and 
Hispanic women had significantly lower odds of initiation RT up to 2 months post-diagnosis  
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Table 9: Bivariate comparisons of health system organizational factors by race/ethnicity 
Organizational Covariate % or mean 
 
 
White 
% or mean 
 
 
Black 
% or mean 
 
 
Hispanic 
p-value 
(from chi-
square test 
or t-test) 
Surgical facility characteristics     
Type/ownership 
   For-profit/private 
   Non-profit/voluntary 
   Government Bed size 
NCI Comprehensive Cancer Center 
ACoSOG-affiliated 
RTOG-affiliated 
Teaching/academic facility 
Rural location 
On-site RT services offered 
Number of beds 
 
6.7% 
78.9% 
14.4% 
2.4% 
23.8% 
26.6% 
47.1% 
13.2% 
77.1% 
358.4 
 
7.9% 
79.9% 
12.2% 
10.7% 
34.8% 
28.8% 
63.3% 
3.2% 
84.6% 
486.2 
 
15.3% 
70.9% 
13.9% 
3.1% 
16.2% 
22.2% 
37.6% 
9.6% 
73.1% 
300.3 
 
<0.001 
<0.001 
0.019 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001~ 
<0.001# 
Relational factors/access to care      
Nearest radiation facility (miles) 2.81 1.84 2.80 <0.001~ 
0.969# 
Nearest radiation facility is located in 
same zip code as patient residence 
 
21.1% 
 
22.7% 
 
17.9% 
 
0.003 
Facility where patient received primary 
surgery is located in same zip code as 
patient residence 
 
 
17.3% 
 
 
13.4% 
 
 
17.5% 
 
 
<0.001 
Average distance traveled for primary 
surgery (miles) 
 
14.9 
 
10.5 
 
12.9 
0.001~ 
0.249# 
Average distance traveled to radiation 
facility, among those who received RT  
(first incidence of use) (miles) 
 
 
17.3 
 
 
12.3 
 
 
15.3 
 
0.041~ 
0.490# 
Notes: ACoSOG: American College of Surgeons Oncology Group; NCI: National Cancer Institute; RT: 
radiation therapy; RTOG: Radiation Therapy Oncology Group member; ~ indicates two-sample t-tests 
between white and black groups; # indicates two-sample t-tests between white and Hispanic groups  
 
Figure 13: Timing of initiation of RT among women who received BCS, by race/ethnic group 
(excluding women who received subsequent mastectomy during each time interval of interest) 
0
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Note: Y-error bars depict 95% 
confidence intervals 
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Table 10: Multivariate logit regressions for breast cancer patients (unstratified) 
Variables Odds Ratios for receipt of radiation therapy after BCS, all ages 
(robust standard errors used) 
@ 
1mo. 
@ 2 
mos. 
@ 3 
mos. 
@ 4 
mos. 
@ 6 
mos. 
@ 1 yr. Ever 
Crude ORs for the effect of race/ethnicity 
Non-Hispanic white (reference) 
Non-Hispanic black 0.44** 0.48** 0.50** 0.52** 0.57** 0.64** 0.78** 
Hispanic 0.78** 0.72** 0.79** 0.89 0.94 1.10 1.00 
Fully adjusted ORs 
Non-Hispanic white (reference) 
Non-Hispanic black 0.54** 0.61** 0.59** 0.62** 0.67** 0.75** 0.93 
Hispanic 0.87 0.79* 0.85 0.99 0.99 1.21 1.08 
Structural/organizational variables 
Surgical facility characteristics (Non-profit is reference) 
Private/for-profit 1.39** 1.33** 1.24** 1.20* 1.23* 1.19+ 1.10+ 
Governmental 0.94 0.89* 0.84** 0.85** 0.86* 0.86* 0.90** 
Teaching facility 1.03 0.99 1.01 1.03 1.04 1.05 0.98 
On site radiation 1.45** 1.37** 1.32** 1.34** 1.34** 1.34** 1.28** 
Fewer beds (<median) 1.09* 1.09* 1.15** 1.19** 1.18** 1.16** 0.98 
NCI Comprehensive 
Cancer Center 
0.79* 0.68** 0.84+ 0.98 1.06 0.96 1.15+ 
ACoSOG-affiliated 1.03 1.08+ 1.02 1 1.01 1.08 1.11** 
RTOG member 1.05 1.05 1.06 1.07 1.08 1.10+ 1.20** 
Distance traveled to surgery (in quartiles; same zip code/zero distance is reference) 
Surgery distance Q1 1.11+ 1.06 1.09 1.06 1.08 1.1 1.09* 
Surgery distance Q2 1.08 1.02 1.07 1.08 1.1 1.09 1.10* 
Surgery distance Q3 0.96 0.97 1 1.01 1.06 1.01 1.02 
Surgery distance Q4 0.97 0.89+ 0.88+ 0.9 0.88+ 0.9 1.01 
Distance to nearest radiation facility provider (in quartiles; same zip code/zero distance is reference) 
Radiation provider Q1 1.02 1 0.9 0.9 0.88+ 0.84* 0.91* 
Radiation provider Q2 1.06 1.01 0.91 0.91 0.91 0.84* 0.92+ 
Radiation provider Q3 0.95 0.93 0.85* 0.86* 0.82** 0.74** 0.87** 
Radiation provider Q4 1.22** 1.1 0.95 0.92 0.9 0.83* 0.81** 
Clinical and patient characteristics 
NCI Combined Index Co-morbidity score (Score = 0 is reference) 
Score=.01to1 0.92* 0.85** 0.88** 0.88** 0.92+ 0.89* 0.84** 
Score=1.01to2 0.72** 0.70** 0.64** 0.61** 0.61** 0.57** 0.67** 
Score : Greater than 2 0.75+ 0.60** 0.53** 0.49** 0.46** 0.41** 0.51** 
Age group (70-74 years is reference) 
70-74 years 1.11* 1.13** 1.09 0.99 1.02 0.86+ 0.92* 
75-79 years 1 0.99 0.87* 0.75** 0.73** 0.54** 0.76** 
80-84 years 0.87* 0.77** 0.56** 0.45** 0.41** 0.29** 0.50** 
85 years and older 0.40** 0.28** 0.19** 0.14** 0.13** 0.09** 0.20** 
Surgery in same month as 
diagnosis 
4.50** 2.22** 1.46** 1.24** 1.11* 0.95 0.53** 
Received chemo during 
time interval of interest 
0.43** 0.14** 0.08** 
 
0.09** 0.23** 1.91** 1.54** 
ER-status (negative, borderline, or unknown is reference 
ER-positive 1.23** 1.35** 1.35** 1.36** 1.34** 1.41** 1.24** 
PR-status (negative, borderline, or unknown is reference) 
PR-positive 1.08+ 1.10* 1.12* 1.12* 1.13* 1.11+ 1.06 
Stage at diagnosis (stage 1 is reference) 
Stage2 0.78** 0.74** 0.66** 0.64** 0.66** 0.67** 0.62** 
Stage3 0.59** 0.48** 0.48** 0.52** 0.52** 0.42** 0.99 
Lymph node status (negative is reference) 
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Variables Odds Ratios for receipt of radiation therapy after BCS, all ages 
(robust standard errors used) 
@ 
1mo. 
@ 2 
mos. 
@ 3 
mos. 
@ 4 
mos. 
@ 6 
mos. 
@ 1 yr. Ever 
Node-positive 0.65** 0.62** 0.68** 0.71** 0.68** 1.06 1.23** 
Node status missing 0.78** 0.34** 0.22** 0.18** 0.17** 0.17** 0.91** 
Grade (well differentiated is reference) 
Moderate  0.99 1.06 1.07 1.13* 1.16** 1.22** 0.97 
Poor 0.90* 0.95 1.03 1.13* 1.20** 1.29** 0.98 
Anaplastic 0.9 0.89 0.81 0.91 0.94 0.87 0.87 
Grade missing 0.83** 0.85** 0.86* 0.87* 0.92 0.97 0.75** 
Medicaid enrolled 0.77** 0.71** 0.66** 0.64** 0.63** 0.58** 0.66** 
Married 1.20** 1.21** 1.22** 1.19** 1.22** 1.32** 1.13** 
Metropolitan residence (metro is reference) 
Urban residence 1 1.02 1 0.9 0.89 0.86+ 0.86** 
Rural residence 1.01 1.04 0.81 0.68* 0.67* 0.73+ 0.73** 
Year of diagnosis (1994 is reference) 
1995 1.02 1.05 1.09 1.07 1.12 1.11 1.18** 
1996 0.99 0.96 1.05 1.09 1.13 1.11 1.21** 
1997 0.89 0.96 1.1 1.13 1.22+ 1.27* 1.49** 
1998 0.83* 0.9 1.01 1.05 1.27* 1.27* 1.62** 
1999 0.69** 0.76** 0.95 1.05 1.28* 1.52** 1.90** 
2000 0.60** 0.68** 0.88 0.95 1.12 1.46** 2.08** 
2001 0.49** 0.59** 0.78** 0.88 1.08 1.27* 1.97** 
2002 0.48** 0.59** 0.75** 0.81* 1.01 1.14 2.18** 
Neighborhood characteristics (by zip code) 
Hi%Black (>median) 1.12** 1.04 1.03 1 1.02 1.04 1.04 
Hi%Hisp (>median) 1.16** 1.08+ 1.04 1.05 1.04 0.97 1.17** 
Hi%White (>median) 1.01 1.02 1.02 1.04 1.05 1.06 0.94+ 
More high school grads 
(>median) 
1.28** 1.18** 1.09+ 1.09+ 1.01 0.99 1.10** 
Lowest quartile of neighborhood median income (zpmedQ1 is reference) 
zpmedQ2 1.06 0.99 0.95 0.96 0.96 1 1.02 
zpmedQ3 0.90+ 0.92 1 1.02 1.04 1.06 1.21** 
zpmedQ4 0.80** 0.84** 0.95 0.95 0.99 1.05 1.28** 
Observations 23020 21411 21078 20933 20814 20699 32691 
Notes: + significant at 10%; * significant at 5%; ** significant at 1%; each logit model excludes women 
who received mastectomy subsequent to breast conserving surgery during the time interval of 
interest, with the exception of “Ever” models, which examine receipt of radiation therapy at any point 
during follow-up of the patient; ACoSOG:  American College of Surgeons Oncology Group; BCS: 
breast conserving surgery; ER: estrogen receptor; NCI: National Cancer Institute; PR: progesterone 
receptor; RTOG: Radiation Therapy Oncology Group 
 
(Table 10).  Comparison of the multivariate odds ratios with the crude/unadjusted odds 
ratios in this table reveals that racial/ethnic disparities in receipt of RT at each time point 
were somewhat attenuated with inclusion of structural/organizational and other covariates. 
In models stratified by age 70 (reflecting the lack of clinical trial evidence and quality 
metrics for women 70 years and older), some important differences by age group emerge 
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(Tables 11 and 12).  In the younger group (65-69 years), the adjusted odds ratio for black 
women receiving RT within 1 year was statistically non-significant (Table 11), whereas the 
adjusted odds ratio for black women receiving RT within 1 year was 0.75 in the unstratified 
model (p<0.01, Table 10) and 0.77 in the model limited to women 70 years and older 
(p<0.05, Table 12).  With respect to the odds ratios for the effect of Hispanic ethnicity, none 
were significant in multivariate models of women 70 years and older (Table 12), whereas in 
multivariate models of women ages 65-69 years old, Hispanic ethnicity corresponded to 
lower odds of initiation of RT at each time interval up to 6 months (Table 11).   
In general, omission of structural/organizational variables, especially surgical facility 
characteristics, yielded changes in effect size and significance of other variables, notably 
race/ethnicity variables.  Younger women who attended a surgical facility with on-site 
radiation services had 1.23 greater odds of ever receiving RT (p<0.01) (Table 11), and 
women who received surgery at a smaller facility with fewer beds were about 1.3 times more 
likely to receive RT 3, and 4 months (p<0.05), controlling for all other factors (Table 11).  
Among younger women, distance traveled to surgery and distance to the nearest radiation 
therapy provider played little role in predicting timing of RT, with the exception of the model 
examining whether women ever received RT, in which case, increasing distance to the 
nearest RT provider was associated with significantly lower odds of receiving RT (as 
compared to the nearest RT facility being located in the same zip code as patient 
residence).  In women 70 years and older, black/white disparities persisted despite inclusion 
of structural/organizational variables and covariates (Table 12).  Importantly, structural and 
organizational variables and distance to care were much more informative in this older age 
group. Specifically, attending a private/for-profit surgical facility was associated with higher 
odds of initiation of RT at each time interval (ORs ranging from 1.13 to 1.39), attending a 
surgical facility with on-site radiation was associated with higher odds of initiation of RT at 
each time interval (ORs ranging from 1.30 to 1.49), and attending a smaller surgical facility 
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with fewer beds was associated with higher odds of initiating RT at each time interval (ORs 
ranging from 1.08 to 1.19).  With respect to distance, increasing distance to nearest 
radiation therapy provider (relative to a RT provider being located in the same zip code as 
patient residence) was associated with lower odds of initiating RT by one year (ORs for RT 
provider distance quartiles: 0.86, 0.82, 0.72, 0.84) (Table 12); this trend was largely true 
across models, although not always statistically significant.   
Table 11: Logit regressions for breast cancer patients <70 years old 
Variables Odds Ratios for receipt of radiation therapy after BCS, among women 
< 70 years old (robust standard errors used) 
@ 1mo. @ 2 
mos. 
@ 3 
mos. 
@ 4 
mos. 
@ 6 
mos. 
@ 1 yr. Ever 
Crude ORs for the effect of race/ethnicity 
Non-Hispanic white  
Non-Hispanic black 0.41** 0.46** 0.42** 0.42** 0.42** 0.37** 0.66** 
Hispanic 0.59** 0.52** 0.51** 0.58** 0.50** 0.54* 0.80+ 
Fully adjusted ORs 
Non-Hispanic white (reference) 
Non-Hispanic black 0.56** 0.70* 0.50** 0.49** 0.60** 0.65+ 0.86 
Hispanic 0.68+ 0.58** 0.52** 0.66+ 0.59* 1.02 0.98 
Structural/organizational variables 
Surgical facility characteristics (non-profit is reference) 
Private/for-profit 1.40* 1.29 1.11 0.98 0.92 1.02 1.02 
Governmental 0.89 0.77* 0.86 0.89 0.87 0.91 0.89 
Teaching facility 1.04 0.88 0.97 1.00 1.01 1.12 0.99 
On site radiation 1.32** 1.48** 1.27+ 1.28+ 1.33* 1.19 1.23** 
Fewer beds 
(<median) 
1.13 1.18+ 1.26* 1.27* 1.16 1.26 0.97 
NCI Comprehensive 
Cancer Center 
0.82 0.68* 0.92 1.24 1.42 1.21 1.07 
ACoSOG-affiliated 1.07 1.16 1.13 1.12 0.98 1.34 1.07 
RTOG member 1.07 1.09 0.99 0.96 0.97 1.18 1.10 
Distance traveled to surgery (in quartiles; same zip code/zero distance is reference) 
Surgery Q1 1.02 0.85 0.90 0.85 0.87 0.84 1.10 
Surgery Q2 0.90 0.88 0.96 0.98 1.04 1.00 1.16 
Surgery Q3 0.91 0.82 1.02 1.04 1.18 1.17 1.17 
Surgery Q4 0.90 0.74* 0.81 0.82 0.86 0.83 1.09 
Distance to nearest radiation facility provider (in quartiles; same zip code/zero distance is reference) 
RT provider Q1 1.04 0.88 0.78 0.82 0.79 0.71 0.70** 
RT provider Q2 1.14 0.97 0.85 0.94 1.04 0.94 0.80* 
RT provider Q3 1.07 1.03 0.93 0.97 0.93 0.88 0.74** 
RT provider Q4 1.23 0.98 0.82 0.88 0.83 0.75 0.67** 
Clinical and patient characteristics 
NCI Combined Index Co-morbidity score (Score = 0 is reference) 
Score=.01to1 0.90 0.89 0.96 0.87 1.01 1.00 0.88* 
Score=1.01to2 0.93 0.82 0.65+ 0.48** 0.61+ 0.60+ 0.66** 
Score>2.0 0.51 0.16** 0.37 0.30+ 0.25** 0.28** 0.47* 
Surgery in same 
month as diagnosis 
4.52** 2.71** 1.85** 1.62** 1.33** 0.82 0.47** 
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Variables Odds Ratios for receipt of radiation therapy after BCS, among women 
< 70 years old (robust standard errors used) 
@ 1mo. @ 2 
mos. 
@ 3 
mos. 
@ 4 
mos. 
@ 6 
mos. 
@ 1 yr. Ever 
Received chemo 
during time interval  
0.40** 0.12** 0.07** 0.08** 0.21** 3.29** 1.36** 
ER-status (negative, borderline, or unknown is reference) 
ER-positive 1.40** 1.56** 1.42** 1.33* 1.36* 1.50* 1.17+ 
PR-status (negative, borderline, or unknown is reference) 
PR-positive 0.97 1.05 1.10 1.07 1.04 1.13 1.13 
Stage at diagnosis (stage 1 is reference) 
Stage2 0.63** 0.59** 0.55** 0.49** 0.53** 0.39** 0.58** 
Stage3 0.65 0.49* 0.62 0.59+ 0.45* 0.30* 1.23 
Lymph node status (negative is reference 
Node-positive 0.53** 0.50** 0.60** 0.67** 0.56** 1.28 1.20* 
Node status missing 0.86 0.43** 0.27** 0.23** 0.19** 0.19** 1.10 
Grade (well-differentiated is reference) 
Moderate  0.93 0.93 0.92 1.08 0.98 1.16 0.82** 
Poor 0.83+ 0.77* 0.78+ 1.00 0.97 1.05 0.82* 
Anaplastic 0.72 0.69 0.49* 0.54 0.54 0.37* 0.56** 
Grade missing 0.79+ 0.69** 0.78 0.73+ 0.71+ 0.95 0.65** 
Medicaid enrolled 0.72** 0.79* 0.67** 0.61** 0.57** 0.46** 0.77** 
Married 1.13+ 1.32** 1.28** 1.12 1.10 1.23 1.09 
Metropolitan residence (metro is reference) 
Urban residence 1.26+ 1.18 1.10 0.82 0.88 0.80 0.92 
Rural residence 1.40 1.47 0.90 0.79 1.30 0.76 0.88 
Year of diagnosis (1994 is reference) 
1995 0.86 0.98 0.76 0.71 0.79 0.64 0.99 
1996 1.04 1.03 0.88 1.04 1.00 0.82 1.07 
1997 0.65* 0.79 0.62+ 0.67 0.77 0.63 1.46** 
1998 0.64** 0.60** 0.49** 0.54* 0.78 0.55+ 1.38* 
1999 0.50** 0.48** 0.51* 0.54* 0.69 0.64 1.67** 
2000 0.49** 0.46** 0.43** 0.45** 0.56* 0.76 2.17** 
2001 0.37** 0.36** 0.37** 0.46** 0.58* 0.77 2.27** 
2002 0.39** 0.40** 0.33** 0.41** 0.61+ 0.74 2.28** 
Neighborhood characteristics (by zip code) 
Hi%Black (>median) 1.05 1.03 0.95 0.93 0.87 0.85 1.01 
Hi%Hisp (>median) 1.06 1.02 0.93 0.99 1.05 0.86 1.13+ 
Hi%White (>median) 0.93 1.07 1.03 1.12 1.18 1.36 0.94 
More high school 
grads (>median) 
1.28** 1.19+ 0.98 0.98 0.89 0.90 1.25** 
Lowest quartile of neighborhood median income (zpmedQ1 is reference) 
zpmedQ2 1.20 1.16 0.99 0.96 0.98 0.97 1.02 
zpmedQ3 1.02 1.15 1.12 1.10 1.18 1.05 1.34** 
zpmedQ4 0.86 0.99 0.95 0.91 0.99 1.07 1.30* 
Observations 4811 4476 4406 4366 4335 4304 6822 
Notes: + significant at 10%; * significant at 5%; ** significant at 1%; each logit model excludes women 
who received mastectomy subsequent to breast conserving surgery during the time interval of 
interest, with the exception of “Ever” models, which examine receipt of radiation therapy at any point 
during follow-up of the patient; ACoSOG:  American College of Surgeons Oncology Group; BCS: 
breast conserving surgery; ER: estrogen receptor; NCI: National Cancer Institute; PR: progesterone 
receptor; RT: radiation therapy; RTOG: Radiation Therapy Oncology Group 
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Table 12: Logit regressions for breast cancer patients 70 years and older 
Variables Odds Ratios for receipt of radiation therapy after BCS, among women 
>/= 70 years old (robust standard errors used) 
@ 1mo. @ 2 
mos. 
@ 3 
mos. 
@ 4 
mos. 
@ 6 
mos. 
@ 1 yr. Ever 
Crude ORs for the effect of race/ethnicity 
Non-Hispanic white (reference) 
Non-Hispanic black 0.45** 0.49** 0.52** 0.54** 0.59** 0.66** 0.79** 
Hispanic 0.85+ 0.80* 0.90 0.99 1.06 1.13 1.03 
Fully adjusted ORs 
Non-Hispanic white (reference) 
Non-Hispanic black 0.53** 0.58** 0.61** 0.65** 0.68** 0.77* 0.95 
Hispanic 0.96 0.88 1.00 1.13 1.17 1.29+ 1.14 
Structural/organizational variables 
Surgical facility characteristics (Non-profit is reference) 
Private/for-profit 1.39** 1.33** 1.26** 1.24* 1.30** 1.22+ 1.13* 
Governmental 0.95 0.92 0.84** 0.84** 0.87* 0.85* 0.91* 
Teaching facility 1.02 1.01 1.01 1.04 1.03 1.04 0.97 
On site radiation 1.49** 1.35** 1.34** 1.37** 1.36** 1.36** 1.30** 
Fewer beds 
(<median) 
1.08+ 1.08+ 1.14** 1.18** 1.19** 1.16** 0.98 
NCI Comprehensive 
Cancer Center 
0.79* 0.68** 0.83 0.93 0.99 0.92 1.18+ 
ACoSOG-affiliated 1.02 1.06 1.00 0.97 1.01 1.05 1.12** 
RTOG member 1.04 1.05 1.07 1.09+ 1.10+ 1.10 1.23** 
Distance traveled to surgery (in quartiles; same zip code/zero distance is reference) 
Surgery Q1 1.13* 1.11+ 1.13+ 1.10 1.12+ 1.13 1.08+ 
Surgery Q2 1.13+ 1.06 1.10 1.10 1.12 1.10 1.09+ 
Surgery Q3 0.96 1.00 1.00 1.01 1.04 0.99 0.99 
Surgery Q4 0.99 0.94 0.91 0.92 0.89 0.90 0.99 
Distance to nearest radiation facility provider (in quartiles; same zip code/zero distance is reference) 
RT provider Q1 1.00 1.02 0.91 0.91 0.89 0.86+ 0.96 
RT provider Q2 1.04 1.01 0.91 0.89 0.88 0.82* 0.95 
RT provider Q3 0.91 0.90+ 0.82** 0.83* 0.79** 0.72** 0.90* 
RT provider Q4 1.21** 1.12 0.97 0.92 0.91 0.84+ 0.85** 
Clinical and patient characteristics 
NCI Combined Index Co-morbidity score (Score = 0 is reference) 
Score=.01to1 0.92+ 0.85** 0.86** 0.89* 0.90* 0.89* 0.83** 
Score=1.01to2 0.69** 0.68** 0.64** 0.62** 0.61** 0.57** 0.66** 
Score>2.0 0.78 0.66** 0.55** 0.51** 0.49** 0.43** 0.51** 
Age group (70-74 years is reference) 
75-79 years 0.91* 0.89** 0.81** 0.78** 0.73** 0.63** 0.83** 
80-84 years 0.79** 0.70** 0.53** 0.48** 0.42** 0.33** 0.55** 
85 years and older 0.36** 0.26** 0.18** 0.15** 0.13** 0.11** 0.22** 
Surgery in same 
month as diagnosis 
4.50** 2.12** 1.39** 1.18** 1.06 0.96 0.54** 
Received chemo 
during time interval  
0.47** 0.16** 0.10** 0.11** 0.27** 1.80** 1.64** 
ER-status (negative, borderline, or unknown is reference 
ER-positive 1.19** 1.31** 1.34** 1.37** 1.35** 1.40** 1.25** 
PR-status (negative, borderline, or unknown is reference) 
PR-positive 1.12* 1.11* 1.13* 1.14* 1.16* 1.12+ 1.04 
Stage at diagnosis (stage 1 is reference) 
Stage2 0.82** 0.78** 0.69** 0.67** 0.69** 0.71** 0.63** 
Stage3 0.57** 0.46** 0.43** 0.48** 0.50** 0.43** 0.94 
Lymph node status (negative is reference) 
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Variables Odds Ratios for receipt of radiation therapy after BCS, among women 
>/= 70 years old (robust standard errors used) 
@ 1mo. @ 2 
mos. 
@ 3 
mos. 
@ 4 
mos. 
@ 6 
mos. 
@ 1 yr. Ever 
Node-positive 0.71** 0.66** 0.70** 0.74** 0.74** 1.03 1.24** 
Node status missing 0.78** 0.34** 0.22** 0.18** 0.17** 0.16** 0.90** 
Grade (well differentiated is reference) 
Moderate  1.01 1.09+ 1.11* 1.13* 1.19** 1.23** 1.01 
Poor 0.92 1.00 1.10 1.16* 1.25** 1.32** 1.02 
Anaplastic 0.96 0.94 0.91 1.02 1.09 1.05 0.98 
Grade missing 0.84** 0.88+ 0.87* 0.89 0.95 0.97 0.77** 
Medicaid enrolled 0.78** 0.69** 0.66** 0.65** 0.63** 0.60** 0.64** 
Married 1.21** 1.18** 1.20** 1.19** 1.24** 1.33** 1.15** 
Metropolitan residence (metro is reference) 
Urban residence 0.93 0.98 0.97 0.92 0.89 0.85+ 0.84** 
Rural residence 0.89 0.93 0.77 0.65* 0.58** 0.71 0.69** 
Year of diagnosis (1994 is reference) 
1995 1.08 1.09 1.17 1.16 1.20+ 1.18 1.24** 
1996 0.99 0.97 1.11 1.13 1.17 1.17 1.26** 
1997 0.98 1.03 1.24* 1.26* 1.33* 1.39** 1.51** 
1998 0.89 1.00 1.17 1.19+ 1.38** 1.40** 1.70** 
1999 0.76** 0.86 1.09 1.20 1.44** 1.67** 1.98** 
2000 0.64** 0.75** 1.02 1.10 1.28* 1.58** 2.07** 
2001 0.53** 0.67** 0.91 1.00 1.21+ 1.35** 1.94** 
2002 0.52** 0.66** 0.89 0.93 1.11 1.20 2.18** 
Neighborhood characteristics (by zip code) 
Hi%Black (>median) 1.14** 1.05 1.05 1.01 1.06 1.07 1.05 
Hi%Hisp (>median) 1.19** 1.09+ 1.06 1.06 1.03 0.97 1.18** 
Hi%White (>median) 1.03 1.00 1.01 1.02 1.02 1.03 0.94 
More high school 
grads (>median) 
1.28** 1.19** 1.12* 1.13* 1.04 1.01 1.07+ 
Lowest quartile of neighborhood median income (zpmedQ1 is reference) 
zpmedQ2 1.03 0.95 0.95 0.96 0.96 1.00 1.02 
zpmedQ3 0.87* 0.86* 0.97 0.99 1.02 1.06 1.18** 
zpmedQ4 0.79** 0.80** 0.95 0.96 0.99 1.05 1.27** 
Observations 18209 16935 16672 16567 16479 16395 25869 
Notes: + significant at 10%; * significant at 5%; ** significant at 1%; each logit model excludes women 
who received mastectomy subsequent to breast conserving surgery during the time interval of 
interest, with the exception of “Ever” models, which examine receipt of radiation therapy at any point 
during follow-up of the patient; ACoSOG:  American College of Surgeons Oncology Group; BCS: 
breast conserving surgery; ER: estrogen receptor; NCI: National Cancer Institute; PR: progesterone 
receptor; RT: radiation therapy RTOG: Radiation Therapy Oncology Group 
 
Other covariates behaved in expected ways; for example, in younger women (Table 
11), greater co-morbidity burden was associated with lower odds of RT, receiving 
chemotherapy during the time interval of interest was associated with lower odds of 
concurrent RT, married women had higher odds of receiving RT, low income status was 
associated with lower odds of RT, and living in a zip code with a more highly educated 
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population was associated with higher odds of initiating RT earlier.  Notably, women 
younger than 70 who received surgery in the same month as diagnosis had higher odds of 
rapid progression to radiation therapy, and women with more advanced stage disease, ER-
positive tumors, and/or node-positive tumors were less likely to initiate RT within each time 
period, presumably due to receipt of chemotherapy in these intervals.  Interestingly, the 
odds of receiving guideline-appropriate RT after BCS in the absence of subsequent 
mastectomy at each time interval decreased slightly with increasing year of diagnosis 
starting in 1997, whereas overall receipt of RT in the full sample (indicated by the “Ever” 
model, column 7) increased over time.  Co-morbidities in the older sub-population (Table 12) 
played a larger role in determining receipt of RT; the odds of initiating RT at each time 
interval decreased significantly with each increasing level of co-morbidity burden. Notably, 
the effect of rural residence was more potent in this older population, decreasing the 
likelihood of receiving RT in general, although the effect did not always attain statistical 
significance.  Behavior of other covariates was similar to that in models of younger women. 
 
Discussion 
 This study examined 38,000 women with breast cancer in SEER-Medicare data to 
understand health care structural and organizational characteristics and their association 
with racial/ethnic differences in receipt of high quality cancer treatment.  Previous, mostly 
cross-sectional, studies on age- and race/ethnicity-related disparities in breast cancer 
provide interesting descriptive data, but are limited in their ability to provide insights into how 
the health care system or health policies may improve quality of care for breast cancer 
patients.  By focusing only on Medicare beneficiaries in the current study, access to 
insurance coverage was effectively controlled.  Accordingly, we were able to explore 
whether characteristics of the health system itself potentially could be used to narrow 
differences in quality of care, and since all patients in our study had insurance provided by 
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the same payer, the role of this important factor in determining treatment was limited.   In 
this study, structural/organizational characteristics of health services, specifically surgical 
facility type/ownership, size, presence of on-site radiation, and distance to RT providers, 
were associated with variation in receipt of RT and timing of initiation of RT.  To some 
extent, these factors also played a role in racial/ethnic variation in treatment, but they did not 
fully account for racial/ethnic disparities in receipt of high quality care.  In this study, 
disparities in treatment by race/ethnicity, especially among black women, persisted even 
when controlling for biological features of the tumor, socioeconomic status, co-morbidity, 
marital status, rural/urban residence, year of diagnosis, and insurance status, in addition to 
structural/organizational health services characteristics.  As well, receipt of RT varied 
significantly by age group, and distance to care and surgical facility characteristics played a 
greater role in determining overall receipt of RT and timing of initiation of RT among women 
ages 70 and older.  Disparities between Hispanic women and non-Hispanic white women 
disappeared with older age, whereas disparities in treatment between non-Hispanic black 
and non-Hispanic white women were apparent in both older and younger age groups.   
With respect to the effects of structural and organizational variables, it is clear from 
these data that several characteristics of surgical providers, including type/ownership, 
presence of on-site radiation services, and size of the surgical facility, are informative in 
predicting receipt and timing of initiation of RT after BCS.  ACoSOG affiliation, NCI 
Comprehensive Cancer designation, and teaching status of the surgical facility, on the other 
hand, were not as informative, in contrast to studies that have found institutional affiliations 
and teaching status to be predictive of treatment quality and health outcomes in the absence 
of other structural and organizational variables (Jerome-D’Emila and Begun, 2005; Laliberte 
et al., 2005; Onega et al., 2009; Chaudry et al., 2001).  Structural/organizational factors did 
not appear to modify the effects of race/ethnicity, a finding that may be explained by SEER 
sampling.  Specifically, although the SEER-Medicare data were designed to reflect diverse 
 91 
geographic communities and racial/ethnic groups (Warren et al., 2002c) they do not 
necessarily reflect racial/ethnic diversity across different types of geographic communities.  
For example, the majority of black women in the SEER-Medicare dataset live in metropolitan 
areas (e.g., Detroit and Atlanta), whereas the majority of Hispanic women in SEER-
Medicare live in certain states (e.g., New Mexico and California).  As such, the bivariate 
findings by race/ethnicity and heath system characteristics in Table 9 (e.g., black women are 
more likely to receive surgery at a teaching/academic health center and/or a NCI 
Comprehensive Cancer Center) may be explained by the fact that black women in SEER-
Medicare are more likely to live in urban areas, where larger hospitals exist.  It is therefore 
difficult to extend findings from SEER-Medicare to the experiences of rural-dwelling black 
and Hispanic women.   
To a lesser extent, increasing distance to radiation providers was associated with 
lower overall receipt of RT and lower odds of initiation of RT within 1 year, although this 
effect was not consistently statistically significant.  This lack of consistent statistical 
significance may be due to the fact that the majority of people in this study lived within 3 
miles of a radiation therapy provider (mean: 2.75; median: 0.16), again perhaps reflective of 
the more urban sampling scheme.  Straight-line distance to care using zip-to-zip centroids, 
although not the absolute best proxy for geographic access, has been shown to be a highly 
correlated with travel time and by extension transportation burden (Phibbs and Luft, 1995), 
and in this study was found to be more important among older women 70 years and older 
(Table 12).  Transportation burden and geographic access to care have been shown to be 
problematic for elderly women seeking health care in other studies (Punglia et al., 2006a; 
Mobley et al., 2006; Mobley et al., 2009).  On the other hand, the trend line depicting receipt 
of RT over time by distance traveled to surgery (Figure 12) suggested that women who 
received surgery within their own zip codes fared less well, a finding that may be logical if 
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women bypass local providers to seek a surgeon at a higher quality health facility, but this 
effect generally was shown to be non-statistically significant in multivariate models.   
Our overall finding that receipt of RT remains sub-optimal is in line with much of the 
literature in this area (Smith et al., 2010; Hershman et al., 2008; Haggstrom et al., 2005; 
Gross et al., 2008; Edwards et al., 2005).  Indeed, consistent with our findings, Freedman 
and colleagues (2009) have shown that although mastectomy rates have decreased over 
time, presumably in favor of BCS, overall definitive therapy (receipt of BCS plus RT or 
mastectomy) has decreased as well.  We observed that the time horizon of follow-up and 
consideration of subsequent mastectomy are important parameters in examination of 
treatment quality.  Many women delay initiation of RT for clinically meaningful reasons, such 
as receiving another anti-cancer regimen like adjuvant chemotherapy; as well, many women 
who received BCS initially subsequently get mastectomy due to positive margins, 
recurrence, or other clinically valid reasons, thereby obviating the necessity of RT.  
Assessment of adherence to RT guidelines for breast cancer may be underestimated if 
timing of receipt of RT and the possibility of subsequent mastectomy after BCS are not 
taken into account.  It is largely unclear whether previous analyses have considered this 
possibility, with the exception of one study using North Carolina cancer registry and 
Medicare data, which found significant changes in results related to adherence to radiation 
therapy guidelines depending on the time period examined and whether follow-up 
mastectomy was taken into account (Weiner et. al., 2009).   
One of the strengths of our study is the examination of initiation of RT at different 
time intervals.  The time interval of one year specified in the ASCO/NCCN quality metric 
may be somewhat lenient, in light of studies that have shown improved outcomes with 
earlier initiation of RT (Gold et al., 2008; Hershman et al., 2006b; Hebert-Croteau et al., 
2004).  The ASCO/NCCN panels relaxed the timing component of the denominator to allow 
for administration and sequencing of multiple anticancer treatments.  However, given the 
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controversy over the optimal timing of initiation of RT, and considering that we have shown 
significant racial/ethnic differences in timing of initiation of RT, it may be that earlier initiation 
of RT is particularly important for vulnerable breast cancer patients (e.g., black women with 
hormone receptor negative, advanced stage disease).   
The relationships between age, adjuvant therapy, and clinical guideline development 
are complex and somewhat controversial.  An important study published in 2004 in the New 
England Journal of Medicine showed that among women 70 years and older with stage I, 
estrogen-receptor positive breast cancer, RT could be safely omitted after lumpectomy when 
women were receiving tamoxifen (Hughes et al., 2004).  The only significant difference 
between groups in which women received RT plus tamoxifen or tamoxifen only was an 
increased risk of local or regional recurrence at 5 years in the group that did not receive RT; 
no differences were found in survival, distant metastases, or rates of mastectomy for local 
recurrence (Hughes et al., 2004).  Although these findings were published after the time 
interval examined in our study and as such, did not affect clinical guidelines we examined, 
preliminary results from this trial were likely presented prior to publication, and providers 
who knew about or participated in the much-anticipated trial may have changed their 
approaches to treating older women with early, ER-positive breast cancer.  It is difficult to 
determine what the impact of this study might have been, how far-reaching its influence 
was, and whether responses to this study, if they existed at the time, varied by institutions 
and racial/ethnic groups across institutions; nevertheless, it is important to consider that 
practice patterns may have begun to change in light of new evidence seemingly in conflict 
with clinical guidelines. 
This study is accompanied by several limitations in addition to the generalizability 
issues associated with use of the SEER-Medicare dataset highlighted previously.  Namely, 
these data do not contain information about hormonal therapy, an important anti-cancer 
therapeutic option which may affect treatment planning (Warren et al., 2002c).  These data 
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also are limited to patients ages 65 and older who are not enrolled in Medicare managed 
care plans; we would expect younger women and those enrolled in managed care plans to 
be healthier, and thus, treatment experiences may be different.  The risks of possible 
misclassification of claims and/or errors in reporting and billing are certainly existent, 
although such misclassification if it exists should be random and therefore should not affect 
study findings.  Another issue related to measurement is the lack of month/day/year date of 
diagnosis; SEER provides only month and year of diagnosis, leading to potential imprecision 
in date classifications.  For example a woman diagnosed on the last day of the month and 
receiving first primary surgery on the first day of the next month is classified as having 
received surgery one month after diagnosis.  Possible omitted variables include more 
precise measures of individual socioeconomic status, and supplemental private health 
insurance.  We have tried to account for these factors in the absence of good data about 
individual wealth, income, education, and unmeasured access to additional health care 
financing by including measures for State-Buy-In (a proxy for low income status and 
Medicaid dual enrollment) and neighborhood (zip-code level) education, income, and 
racial/ethnic composition as a measure of local social support (Mobley et al., 2009).  Other 
possible unmeasured factors at work are patient health seeking behavior, trust in the health 
care system, and provider intent; we cannot determine from these data whether women 
were referred to radiation oncologists and did not attend appointments or were never 
referred at all.  As an example, in adjusted models of women under the age of 70, the 
disparity between black and white women in timing of initiation of RT was significant at each 
time interval up to 6 months and non-significant at 1 year and for overall receipt. One 
possible explanation for this difference in early initiation is that black women delay initiation 
of RT because they more often seek second opinions or because health care providers are 
not initially convinced that an unmarried, older black woman has the social support to 
successfully complete treatment (on the contrary, many would argue that black women have 
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very rich social support networks extending beyond that of a married partner).  
Unfortunately, we cannot measure intentions of or intermediary discussions with health 
providers, only the outcome of interest – did women receive RT or not?  Future studies 
could employ the use of chart reviews or qualitative interviews to better understand the 
nuances of the decision making process around treatment. 
We have shown that racial/ethnic minority groups and elderly women who received 
BCS initiated radiation therapy later than other women and that structural and organizational 
health services factors explained part but not all differences observed in adjuvant treatment.  
Characteristics of the surgical facility where women receive breast conserving surgery 
(including presence of on-site radiation services, type/ownership, and size) were informative 
in predicting timing of subsequent initiation of RT, and for women older than 70 years, 
distance to radiation providers may present an additional burden to seeking care.  In terms 
of implications of this work, interventions that target facilities performing less well as a group 
may be warranted.  On the other hand, since we have shown that distance to RT providers 
may influence overall receipt of RT and initiation of RT within 1 year, interventions that offer 
transportation options for older women may lead to better uptake of RT, among women 
healthy enough to undergo treatment.  Recognizing the importance of such health system 
level variables in the context of significant sub-population variation in breast cancer 
treatment quality may help policymakers, clinicians, and other stakeholders better identify 
women at risk for poor quality care and may inspire more creative inclusion strategies for 
community-based programs and clinical trial investigations. 
CHAPTER 5:  EFFECT OF STRUCTURAL/ORGANIZATIONAL CHARACTERISTICS OF 
HEALTH SERVICES ON RACIAL/ETHNIC AND AGE-RELATED DISPARITIES IN THE 
TIMELY RECEIPT OF CHEMOTHERAPY IN BREAST CANCER PATIENTS 
 
Abstract 
Purpose 
To explore whether factors related to the health care system help explain a portion of 
extant disparities in breast cancer care quality, we retrospectively examined the 
relationships between race/ethnicity, age, and structural/organizational characteristics of 
oncology providers in terms of (1) use of adjuvant chemotherapy over time and (2) 
differences in timing of initiation of adjuvant chemotherapy.  The primary outcome of interest 
was postoperative receipt of adjuvant chemotherapy for stage II and III breast cancers. 
 
Methods 
This study was a retrospective analysis of secondary data collected for ongoing 
surveillance and billing/administrative reasons.  Female Medicare beneficiaries ages 65 and 
older living in Surveillance Epidemiology and End Results (SEER) registry regions were the 
focus of this study.  Women whose first or only cancer diagnosis was primary breast cancer 
in 1994-2002, with Medicare claims through 2003, who had received surgery (lumpectomy 
or mastectomy) were included.  Women with in situ and metastatic (stage IV) cancers were 
excluded, as were women receiving neoadjuvant chemotherapy and women with end stage 
renal disease.  This study was limited to non-Hispanic white, non-Hispanic black, and 
Hispanic patients.  Timing of initiation of chemotherapy was measured as a binary variable 
indicating whether the patient initiated chemotherapy within several time intervals post-
diagnosis.  Diffusion curves were used to describe trends in receipt of adjuvant
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chemotherapy across sub-populations over time, and multivariate logistic regression, 
stratified by hormone receptor status and age group, was employed to examine the potential 
role of structural/organizational characteristics of health services, including size, ownership, 
teaching status, National Cancer Institute (NCI) Cancer Center designation, and American 
College of Surgeons Oncology Group (ACoSOG) affiliations of the surgical providers, and 
distance to care, in explaining differences in treatment, controlling for known covariates.   
 
Results 
The study included 20,898 women who met inclusion/exclusion criteria, of whom 8% 
were non-Hispanic black and approximately 4% were Hispanic.  In total, 68% of women 
(14,220) were hormone receptor positive, of whom 98% were estrogen receptor (ER) 
positive and 79% were progesterone receptor (PR) positive, leaving 6,678 women who were 
neither ER nor PR positive.  Receipt of adjuvant chemotherapy increased significantly from 
1994-2002, with approximately 24% of all women diagnosed in 1994 receiving adjuvant 
chemotherapy compared with 45% of all women diagnosed in 2002.  Receipt of adjuvant 
chemotherapy and timing of initiation differed by age group, hormone receptor status, and to 
a lesser extent by race/ethnicity.  In bivariate analyses, black women were more likely to 
receive surgery at an NCI-designated Comprehensive Cancer Center (p<0.001), an 
academic or teaching facility (p<0.001), an ACoSOG-affiliated facility (p<0.001), or larger 
hospitals (p<0.001), and black women lived closest to chemotherapy providers (p<0.001); 
Hispanic women were more likely to be treated at for-profit health care facilities and resided 
furthest away from a chemotherapy provider (p<0.001).  Inclusion of health services-related 
structural/organizational variables in multivariate models offered little explanatory insight for 
differences in receipt or timing of initiation of adjuvant chemotherapy. 
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Conclusions 
Although use of adjuvant chemotherapy generally has increased over time, 
substantial variation in uptake exists, and overall use remains low in stage II and III, 
hormone receptor negative patients despite the existence of clinical guidelines encouraging 
its use.  Given the complexity of decision making processes around systemic therapy and 
recognizing the long-term benefit of chemotherapy in hormone receptor negative patients, 
public health interventions should seek to identify women potentially at risk for under-
treatment, including the healthy elderly, the poor, and vulnerable minority groups, and to 
increase access to information about the risks and benefits of adjuvant chemotherapy 
among both patients and clinicians.  
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Introduction 
Poorer outcomes in breast cancer among vulnerable sub-populations, including 
elderly women and racial/ethnic minorities, are well documented (Edwards et al., 2005; Lund 
et al., 2008) and may be due to variation in quality of breast cancer treatment and 
differential adoption of treatment guidelines across sub-populations.  As evidence has 
accumulated over time, clinical guidelines in breast cancer have evolved accordingly.  Since 
1990, National Institutes of Health (NIH) consensus statements have encouraged the use of 
adjuvant chemotherapy to prevent breast cancer recurrence.  In 1996, the National 
Comprehensive Cancer Network (NCCN) modified guidelines to read that all invasive breast 
cancer patients with node positive disease and/or tumor sizes larger than 1cm should 
receive multicycle adjuvant cytotoxic poly-chemotherapy (Carlson et al., 1996).  In 2000, 
NIH revised its guidelines to read that all patients younger than 70 with invasive cancers 
larger than 1cm (any lymph nodal status or hormone receptor status) should receive 
adjuvant poly-chemotherapy, unless the patient refuses.  In more recent years, a 
combination of increased use of hormone receptor testing, development of new adjuvant 
endocrine therapy options, and improved understanding of the role of adjuvant 
chemotherapy in hormone receptor positive patients has led to a more refined view, with 
clear guidelines for use of adjuvant chemotherapy in hormone receptor negative patients 
and case-by-case consideration of adjuvant chemotherapy in hormone receptor positive 
patients.  For stage II-III, hormone receptor negative tumors, however, adjuvant 
chemotherapy essentially has been advised since the early 1990s, and as such, the 
American Society for Clinical Oncology (ASCO) and NCCN recently created a quality metric 
to help monitor and to further encourage its use (Desch et al., 2008).   
Translating evidence into practice is not always as straightforward as it would seem 
(Davis et al., 2003; Gold and Taylor, 2007; Shiffman et al., 2004; Waitman and Miller, 2004).  
Indeed, there are many barriers to adoption of evidence-based guidelines, including poor 
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dissemination systems, provider resistance or lack of awareness of new evidence, the 
fragmented nature of the health care financing system, lack of effective monitoring, and lack 
of incentives to change practices (Davis et al., 2003; Grol, 2001; McGlynn et al., 2003).  
Previous studies have demonstrated that black women, more often than other women with 
the same stage disease, fail to receive adjuvant treatment for breast cancer (Bradley, Given, 
and Roberts, 2001; O’Malley et al., 2001; Shavers and Brown, 2002).  Several descriptive 
studies have examined receipt of adjuvant chemotherapy by race/ethnicity among breast 
cancer patients and found that black and Hispanic women are substantially less likely to 
receive appropriate care, even after controlling for insurance status, socioeconomic status, 
age, and co-morbidities (Banerjee et al., 2007; Bhargava and Du, 2009; Bickell et al., 2006).  
Most evidence suggests that when women across racial/ethnic groups receive equal 
treatment, equal outcomes follow (Dignam et al., 1997; Roach et al., 1997; Yood et al., 
1999).  However, one clinical trial limited to patients with metastatic breast cancer showed 
that even with identical treatment and controlling for clinicopathologic features (including 
estrogen receptor status), health disparities between black and white women in terms of 
survival persisted (Polite et al., 2008).  This trial also demonstrated, as other studies have, 
that black patients were at no greater risk for chemotherapy-related hematologic toxicity 
than white patients and that patterns of tumor response were similar for black and white 
women with clinically equivalent disease (Polite et al., 2008; Newman et al., 2003; Smith et 
al., 2005).  The authors therefore concluded that differences in co-morbidity and/or receipt of 
subsequent adjuvant treatment may have explained the difference in survival between 
blacks and whites (Polite et al., 2008). 
Age and breast cancer are closely and meaningfully related (Vogel, 2008).  The 
majority of breast cancer diagnoses occur in women older than 60; breast cancer incidence 
rises dramatically and non-linearly with age, a striking trend which is explained biologically 
by the important role of reproductive factors and ovarian estrogens in breast cancer etiology 
 101 
(Colditz, Baer, and Tamimi, 2006).  In the past, clinical trials exploring use of adjuvant 
chemotherapy often failed to recruit enough women older than 70 years to have sufficient 
power to report benefits and risks of chemotherapy in older women; as a result, many 
clinical guidelines and the ASCO/NCCN quality metrics were limited to women younger than 
70 (Desch et al., 2008).  However, many experts agree that such an age-specification sets a 
low bar for quality, given observational evidence showing that women older than 70 benefit 
as much as younger women from chemotherapy (Wildiers and Brain, 2005).  Moreover, a 
randomized trial published recently showed that women older than 70 treated less 
aggressively with chemotherapy fared worse (Muss, 2009).   
In light of this evidence, it is critically important that the health system itself is 
designed in such a way that all women have access to life-prolonging cancer treatments, 
regardless of race/ethnicity, age, or socioeconomic status.  Certain types of health services, 
such as National Cancer Institute (NCI)-designated Cancer Centers, may be distributed 
unevenly across racial/ethnic and elderly sub-populations, and access to care, including 
distance to healthcare, also may vary across sub-populations.  However, it is unclear 
whether such factors affect timely receipt of high quality breast cancer care and subsequent 
outcomes.  Additionally, it is unclear whether evidence-based treatment practices diffuse 
more slowly within certain sub-populations over time (Groeneveld et al., 2005).  The 
interactive effects of structural/organizational characteristics of health services and high 
quality care have been explored in literatures of other diseases (Bach et al., 2004; 
Birkmeyer et al., 2005; Gooden et al., 2008; Groeneveld et al., 2005; Morris et al., 2008; 
Talcott et al., 2007).  The relationships between health system variables, race/ethnicity, and 
age have been explored much less systematically and comprehensively in the breast cancer 
treatment literature.  One study conducted in North Carolina among Medicaid beneficiaries 
showed that poor quality breast cancer care was related to older age, living in a low-
population density county, receiving surgery at a smaller hospital, and living in a low-
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specialist density county (Anderson et al., 2008).  In a different study examining receipt of 
radiation therapy, after controlling for health system characteristics (hospital teaching status, 
regional specialist supply, and surgical volume), race/ethnicity was no longer significantly 
predictive of treatment quality (Jerome-D’Emilia and Begun, 2005).  We therefore aimed to 
expand upon existing work in this area by examining trends in receipt and timing of initiation 
of adjuvant chemotherapy over a ten-year period and by determining whether differences in 
structural/organizational characteristics of health services, including distance to care and 
institutional affiliations, explained a portion of existing disparities in treatment.   
 
Methods 
Data Source and Patient Population 
The linked Surveillance, Epidemiology and End Results (SEER)-Medicare dataset 
was used in the current study and included breast cancer cases diagnosed in 1994-2002.  
The SEER program was designed by the NCI to be an epidemiologic surveillance system for 
incident cancers and covers 26% of the US population (Warren et al., 2002c).  Part A 
(inpatient care, skilled nursing facilities, home health, and hospice care) and Part B 
(outpatient care, durable medical equipment, and physician services) claims were linked to 
individuals with first or only primary breast cancers identified by SEER registrars among 
patients enrolled in Medicare (Warren et al., 2002).  Clinical and socio-demographic 
information for the study was taken from the Patient Entitlement and Diagnosis Summary 
File (PEDSF), whereas cancer treatment information, co-morbidities, and 
structural/organizational variables for health service providers were provided in the Medicare 
claims (Warren et al., 2002c).   
To be included in this study, women must have been continuously enrolled in 
Medicare parts A and B fee-for-service during the one-year period prior to diagnosis and at 
least one year post-diagnosis, or until death, whichever occurred first.  Our study was limited 
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in scope to non-Hispanic white, non-Hispanic black, and Hispanic patients, due to concerns 
about insufficient numbers of other racial/ethnic groups for sub-group analyses.  Men were 
excluded, as were women younger than 65 and women who had end stage renal disease 
(ESRD).  In situ and metastatic (stage IV) cases were excluded, as were cases diagnosed at 
death or autopsy.  Only women who received primary surgery (defined as breast conserving 
surgery or aggressive surgery/mastectomy) as the first anti-cancer treatment were included; 
as such, patients receiving neoadjuvant chemotherapy prior to surgery were excluded.  
Because care-seeking behavior may be different among individuals previously diagnosed 
with breast cancer, women with prior histories of breast cancer were excluded.  Finally, in 
cases of multiple primary tumors, to eliminate any confusion about which cancer-directed 
treatments were targeted to which cancer, women with additional cancer diagnoses within 
one year of the index breast cancer diagnosis were excluded.  The effects of these 
inclusion/exclusion criteria on overall sample size are summarized in Figure 14.   
 
Dependent Variable 
Initiation of post-operative adjuvant chemotherapy was examined as a binary 
indicator of any chemotherapy use and initiation of chemotherapy during several specified 
time periods.  The ASCO/NCCN quality metric specifies that patients with stage II-III, 
hormone receptor negative breast cancer must begin adjuvant chemotherapy within four 
months of diagnosis, but completion of a full recommended course is not part of the metric 
(Desch et al., 2008).  Although incomplete use of chemotherapy may have implications for 
treatment efficacy, chemotherapeutic regimens used may vary across patients, leading to 
clinically appropriate variation in dosage, timing of cycles, and administration.  Adherence to 
recommended chemotherapy schedules over time therefore cannot be assessed easily.  
The four month time allowance specified in the metric was intended to provide sufficient time 
for surgery and medical consultation, but may be overly lenient.  As such, additional time 
 104 
intervals (1-3 months) were examined to detect differences in timing of initiation of adjuvant 
chemotherapy.   
Figure 14: Sample size diagram based on inclusion/exclusion criteria 
First or only primary breast cancer cases from SEER areas diagnosed in 1994+, female only, N=254,803
INCLUDED EXCLUDED
65 or older
White, black, or Hispanic
Invasive cancer (stage I-IV)
N= 128,895
Original reason for entitlement is 
ESRD; diagnosed at autopsy or 
death; stage is in situ or missing
N= 125,908
Enrolled in Medicare HMO or 
lapse in parts A & B Medicare 
coverage
N= 44,376
No current ESRD diagnosis
N= 84,242
Has current ESRD
N= 277
Continuous parts A & B Medicare 
coverage 12 mos pre/post 
diagnosis
N= 84,519
No surgery
N= 1,395
Diagnosed in 1994-2002
N= 54,524
Stage IV disease
N= 5,070
Received surgery
N= 53,129
Stage I-III disease only
N= 79,172
Diagnosed in 2003 or later
N= 24,648
Additional cancer diagnosis in 1yr
N= 2,524
Cancer treatments (claims) found 
before diagnosis
N= 1,776
No additional cancer in 1yr
N= 48,829
No cancer treatments (claims) 
found before diagnosis
N= 51,353
Got neoadjuvant chemotherapy
N= 551
Stage I disease
N= 27,380
No neoadjuvant chemotherapy
N= 20,898
Stage II or III disease only
N= 21,449
 
Notes: SEER: Surveillance, Epidemiology and End Results; ESRD: End Stage Renal Disease; HMO: 
Health Maintenance Organization 
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As well, although the ASCO/NCCN quality metric is limited to hormone receptor 
negative patients, reflecting more recent evidence about the limitations of chemotherapy in 
hormone receptor positive patients (Desch et al., 2008), clinical guidelines in the early 1990s 
encouraged the use of chemotherapy based on size of the tumor regardless of hormone 
receptor status (and indeed before the proliferation of hormone receptor testing).  Therefore, 
for exploratory purposes, we also examined trends in use of chemotherapy among hormone 
receptor positive patients during a time period when guidelines were changing with respect 
to hormone receptor status. 
Because women receive chemotherapy from various types of facilities, multiple files 
were examined in order to fully capture the therapeutic experiences of women, including the 
MEDPAR (inpatient), carrier claims, outpatient, and durable medical equipment (DME) files 
(i.e., some oral chemotherapy agents may be found in the DME file) (Virnig et al., 2002).  
Identification of breast cancer-related therapy has been discussed at length elsewhere 
(Cooper et al., 2002; Lamont et al., 2002; Virnig et al., 2002; Warren et al., 2002b).  Based 
upon previous analyses and consultation with clinical and billing specialists, we identified 
relevant codes for this analysis from the Healthcare Common Procedure Classification 
System (HCPCS), the International Statistical Classification of Diseases and Related Health 
Problems, 9th revision, clinical modification (ICD-9-CM), and National Drug Codes (NDC), 
the latter of which have been used in DME files to classify chemotherapy drugs.  Diagnostic, 
procedural, and drug codes used in this analysis are summarized in Table 13, excepting the 
numerous drug-specific NDC codes that were included in searches of the DME claims 
(codes available upon request). 
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Table 13: Identification of surgery and chemotherapy in Medicare claims 
Treatment Primary means of identification 
Diagnostic codes  ICD-9-CM  diagnosis codes:  174.0, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9 
Other:  V10.3 
Aggressive surgery ICD-9-CM procedure: 85.41, 85.42, 85.43, 85.44, 85.45, 85.46, 85.47, 85.48 
CPT/HCPCS: 19180, 19182, 19200, 19220, 19240, 19260-19272, 19303-19307 
Breast conserving 
surgery 
ICD-9-CM procedure:  85.20, 85.21, 85.22, 85.23, 85.24, 85.25  
CPT/HCPCS: 19120, 19125, 19126, 19160, 19162, 19301, 19302 
Chemotherapy ICD-9-CM procedure:  99.25, 285.3, 999.81 
CPT/HCPCS: 51720, 96400-96549, 99555, Q0083-Q0085 (oral), C9127, C9415, C9420, 
C9421, C9431, C8953-C8955, S9329-S9331, G0355, G0357-G0363, G9021-G9032, 
J8510, J8520, J8521, J8530-J8999 (oral), J9000-J9999 (IV)  
Revenue Center Code: 0331, 0332, 0335 
DRG: 410, 492 
Other: V58.1, V58.11, V66.2, V67.2, V87.41, NDC codes 
Notes: CPT: Current Procedural Terminology; DRG: Diagnostic Related Group HCPCS: Healthcare 
Common Procedure Classification System; ICD-9-CM: International Statistical Classification of 
Diseases and Related Health Problems, 9th revision, clinical modification; NDC: National Drug Code  
 
Independent Variables of Interest 
Structural/organizational characteristics of oncologic health services included 
characteristics of the surgical facility women attended and distance to providers.  
Specifically, surgical facility type/ownership, bed size, teaching status, NCI Cancer Center 
designation and American College of Surgeons Oncology Group (ACoSOG) affiliation were 
available in the SEER-Medicare data.  ACoSOG membership is believed to be a proxy for 
organizational clinical expertise in the absence of information about Commission on Cancer 
(CoC) accreditation, which is not available in the SEER-Medicare data; in general, most 
ACoSOG hospitals are CoC accredited.  Distance to providers (distance traveled for surgery 
and distance to nearest chemotherapy provider) was calculated using zip code centroid to 
zip code centroid minimum distance algorithms (Meden et al., 2002; Nattinger et al., 2001; 
Schroen et al., 2005; Shea et al., 2008).  Specifically, distances were determined by 
assigning spatial coordinates (latitudes and longitudes) to 5 digit ZIP codes and using 
spherical geometry to calculate distances between points. Nearest facility analysis was 
performed by executing a Cartesian product of all patients and providers, calculating, all 
distances by the above method, and selecting the minimum distance for each patient.   
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Race/ethnicity was defined as non-Hispanic white, non-Hispanic black, and Hispanic, 
according to SEER registry definitions which are believed to be more accurate than 
Medicare assessment of race/ethnicity (Bach et al., 2002).  Age was also an important 
patient-level attribute of interest.  Due to major differences in age-specific guidelines and 
practicing patterns reflecting aforementioned lack of information about the effects of 
adjuvant chemotherapy in women 70 years and older, we stratified analyses by age group 
(65-69 years old versus 70 years and older) and included age as a categorical independent 
variable in the models of women 70 years and older. 
 
Control Variables 
Extensive review of the breast cancer literature revealed that several potentially 
confounding variables must be considered in any analysis of patient treatment and 
outcomes.  Tumor biology, for example, influences clinician decision making and suitability 
of the patient for therapeutic treatment (Andre and Puztai, 2006; NCCN, 2008).  As such, 
features of tumor biology, including stage of disease and histologic grade, as reported by 
SEER registrars were included categorically in analytic models.   
Social support has been shown to influence receipt of and adherence to anti-cancer 
therapeutic regimens (Banerjee et al., 2007).  Due to limitations in using registry-based 
claims data, social/familial support could be obtained only by examining marital status, so a 
categorical indicator for marriage status was included in analytic models.  Additionally, we 
included a measure of neighborhood racial and ethnic cohesion, measured by assessing 
proportions of white, black, and Hispanic residents within the zip code of residence (Haas et 
al., 2008; Schootman et al., 2009).   
Socioeconomic status, which is related to race/ethnicity and access to healthcare 
(Bao et al., 2007; Bharghava and Du, 2009), was considered by including a variable for 
indication of any State-Buy-In months within a one-year period (an indicator for Medicaid 
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enrollment, but more accurately, low-income status) (Bach et al., 2002).  We also included 
measures of neighborhood socioeconomic context by including in analytic models zip code 
area median income and proportion of residents with less than a high school education.   
Presence of a serious co-morbidity may affect cancer care planning (Du et al., 2008; 
Tammemagi et al., 2005), and co-morbidity burden generally increases with age.  As well, 
black women may be at greater risk for co-morbid disease than white women (Banerjee et 
al., 2007).  As such, co-morbidities were assessed using the NCI combined index method 
described by Klabunde and colleagues (2007), which uses breast cancer specific weighted 
co-morbidity scores for conditions identified by Charlson as important predictors of mortality.   
Based upon diagnostic codes identified in either the inpatient or physician claims during the 
12 month period prior to cancer diagnosis, the NCI combined index has been shown to be a 
better predictor of non-cancer mortality among breast cancer survivors than other commonly 
used co-morbidity measures (Klabunde et al., 2007).   
Finally, year of diagnosis dummy variables were included as covariates to adjust for 
cohort effects and secular changes in healthcare policies and practices over time.   
 
Statistical Analysis 
Receipt of adjuvant chemotherapy within several specified time frames was 
examined descriptively and modeled analytically using multivariate logistic regression.  
Diffusion curves (Rogers, 1995a) comparing proportions of sub-populations (by age group, 
race/ethnicity, and patients using health services with certain structural/organizational health 
services characteristics) receiving adjuvant chemotherapy by year were constructed and 
evaluated using chi-squared tests (Chernoff and Lehmann, 1954; Pagano and Gauvreau, 
2000).  The overall timing of initiation of chemotherapy by month among racial/ethnic groups 
was determined, and bivariate analyses compared receipt of chemotherapy and distribution 
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of structural/organizational factors by racial/ethnic group and age group, using chi-squared 
tests (Chernoff and Lehmann, 1954; Pagano and Gauvreau, 2000).  
As anticipated, major differences in chemotherapy use were observed according to 
hormone receptor status and age; as such, all multivariate logit models were stratified 
according to age-group (<70 years versus 70 years and older) and hormone receptor status 
(ER and/or PR positive versus not) to reflect distinct treatment patterns in these different 
groups.  In building analytic multivariate logit models, modifying or confounding power of key 
structural and organizational variables was explored (Hosmer and Lemeshow, 2000; Mickey 
and Greenland, 1989; Rothman et al., 2008).  A 10%-change in the effect of race/ethnicity 
on receipt of adjuvant chemotherapy was used as a threshold for modification and 
confounding, and Wald tests with a p-value threshold of 0.05 were examined for predictive 
potential of structural and organizational variables (Mickey and Greenland, 1989).  
Interactions of race/ethnicity and time and race/ethnicity and age were of interest, allowing 
us to examine whether trends in chemotherapy varied by race/ethnicity over time or with age 
(Groeneveld et al., 2005).  However, exploratory analyses showed that interactions terms 
were jointly non-significant and did not modify the main effect of race/ethnicity; therefore, 
these terms were omitted from final models.   
Given evidence of regional variation in breast cancer treatment and outcomes 
(Bettencourt et al., 2007; Canto et al., 2001), we also tested the confounding potential of 
rural/urban residence and SEER registry region.  These variables were measured 
categorically, with rurality/urbanicity defined as:  metropolitan (250,000+ per county), urban 
(2,500-250,000 per county), and rural areas (<2500 per county) from the source geographic 
cancer registry (Gorin et al., 2005).  Due to the lack of predictive and confounding power of 
these regional/geographic variables across models, final models omitted rural/urban 
residence and SEER region as covariates. 
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Additional tests were employed to determine the most appropriate variable 
specification for the final analytic models (e.g., use of the continuous versus categorical 
forms of co-morbidity index score) (Rothman et al., 2008; Wooldridge, 2006).  Corrected 
Huber-White standard errors were reported for all regressions, and tests for multicollinearity 
among variables were conducted (Wooldridge, 2006).  The general form for the logit model 
used in this analysis is: 
 
Pr(Chemoi) = f(β0 + β1Race/Ethnicityi + β2Structi + β3Timei + γZi+ εi) 
 
where “Chemo” is chemotherapy, “Race/Ethnicity” is non-Hispanic white, non-
Hispanic black, or Hispanic, “Struct” is a vector of health services 
structural/organizational variables, “Time” is year of diagnosis, “Z” is a vector of all 
other patient and community control variables, and “ε” is the error term. 
 
Results 
After applying inclusion/exclusion criteria to the population of women in SEER-
Medicare diagnosed with incident breast cancer in 1994-2002, 20,898 women were included 
in the current study. Descriptive characteristics of the sample are summarized in Table 14 
by age group and race/ethnicity.  Approximately 8% of women were identified as non-
Hispanic black, and 4% were identified as Hispanic; the rest were non-Hispanic white.  The 
median age at diagnosis was 76.6 years.  In total, 68% of women (14,220) were endocrine 
receptor positive, of whom 98% (13,915) were estrogen receptor (ER) positive and 79% 
(11,215) were progesterone receptor (PR) positive leaving 6,678 women who were neither 
ER nor PR positive.  Black women less often had hormone receptor positive tumors, were 
more likely to have been diagnosed with stage III disease, and had greater co-morbidity 
burden.  In addition, black women were least likely to be married, and black and Hispanic 
women were more likely to be identified as low income (Table 14).   
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Table 14: Descriptive statistics of full patient sample meeting inclusion criteria 
 
 
Characteristic 
% or 
mean  
(N=20,898) 
% or 
mean 
(N=3360) 
% or 
mean 
(N=336) 
% or 
mean 
(N=193) 
% or 
mean 
(N=15102) 
% or 
mean 
(N=1260) 
% or 
mean 
(N=647) 
 
OVERALL 
< 70 
years, 
White 
< 70 
years, 
Black 
< 70 
years, 
Hispanic 
>/= 70 
years, 
White 
>/= 70 
years, 
Black 
>/= 70 
years, 
Hispanic 
Patient/demographic characteristics 
Age at diagnosis 76.6 67.46 67.33 67.44 78.72 78.54 78.01 
Married 38.5% 58.6% 30.1% 50.8% 35.9% 21.5% 29.2% 
Low income 21.6% 14.0% 47.0% 53.9% 18.5% 50.3% 53.8% 
Patient residence 
    Metro  
    Urban  
    Rural 
       
83.8% 81.9% 89.9% 88.1% 83.1% 93.5% 88.4% 
14.3% 16.1% 9.5% 11.9% 14.9% 5.9% 10.7% 
1.9% 2.0% 0.6% 0.0% 2.0% 0.6% 0.9% 
Year of diagnosis  
    1994 9.1% 9.6% 8.9% 9.3% 9.0% 8.6% 8.3% 
    1995 8.7% 8.8% 9.2% 9.3% 8.6% 8.6% 9.1% 
    1996 8.1% 8.3% 6.8% 8.3% 8.1% 8.2% 7.4% 
    1997 8.1% 7.6% 7.1% 7.8% 8.2% 7.9% 9.3% 
    1998 8.1% 7.5% 7.7% 5.2% 8.3% 8.1% 8.8% 
    1999 8.2% 8.6% 7.7% 7.8% 8.1% 8.7% 9.3% 
    2000 16.3% 16.2% 19.0% 19.7% 16.2% 18.0% 15.3% 
    2001 16.9% 17.5% 14.9% 17.1% 17.0% 15.3% 17.3% 
    2002 16.4% 16.0% 18.5% 15.5% 16.5% 16.7% 15.1% 
Clinical characteristics 
Stage 
    Stage II 
    Stage III 
       
86.8% 90.0% 83.0% 88.6% 86.7% 81.8% 84.1% 
13.2% 10.0% 17.0% 11.4% 13.3% 18.2% 15.9% 
ER/PR status 
    ER+ 
    ER- 
    ER unk/bord 
    PR+ 
    PR- 
    PR unk/bord 
       
66.6% 69.6% 49.7% 59.6% 67.5% 54.4% 63.5% 
16.3% 17.3% 27.7% 17.6% 15.4% 21.4% 15.6% 
17.1% 13.1% 22.6% 22.8% 17.0% 24.2% 20.9% 
53.7% 57.4% 37.8% 52.3% 54.2% 42.5% 52.1% 
27.7% 27.2% 32.1% 25.0% 27.8% 37.8% 25.4% 
18.6% 18.6% 25.3% 22.9% 14.8% 24.4% 22.3% 
NCICI score 0.30 0.17 0.38 0.27 0.31 0.43 0.37 
Lymph nodes 
    Node positive 
    Status missing 
       
53.9% 62.9% 65.2% 59.1% 51.9% 50.4% 53.9% 
15.3% 5.1% 8.6% 4.1% 17.4% 20.0% 17.2% 
Treatment 
Received chemo 
within 1 month 
of diagnosis 10.7% 21.8% 16.1% 14.5% 8.4% 7.5% 10.2% 
Received chemo 
within 4 months 
of diagnosis 29.4% 58.2% 52.1% 52.8% 22.8% 24.2% 25.1% 
Ever received 
post-operative 
chemotherapy 35.0% 62.5% 59.5% 59.4% 28.5% 30.8% 30.2% 
Received surgery 
in same month 
as diagnosis 65.8% 67.2% 61.6% 60.6% 65.8% 63.5% 65.8% 
Notes: ER: Estrogen Receptor; NCICI:  National Cancer Institute Combined Co-morbidity Index; PR: 
Progesterone Receptor; SEER: Surveillance, Epidemiology, and End Results 
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Bivariate Analyses:  Adjuvant Chemotherapy and Patient Characteristics 
In exploratory analyses, significant differences existed in overall receipt and timing of 
initiation of adjuvant chemotherapy by patient-level characteristics of interest, including age 
and hormone receptor status and to a lesser extent by race/ethnicity (Table 14 and Figure 
15).  Overall use of adjuvant chemotherapy increased significantly from 1994 to 2002 across 
age groups and racial/ethnic groups, but remained quite low overall (45%) even in 2002.  
Among women ages 65-69 years old, 60% ever received adjuvant chemotherapy, compared 
to only 30% of women older than 70 (Table 14).  Among younger women (65-69 years old), 
significant differences were observed by race/ethnicity in timing of initiation of chemotherapy 
within 1 month of diagnosis (22% in white women compared to 16% and 15% in black and 
Hispanic women, respectively; p=0.004) and 4 months of diagnosis (58% in white women 
compared to 52% and 53% in black and Hispanic women, respectively; p=0.04).  In terms of 
trends over time in timing of initiation of adjuvant chemotherapy, initiation within 4 months of 
diagnosis was more common among younger women, and initiation within this time interval 
generally increased from 1994-2002, as evidenced by Figure 15.   
In exploratory analyses, hormone receptor status played an important role in 
determination of overall receipt and timing of initiation of adjuvant chemotherapy (Figure 15).  
Women with hormone receptor positive tumors (ER and/or PR-positive) were significantly 
less likely to receive chemotherapy (results not shown) and to initiate chemotherapy within 
four months of diagnosis (Figure 15).  Overall use of adjuvant chemotherapy and earlier 
initiation of adjuvant chemotherapy increased from 1994-2002 regardless of hormone 
receptor status.  In 1994, 28% of women whose tumors were not ER/PR-positive and 17% 
of women with hormone receptor positive tumors initiated chemotherapy within 4 months of 
diagnosis; by 2002, approximately 40% of women whose tumors were not ER/PR-positive 
and 31% of women with hormone receptor positive tumors initiated chemotherapy by 4 
months post-diagnosis.     
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Figure 15: Trends in receipt of adjuvant chemotherapy within 4 months of diagnosis, 
by patient characteristics, among women with sate II-III breast cancers who received 
surgery 
 114 
Bivariate Analyses:  Adjuvant Chemotherapy and Health Services Characteristics 
Figures 16 and 17 depict trends in any use of adjuvant chemotherapy over time 
according to select structural and organizational characteristics of health services, including 
teaching status, type/ownership, NCI Comprehensive Cancer Center designation, and 
distance to care.  From these graphs, it is evident that overall receipt of adjuvant 
chemotherapy was low, and few differences existed according to structural and 
organizational factors.  During certain years, women receiving surgery at for-profit facilities 
and NCI Comprehensive Cancer Centers appeared to be more likely to receive subsequent 
chemotherapy, but these relationships were not consistently statistically significant (Figure 
16).  In general, living in a zip code where the nearest chemotherapy facility was in the 
same zip code was not associated with receipt of adjuvant chemotherapy, but in 1997, 
1999, and 2001, living nearer to a chemotherapy facility was associated with greater rates of 
adjuvant chemotherapy use (Figure 17).  According to Table 15, structural/organizational 
characteristics of health services were distributed unequally across racial/ethnic sub-
populations.  Hispanic women were treated more often at for-profit surgical facilities (16% 
compared to 7% in whites and 8% in blacks; p<0.001), and black women received surgery 
more often at NCI Comprehensive Cancer Centers (9% compared to 2% in white women 
and 3% in Hispanic women; p<0.001), ACoSOG-affiliated facilities (32% compared to 22% 
in white women and 15% in Hispanic women; p<0.001), and teaching/academic health 
centers (62% compared to 48% in white women and 41% in Hispanic women; p<0.001) 
(Table 15).  Hispanic women lived the furthest away from a chemotherapy provider (4.2 
miles on average; p<0.001), and non-Hispanic white women traveled the furthest for surgery 
(16 miles on average; p<0.001) (Table 15). 
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Figure 16: Receipt of adjuvant chemotherapy at any time after surgery, among 
women with stage II-III breast cancers - trends by surgical provider characteristics 
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Figure 17: Receipt of adjuvant chemotherapy at any time after surgery, among 
women with stage II-III breast cancers - trends by proximity to health services 
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Table 15: Bivariate comparisons of health system organizational factors by race/ethnicity 
 
 
 
Organizational Covariate 
% or mean 
(SD) 
 
 
White 
% or mean 
(SD) 
 
 
Black 
% or mean 
(SD) 
 
 
Hispanic 
p-value 
(from chi-
square test 
or t-test) 
Surgical facility characteristics     
Type/ownership     
For-profit/private 6.9% 8.4% 15.7% <0.001 
Non-profit/voluntary 78.5% 77.9% 69.7% <0.001 
Government 14.5% 13.7% 14.6% 0.682 
NCI Comprehensive Cancer Center 2.3% 9.5% 3.0% <0.001 
ACoSOG-affiliated 22.3% 32.4% 14.9% <0.001 
Teaching/academic facility 48.5% 61.6% 41.1% <0.001 
Rural location 14.0% 4.9% 9.9% <0.001 
Number of beds 353 (226.2) 465 (259) 302 (219) <0.001~ 
<0.001# 
Relational factors/access to care      
Nearest chemotherapy facility (miles) 3.2 (6.2) 1.9 (3.9) 4.2 (10.0) <0.001~ 
<0.001# 
Nearest chemotherapy facility is located 
in same zip code as patient residence 
 
84.9% 
 
80.2% 
 
87.4% 
 
<0.001 
Facility where patient received primary 
surgery is located in same zip code as 
patient residence 
 
 
17.5% 
 
 
14.9% 
 
 
16.3% 
 
 
0.027 
Average distance traveled for primary 
surgery (miles) 
 
15.6 (61.6) 
 
11.5 (50.9) 
 
11.5 (31.8) 
0.011~ 
0.061# 
Average distance traveled to 
chemotherapy provider, among those 
who received chemotherapy (first 
incidence of use) (miles) 
 
 
 
17.5 (55.4) 
 
 
 
11.5 (31.4) 
 
 
 
13.3 (23.5) 
 
 
0.029~ 
0.53# 
Notes: ACoSOG: American College of Surgeons Oncology Group; NCI: National Cancer Institute; ~ 
indicates two-sample t-tests between white and black groups; # indicates two-sample t-tests between 
white and Hispanic groups 
 
Multivariate Analyses 
In stratified multivariate models (Tables 16-19), the effects of race/ethnicity were not 
statistically significant, and adding structural/organizational factors to the models did not 
appear to confound or modify the main relationships between race/ethnicity and receipt or 
timing of initiation of adjuvant chemotherapy.  Across models, characteristics of the surgical 
facility where women were treated were not predictive of receipt or timing of initiation of 
adjuvant chemotherapy at the 5% level of significance.  Distance to care as a predictor of 
receipt and timing of initiation of adjuvant chemotherapy did not attain statistical significance 
in most multivariate models; however, among women 70 and older (Tables 17 and 19), 
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increasing distance to a chemotherapy facility was consistently associated with lower odds 
of initiation of adjuvant chemotherapy, although the effect was often statistically non-
significant (ORs ranging from 0.74 to 0.99).   
In models of women whose tumors were not hormone receptor positive (i.e., those 
women for whom clinical guidelines clearly recommended adjuvant chemotherapy during 
the entire time period examined) (Tables 16 and 17), women with ER-borderline or ER-
unknown tumors had significantly lower odds of initiating chemotherapy within 4 months 
(OR: 0.27 among women 65-69 years old, p<0.05; OR: 0.35 among women 70 years and 
older, p<0.01) and lower odds of ever receiving chemotherapy (OR: 0.36 among women 65-
69 years old, p<0.10; OR: 0.37 among women 70 years and older, p<0.01), compared to 
women whose tumors were known to be ER-negative.  In terms of other covariates in 
models of women with non-positive hormone receptor statuses, having positive lymph nodes 
and being diagnosed as stage III (relative to stage II) were associated with significantly 
higher odds of initiation of chemotherapy within 4 months and overall (Tables 16 and 17).  
Among women 70 and older with non-positive hormone receptor status (Table 17), poorer 
histologic grade was associated with significantly higher odds of initiation of chemotherapy 
(ORs ranging from 1.62 to 3.09, p<0.05), and greater co-morbidity was associated with 
significantly lower odds of initiation of chemotherapy (ORs ranging from 0.59 to 0.69 in third 
and fourth co-morbidity quartiles, p<0.01).  Finally, regardless of age or hormone receptor 
stratification, increasing year of diagnosis was significantly associated with greater odds of 
initiating adjuvant chemotherapy at each time period examined and overall (Tables 16-19), 
indicating that use of adjuvant chemotherapy increased over time, particularly since 1997, 
after which point, odds ratios on year of diagnosis were statistically significant across 
models.   
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Table 16: Multivariate logit regressions for breast cancer patients <70 years old with non-
positive (i.e. negative, borderline, or unknown) hormone receptor status 
Variables Odds Ratios for receipt of adjuvant chemotherapy, among 
women < 70 years old (robust standard errors used) 
@ 4 mos. Ever 
Non-Hispanic white (reference) 
Non-Hispanic black 0.84 0.76 
Hispanic 1.58 1.63 
Structural/organizational variables 
Surgical facility characteristics 
Non-profit (reference) 
Private/for-profit 1.07 1.05 
Governmental 1.04 0.94 
Teaching facility 0.86 0.73+ 
Fewer beds (<median) 1.02 0.91 
NCI Comprehensive Cancer 
Center 
0.60 0.98 
ACoSOG-affiliated 1.04 0.91 
Distance traveled to surgery (in quartiles) 
Same zip code (reference) 
Surgery distance Q1 1.27 1.65+ 
Surgery distance Q2 0.88 1.22 
Surgery distance Q3 0.93 1.24 
Surgery distance Q4 1.37 1.73+ 
Distance to nearest chemotherapy provider (in quartiles) 
Same zip code (reference) 
Chemotherapy distance Q1 1.24 1.30 
Chemotherapy distance Q2 1.08 0.95 
Chemotherapy distance Q3 1.14 1.00 
Chemotherapy distance Q4 1.16 0.91 
Clinical and patient characteristics  
NCI Combined Index Co-morbidity score (in quartiles) 
None (score=0) (reference) 
Co-morbidity Q1 0.95 0.98 
Co-morbidity Q2 1.27 1.33 
Co-morbidity Q3 0.78 0.76 
Co-morbidity Q4 0.32** 0.40** 
Surgery received in same month 
as diagnosis 
1.30 1.28 
ER-negative (reference) 
ER-borderline or unknown 0.27* 0.36+ 
PR-negative (reference) 
PR-borderline or unknown 1.14 0.72 
Stage2 (reference) 
Stage3 1.93* 1.64+ 
Node-negative (reference) 
Node-positive 4.33** 4.45** 
Node status missing 1.05 0.96 
Grade  
Well differentiated (reference) 
Moderately differentiated 1.17 1.10 
Poorly differentiated 1.51 1.36 
Anaplastic 1.02 0.86 
Grade missing 0.80 0.70 
Low income proxy (State-Buy-In) 0.49** 0.53** 
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Variables Odds Ratios for receipt of adjuvant chemotherapy, among 
women < 70 years old (robust standard errors used) 
@ 4 mos. Ever 
Married 1.54** 1.74** 
Year of diagnosis 
1994 (reference) 
1995 1.46 1.45 
1996 0.72 0.80 
1997 1.16 1.41 
1998 1.85+ 2.09* 
1999 3.26** 3.11** 
2000 2.41** 2.58** 
2001 2.87** 3.44** 
2002 2.00* 2.91** 
Observations 1082 1086 
Notes: + significant at 10%; * significant at 5%; ** significant at 1%; Models also control for 
neighborhood characteristics by zip code (odds ratios not reported here); RT: radiation therapy; ER: 
estrogen receptor; PR: progesterone receptor; Hisp:  Hispanic 
 
 121 
Table 17: Multivariate logit regressions for breast caner patients 70 years and older with non-
positive (i.e., negative borderline, or unknown) hormone receptor statuses 
Variables Odds Ratios for receipt of adjuvant chemotherapy, among 
women 70 years and older (robust standard errors used) 
@ 4 mos. Ever 
Non-Hispanic white (reference) 
Non-Hispanic black 1.04 1.15 
Hispanic 1.49+ 1.36 
Structural/organizational variables 
Surgical facility characteristics 
Non-profit (reference) 
Private/for-profit 1.17 1.2 
Governmental 0.83 0.87 
Teaching facility 0.94 1.01 
Fewer beds (<median) 1.03 1.09 
NCI Comprehensive Cancer 
Center 
0.84 0.85 
ACoSOG-affiliated 1.07 1.00 
Distance traveled to surgery (in quartiles) 
Same zip code (reference) 
Surgery distance Q1 0.88 0.93 
Surgery distance Q2 0.85 0.9 
Surgery distance Q3 0.86 0.97 
Surgery distance Q4 0.79+ 0.89 
Distance to nearest chemotherapy provider (in quartiles) 
Same zip code (reference) 
Chemotherapy distance Q1 0.86 0.92 
Chemotherapy distance Q2 0.74* 0.91 
Chemotherapy distance Q3 0.8 0.86 
Chemotherapy distance Q4 0.92 0.99 
Clinical and patient characteristics  
NCI Combined Index Co-morbidity score 
None (score=0) (reference) 
Co-morbidity Q1 0.92 0.94 
Co-morbidity Q2 0.79 0.76* 
Co-morbidity Q3 0.64** 0.69** 
Co-morbidity Q4 0.59** 0.62** 
Age 70-74years (reference) 
Age 75-79years 0.45** 0.48** 
Age 80-84years 0.18** 0.21** 
Age 85years and up 0.04** 0.07** 
Surgery received in same 
month as diagnosis 
1.20* 1.02 
ER-negative (reference) 
ER-borderline or unknown 0.35** 0.37** 
PR-negative (reference) 
PR-borderline or unknown 0.84 0.96 
Stage2 (reference) 
Stage3 1.50** 1.48** 
Node-negative (reference) 
Node-positive 4.00** 3.52** 
Node status missing 1.03 0.98 
Grade  
Well differentiated (reference) 
Moderately differentiated 2.00** 1.75** 
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Variables Odds Ratios for receipt of adjuvant chemotherapy, among 
women 70 years and older (robust standard errors used) 
@ 4 mos. Ever 
Poorly differentiated 3.02** 2.81** 
Anaplastic 3.09** 2.64** 
Grade missing 1.79** 1.62* 
Low income proxy (State-Buy-
In) 
0.59** 0.59** 
Married 1.14+ 1.22** 
Year of diagnosis 
1994 (reference) 
1995 1.08 0.95 
1996 1.11 1.21 
1997 1.53* 1.38+ 
1998 1.81** 1.45* 
1999 2.15** 1.74** 
2000 2.66** 2.21** 
2001 2.52** 1.94** 
2002 2.56** 3.04** 
Observations 4823 4827 
Notes: + significant at 10%; * significant at 5%; ** significant at 1%; Models also control for 
neighborhood characteristics by zip code (odds ratios not reported here); RT: radiation therapy; ER: 
estrogen receptor; PR: progesterone receptor 
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Table 18: Multivariate logit regressions for breast cancer patients < 70 years old with positive 
hormone receptor (ER+ or PR+) status 
Variables Odds Ratios for receipt of adjuvant chemotherapy, among 
women < 70 years old (robust standard errors used) 
@ 4 mos. Ever 
Non-Hispanic white (reference) 
Non-Hispanic black 0.7 0.93 
Hispanic 1.11 1.1 
Structural/organizational variables 
Surgical facility characteristics 
Non-profit (reference) 
Private/for-profit 1.16 1.00 
Governmental 0.92 0.85 
Teaching facility 0.95 0.91 
Fewer beds (<median) 0.92 0.94 
NCI Comprehensive Cancer 
Center 
0.66 0.8 
ACoSOG-affiliated 0.97 1.00 
Distance traveled to surgery (in quartiles) 
Same zip code (reference) 
Surgery distance Q1 0.91 0.88 
Surgery distance Q2 0.83 0.74+ 
Surgery distance Q3 0.85 0.78 
Surgery distance Q4 0.86 0.77 
Distance to nearest chemotherapy provider (in quartiles) 
Same zip code (reference) 
Chemotherapy distance Q1 0.91 0.96 
Chemotherapy distance Q2 0.88 0.82 
Chemotherapy distance Q3 1.11 1.15 
Chemotherapy distance Q4 0.97 1.03 
Clinical and patient characteristics  
NCI Combined Index Co-morbidity score (in quartiles) 
None (score=0) (reference) 
Co-morbidity Q1 0.84 0.86 
Co-morbidity Q2 0.75+ 0.85 
Co-morbidity Q3 0.63* 0.77 
Co-morbidity Q4 0.31** 0.36** 
Surgery received in same 
month as diagnosis 
1.31** 1.31** 
Stage2 (reference) 
Stage3 1.67** 1.65** 
Node-negative (reference) 
Node-positive 4.81** 4.36** 
Node status missing 0.92 1.02 
Grade  
Well differentiated (reference) 
Moderately differentiated 1.28+ 1.2 
Poorly differentiated 2.34** 2.27** 
Anaplastic 1.58 1.33 
Grade missing 1.41+ 1.37+ 
Low income proxy (State-Buy-
In) 
0.66** 0.64** 
Married 0.97 1.00 
Year of diagnosis 
1994 (reference) 
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Variables Odds Ratios for receipt of adjuvant chemotherapy, among 
women < 70 years old (robust standard errors used) 
@ 4 mos. Ever 
1995 0.86 0.97 
1996 1.26 1.34 
1997 2.10** 2.29** 
1998 3.08** 3.20** 
1999 3.31** 3.84** 
2000 4.24** 4.45** 
2001 5.01** 5.23** 
2002 5.05** 6.86** 
Observations 2398 2398 
Notes: + significant at 10%; * significant at 5%; ** significant at 1%; Models also control for 
neighborhood characteristics by zip code (odds ratios not reported here); RT: radiation therapy; ER: 
estrogen receptor; PR: progesterone receptor 
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Table 19: Multivariate logit regressions for breast cancer patients 70 years and older, with 
positive hormone receptor (ER+ or PR+) status 
Variables Odds Ratios for receipt of adjuvant chemotherapy, among 
women 70 years and older (robust standard errors used) 
@ 4 mos. Ever 
Non-Hispanic white (reference) 
Non-Hispanic black 1.16 1.14 
Hispanic 0.92 0.9 
Structural/organizational variables 
Surgical facility characteristics 
Non-profit (reference) 
Private/for-profit 1.16 1.11 
Governmental 1.04 1.03 
Teaching facility 0.91 0.96 
Fewer beds (<median) 1.12 1.04 
NCI Comprehensive Cancer 
Center 
0.77 0.88 
ACoSOG-affiliated 1.05 1.07 
Distance traveled to surgery (in quartiles) 
Same zip code (reference) 
Surgery distance Q1 1.08 0.95 
Surgery distance Q2 1.07 0.94 
Surgery distance Q3 1.04 0.94 
Surgery distance Q4 0.91 0.84+ 
Distance to nearest chemotherapy provider (in quartiles) 
Same zip code (reference) 
Chemotherapy distance Q1 0.85 0.92 
Chemotherapy distance Q2 0.77* 0.83+ 
Chemotherapy distance Q3 0.85 0.91 
Chemotherapy distance Q4 0.87 0.94 
Clinical and patient characteristics  
NCI Combined Index Co-morbidity score 
None (score=0) (reference) 
Co-morbidity Q1 1.01 1.08 
Co-morbidity Q2 0.72** 0.79* 
Co-morbidity Q3 0.84 0.89 
Co-morbidity Q4 0.55** 0.70** 
Age 70-74years (reference) 
Age 75-79years 0.49** 0.54** 
Age 80-84years 0.17** 0.23** 
Age 85years and up 0.04** 0.10** 
Surgery received in same 
month as diagnosis 
1.32** 1.17** 
Stage2 (reference) 
Stage3 1.74** 1.68** 
Node-negative (reference) 
Node-positive 4.23** 3.20** 
Node status missing 0.95 1.03 
Grade  
Well differentiated (reference) 
Moderately differentiated 1.31** 1.22* 
Poorly differentiated 1.99** 1.88** 
Anaplastic 1.77* 1.57* 
Grade missing 1.44** 1.40** 
Low income proxy (State-Buy- 0.63** 0.66** 
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Variables Odds Ratios for receipt of adjuvant chemotherapy, among 
women 70 years and older (robust standard errors used) 
@ 4 mos. Ever 
In) 
Married 1.25** 1.21** 
Year of diagnosis 
1994 (reference) 
1995 1.14 1.29+ 
1996 1.40* 1.32* 
1997 1.82** 1.74** 
1998 2.54** 2.26** 
1999 3.00** 2.54** 
2000 4.18** 3.31** 
2001 4.07** 2.94** 
2002 4.03** 4.98** 
Observations 10188 10189 
Notes: + significant at 10%; * significant at 5%; ** significant at 1%; Models also control for 
neighborhood characteristics by zip code (odds ratios not reported here); RT: radiation therapy; ER: 
estrogen receptor; PR: progesterone receptor 
 
Discussion 
With a goal of examining structural/organizational reasons for disparities in receipt of 
adjuvant therapy, our study explored treatment patterns in adjuvant chemotherapy among 
women diagnosed with breast cancer between 1994 and 2002.  Given the lack of quality 
metrics for women older than 70 years juxtaposed against recent demonstrable benefits of 
adjuvant chemotherapy in older women (Elkin et al., 2006; Giordano et al., 2006; Owusu et 
al., 2007) both younger (65-70 years) and older (70 and older) Medicare beneficiaries were 
studied in the current analysis, providing additional timely and important evidence with 
respect to age. 
Contrary to expectations, we found no evidence of a racial/ethnic disparity in receipt 
and timing of receipt of adjuvant chemotherapy in multivariate models.  The lack of 
racial/ethnic differences in receipt of chemotherapy after consideration of other potential 
confounders is in contrast with evidence from Giordano and colleagues (2006), but is 
consistent with evidence from Lund and colleagues (2008), Du and Goodwin (2001), and 
recent findings from Bhargava and Du (2009) showing that racial disparities in receipt of 
adjuvant chemotherapy among women ages 65-69 years old were largely explained by 
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area-level poverty (which we accounted for by using zip code-level median income).  
Studies of timing of chemotherapy use in other cancers, including lung cancer, have shown 
that black patients tend to experience more delays in initiation of chemotherapy (Shugarman 
et al., 2009), but that finding was not corroborated in this study of breast cancer patients.   
Structural and organizational characteristics of health services played a very minor 
role in determining receipt and timing of receipt of adjuvant chemotherapy.  Among women 
ages 70 and older, increasing distance to chemotherapy providers was associated with 
lower odds of receiving adjuvant chemotherapy at one year and overall, but this effect was 
not always statistically significant (Tables 17 and 19).  If distance to care does play a role in 
determining receipt of adjuvant treatment, this finding may have implications for workforce 
planning, amidst concerns about oncology provider supply, particularly in rural areas, and 
the aging oncology workforce.  Further, if distance to care presents an obstacle to elderly 
women, public health programs focused of providing reliable transportation options may 
benefit women.  Given the limitations of using straight-line distances between patient zip 
code centroid and provider zip code centroid in determining geographic to care, it is possible 
that our measures were too imprecise to detect the true effect of distance and what role it 
may have played in terms of health care seeking burden.  After all, health care markets 
transcend zip codes.  As such, future research should attempt to explore the issues around 
geographic access to care as it relates to treatment planning and perceived burden of 
seeking oncology services (specifically adjuvant therapy) among elderly women.   
The absence of a statistically significant effect of other types of structural or 
organizational health services characteristics on timing of receipt of chemotherapy may 
suggest that factors like NCI Cancer Center designation and teaching status of the surgical 
facility have no impact on timing of initiation or overall receipt of adjuvant chemotherapy.  On 
the other hand, features of SEER-Medicare sampling, problems with measurement of 
structural/organizational variables, and/or omission of unobservable variables could explain 
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this finding.  For instance, although SEER is one of the largest national cancer registry 
programs in the world, SEER largely samples black and Hispanic cancer patients from 
specific areas which may not be representative of the experiences of all black and Hispanic 
persons in the United States (Warren et al., 2002c).  Black patients tend to be oversampled 
from urban areas like Detroit and Atlanta, limiting the ability of SEER-Medicare to reflect on 
the experiences of rural blacks, whereas Hispanic patients tend to be oversampled from 
New Mexico and California, limiting the ability of SEER-Medicare to reflect on the 
experiences of rural Hispanic patients living in the southeastern United States, for example.  
The bivariate analyses comparing health system organizational/structural factors by 
race/ethnicity (Table 15) support such a statement, as black women in this study were more 
likely to be treated at larger hospitals, NCI Comprehensive Cancer Centers, academic 
facilities, etc., all of which have been associated with improved treatment quality and/or 
health outcomes (Chaudhry et al., 2001; Hebert-Croteau et al., 2005; Laliberte et al., 2005; 
Onega et al., 2009) and which are reflective of more urban health facilities.  Tables 14 and 
15 further suggest that rural-dwelling Hispanic women may be under-represented in the 
current study.  If organizational features of health services are associated with geographic 
location of health facilities as we might expect then this study’s inability to sample rural-
dwelling black and Hispanic women may have limited its power to detect meaningful 
relationships between race/ethnicity and health system factors.  Another limitation may be 
related to the types of structural and organizational measures used; specifically, only 
information from hospital-affiliated surgical facilities was available.  Thus, we could not 
explore how structural/organizational characteristics of non-hospital affiliated facilities 
affected treatment planning.  We also could not say anything about the providers and 
facilities patients consulted after initial surgery; clearly, although the surgical facility plays a 
role in subsequent care, other providers outside of the surgical facility are important.  The 
lack of such information indicates a critical need for better data and improved access to data 
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resources about the health systems providing care to cancer patients, including structural 
and organizational characteristics of non-hospital-affiliated facilities and providers in the 
community.   
We found that receipt of adjuvant chemotherapy in stage II and III, hormone receptor 
negative breast cancers was somewhat low, at approximately 51% for women diagnosed in 
2002, despite the fact that evidence supporting its use has existed since the 1980s.  The 
decision making process around chemotherapy use is complex, given the serious side 
effects and logistical burdens patients face when considering whether or not to undergo 
chemotherapy.  As such, reasons for underuse of adjuvant chemotherapy are multifaceted 
and cannot be completely understood in a retrospective observational study of this nature.  
In this study, underuse among women with non-positive hormone receptor statuses was 
highly associated with increasing age, earlier year of diagnosis, being unmarried, lower 
socioeconomic status, and certain tumor characteristics, controlling for all other factors.  
Despite the high predictive power of these variables, we were unable to directly measure 
intent, treatment choice, or other behavioral factors that may have affected receipt of care.  
Additional reasons for underuse may not be observable in this dataset; for example, it is 
unclear whether women who did not receive chemotherapy were actually offered 
chemotherapy and refused it, or were never offered chemotherapy at all.   
As expected, age played an enormous role in determining receipt of adjuvant 
chemotherapy consistent with many prior studies (Bhargava and Du, 2009; Du et al., 2003; 
Du and Goodwin, 2001; Goodwin et al., 2006).  This relationship persisted over time despite 
increasing controversy during the time period examined about omission of potentially life-
prolonging therapy in older women (Wildiers and Brain, 2005).  Due to insufficient 
accumulation of clinical trial evidence about the effects of adjuvant chemotherapy in older 
women, the ASCO/NCCN quality metrics for use of chemotherapy for breast cancer were 
limited to women younger than 70 years old (Desch et al., 2008).  However, many experts 
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have argued that the lack of inclusion of older women in clinical trials should not preclude 
older women from receiving life-prolonging breast cancer treatments (Ballard-Barbash et al., 
1996; Passage and McCarthy, 2007; Wildiers and Brain, 2005).  Several studies now have 
shown substantial benefits of chemotherapy in older women (Elkin et al., 2006; Giordano et 
al., 2006; Owusu et al., 2007), and at least one randomized trial has shown that omission of 
aggressive chemotherapy among women older than 70 leads to poorer outcomes (Muss, 
2009).  Rather than focusing on age as a sole criterion for treatment, many authors have 
argued that co-morbidity burden and/or functional status are more appropriate 
considerations for treatment planning among elderly cancer patients (Barni et al., 2010; 
Bouchardy et al., 2007).  Our study echoed previous findings that women with more co-
morbidities were less likely to receive adjuvant chemotherapy, controlling for all other factors 
(Du and Goodwin, 2001) and that black women tended to have greater co-morbidity burden 
(Tammemagi et al., 2005). 
This study has several strengths, including its use of a large, population-based 
cancer registry linked with Medicare claims data and longitudinal examination of trends in 
breast cancer care.  We have also addressed a potential source of omitted variable bias that 
some previous studies failed to consider or measured inadequately – insurance status – by 
limiting our study to insured Medicare beneficiaries enrolled in parts A and B fee-for-service.  
Our study contributes to the existing literature in use of adjuvant chemotherapy for breast 
cancer by documenting low utilization of adjuvant chemotherapy over time by important 
patient sub-populations, illustrating differences in timing of initiation of chemotherapy (which 
may be related to subsequent health outcomes [see Hershman et al., 2006a, for example]), 
and by showing that potential age-related disparities in treatment may exist among healthy 
elderly women with good functional status.  If use of chemotherapy is indeed inappropriately 
low in hormone receptor negative patients, then combined with recent data on the likely 
benefit of adjuvant chemotherapy in the older breast cancer population, it may be that 
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outcomes could be improved for a substantial number of older patients.  Based on these 
findings, future studies should seek to explore the more nuanced reasons why older women 
do not receive chemotherapy and the appropriateness (or inappropriateness) of 
chemotherapy omission, to examine the effects of timing of chemotherapy initiation on 
health outcomes, and to sample more representatively minority sub-populations from 
diverse geographic regions in the United States.   
CHAPTER 6:  TIMING OF RECEIPT OF BREAST CANCER TREATMENT, 
RACE/ETHNICITY, AND LONG-TERM HEALTH OUTCOMES 
 
Abstract 
Purpose 
Optimal timing of anticancer therapy, including radiation therapy and adjuvant 
chemotherapy, is an unresolved issue in breast cancer care.  Treatment delays may be 
predictive of long-term health outcomes and are more common in racial/ethnic minority 
groups.  Accordingly, we examined racial/ethnic variation in (1) all-cause and breast cancer-
specific mortality five years after diagnosis as a function of timing of radiation therapy after 
breast conserving surgery among stage I-III breast cancers and (2) all-cause and breast 
cancer-specific mortality five years after diagnosis as a function of timing of adjuvant 
chemotherapy among stage II-III breast cancers. 
 
Methods 
We conducted a retrospective analysis of secondary data using Surveillance, 
Epidemiology, and End Results (SEER) data linked with Medicare claims for women ages 
65 and older diagnosed with primary breast cancer in 1994-2002, with vital status follow-up 
through 2007.  We examined the effect of therapeutic timing on five-year all-cause mortality 
and breast cancer-specific mortality in multivariate logistic regressions.  Timing of initiation 
of adjuvant radiation therapy (RT) and adjuvant chemotherapy, both measured in months 
since diagnosis, were independent variables of interest in separate regressions.  
Race/ethnicity, defined by SEER as non-Hispanic white, non-Hispanic black, or Hispanic, 
was an important independent variable of interest.  Control variables included stage; 
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histologic grade; hormone receptor status; axillary lymph node involvement; co-morbidity 
score; marital status at diagnosis; State-Buy-In months (a proxy for low income status) 
(Bach et al., 2002); year of diagnosis; and zip code level income, education, and 
neighborhood racial composition.  
 
Results 
 In total, 38,574 women met criteria for models examining timing of initiation of RT, of 
whom 6% (2,273) were black and 4% (1,336) were Hispanic; within this sample, 58% of 
white women, 51% of black women, and 58% of Hispanic women ever received RT 
(p<0.001).  In total, 20,989 women met criteria for models examining timing of initiation of 
chemotherapy, of whom 8% (1,596) were black and 4% (840) were Hispanic; within this 
sample, 35% of white women, 37% of black women, and 37% of Hispanic women ever 
received chemotherapy (p=0.111).  In bivariate analyses, compared to white women, black 
women had higher 5-year breast cancer specific mortality (p<0.001) and higher all-cause 
mortality (p<0.001).  Timing of initiation of RT varied significantly by race/ethnicity; among 
women who did not receive chemotherapy, 54% of non-Hispanic white women initiated RT 
within 6 months of diagnosis, compared to 44% of black women and 55% of Hispanic 
women (p<0.001).  Among women who received chemotherapy, 48% of non-Hispanic white 
women initiated RT within 6 months, compared to 37% of black women and 39% of Hispanic 
women (p<0.001).  In multivariate models stratified by age group and receipt of another 
adjuvant treatment, receipt of RT more than 1 year post-diagnosis was associated with 
higher odds of all-cause and breast cancer specific mortality (ORs ranging from 3.88 to 
13.04, p<0.01).  Initiation of chemotherapy beyond four months post-diagnosis was 
associated with higher odds of all-cause mortality (ORs ranging from 1.67 to 2.79, p<0.05) 
and breast cancer-specific mortality (ORs ranging from 1.69 to 3.89).  The effect of timing of 
chemotherapy was more important among younger women ages 65-69 years old.  After 
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controlling for other covariates, race/ethnicity was only predictive of mortality in models 
assessing the effect of timing of chemotherapy among women who also received RT. 
 
Conclusions 
 In this study, black and Hispanic women experienced more treatment delays and 
were less likely to receive guideline-recommended care compared to white women.  Black 
and Hispanic women also were more likely to have clinical characteristics associated with 
poorer prognosis.  Delays in initiation of RT beyond 6 months and delays in initiation of 
chemotherapy beyond 4 months generally were associated with worse health outcomes, as 
did certain clinical characteristics including advanced stage, having positive lymph nodes, 
and negative hormone receptor status.  It is therefore critically important that elderly minority 
women at risk for under-treatment and delayed treatment be informed of the potential 
benefits and risks of adjuvant therapy and initiate treatment as soon as possible after 
diagnosis.   
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Introduction 
Surpassed only by lung cancer mortality, breast cancer is the second most fatal 
cancer among women, with an estimated 41,000 deaths attributable to breast cancer in 
2008 (American Cancer Society [ACS], 2008).  Although prognosis is generally good for 
breast cancers diagnosed early (i.e., 85-100% of stage I and II patients are alive after five 
years of follow-up), 5-year survival rates for patients with stage III and IV disease are only 
58% and 19%, respectively (Gloeckler Ries et al., 2003).  Recent reductions in overall 
breast cancer mortality likely reflect the development and uptake of screening interventions 
and innovative treatment options (Berry et al., 2005).  However, breast cancer-specific 
mortality remains disproportionately higher among black women, even after controlling for 
differences in stage of disease, tumor biology (e.g., estrogen receptor [ER] and 
progesterone receptor [PR] status), and insurance access (ACS, 2008; Bach et al., 2002a).   
Racial/ethnic variation in mammography use and timely detection of early stage 
breast cancer has been widely studied, and both have been the target of many public health 
interventions and advocacy campaigns (Campbell, 2002; Hahn et al., 2007).  Differences in 
treatment are now the focus of many studies examining health disparities in breast cancer 
(Banerjee et al., 2007; Bigby and Holmes, 2005; Curtis et al., 2008; Du and Simon, 2005; 
Gorin et al., 2006; Lund et al., 2008).  In general, black women are more likely to experience 
treatment delays after diagnosis and less likely to receive cancer-directed surgery, radiation 
therapy (RT) after breast conserving surgery (BCS), and hormonal therapy, even after 
controlling for age, tumor size, stage, ER/PR status, and nodal status (Lund et al., 2008).   
Many nagging questions remain with respect to optimal breast cancer treatment 
strategies, including questions about sequencing and compatibility of multiple systemic 
adjuvant therapies (Bartelink, 2007; Gradishar and O’Regan, 2003) as well as impact of 
delays in initiation of radiotherapy and chemotherapy on recurrence and survival (Hartsell et 
al., 1995; Hebert-Croteau et al., 2002; Lohrisch et al., 2006).  Appropriate timing of breast 
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cancer care is an important unresolved issue in the literature.  Some studies have 
demonstrated that 2-3 month delays in initiation of RT are associated with higher mortality 
and/or local recurrence (Gold et al., 2008; Hebert-Croteau et al., 2004; Hershman et al., 
2006b; Wyatt et al., 2008).  Similarly, other studies have found that delays of 2-3 months in 
initiation of adjuvant chemotherapy after surgery correspond to higher mortality (Hershman 
et al., 2006a) and/or inferior survival (Lohrisch et al., 2006).  On the other hand, some 
studies report that timing of initiation of RT and chemotherapy does not significantly affect 
long-term survival (Hartsell et al., 1995; Hebert-Croteau et al., 2004; Hershman et al., 
2006a; Shannon et al., 2003), and a recently published Cochrane review article by Hickey 
and colleagues (2006) on the topic concludes that different approaches to sequencing and 
timing of chemotherapy and RT do not significantly alter survival or recurrence as long as 
RT is initiated within 7 months of surgery.  At least two studies have shown that delays in 
breast cancer diagnosis and treatment are more common among black women (Gorin et al., 
2006; Lund et al., 2008); as such, if timing of initiation of RT or chemotherapy is important, 
differential timing of receipt of these by race/ethnicity may explain in part disparities in health 
outcomes.   
The impetus for developing quality metrics for breast cancer was motivated by, and 
based upon, the existence of well-established clinical guidelines (Desch et al., 2008).  
Quality metrics published by the American Society for Clinical Oncology (ASCO)/National 
Comprehensive Cancer Network (NCCN) not only specify appropriate type of therapy and 
clinical indications for use in breast cancer patients, but also time frames within which such 
therapy should commence (Desch et al., 2008).  Specifically, a quality metric is defined by a 
count numerator and an appropriate denominator indicating the eligible patient population 
that should receive the treatment or procedure (Hassett et al., 2008).  Defining the 
denominator requires specificity in timing; over what period should care be considered 
adherent if the treatment/procedure is received?  (Hassett et al., 2008)  Current breast 
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cancer quality metrics published by ASCO/NCCN specify that RT after BCS should be 
received within 1 year of diagnosis for stage I-III cancers and that postoperative, adjuvant 
chemotherapy should be received within 4 months of diagnosis for stage II-III, hormone 
receptor negative cancers (Desch et al., 2008).  Given the controversy over the clinical 
significance of timing of treatment and concurrent existence of quality metrics based upon 
time-sensitive endpoints, we assessed the effect of timing of initiation of RT and 
chemotherapy on 5-year, all-cause and disease-specific mortality.  Recognizing that each 
type of therapy is clinically indicated for different patient populations, this study examined 
timing of radiation therapy among women with stage I-III breast cancers who first received 
BCS, and timing of postoperative, adjuvant chemotherapy was examined among women 
with stage II-III breast cancers who received any surgery (either mastectomy or BCS) in 
separate regressions (Carlson et al., 1996; Desch et al., 2008; NIH, 1990; NIH, 2000).    
 
Methods 
Data Source and Patient Population 
Surveillance, Epidemiology, and End Results (SEER) data linked with Medicare 
claims data were used to examine the effect of therapeutic timing on long-term health 
outcomes for the population of women ages 65 and older diagnosed with primary breast 
cancer in 1994-2002, with vital status follow-up through 2007.  SEER data contain 
information about basic demographics, diagnosis, staging, tumor characteristics, and initial 
mode of treatment and have been linked to claims data for the population of older women 
insured by Medicare in order to provide more detailed information about cancer treatment, 
healthcare cost and utilization patterns, co-morbid conditions, and timing of treatment 
(Warren et al., 2002c).   
Inclusion/exclusion criteria for the current study required that subjects be females 
with a new diagnosis of American Joint Committee on Cancer (AJCC) stage I-III primary 
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breast cancer first reported during the study period.  Women with a prior breast cancer 
diagnosis, unknown or unclassified stage of disease, in situ disease, or stage IV disease 
were excluded.  In addition, women of racial/ethnic background other than non-Hispanic 
white, non-Hispanic black, and Hispanic were excluded, due to concerns about insufficient 
power to conduct sub-analyses, given the low number of these individuals in SEER registry 
areas.  Additionally, to ensure that we captured complete medical claims and treatment 
information, we included only women who were enrolled in parts A and B Medicare fee-for-
service in the 12 months prior to diagnosis and post-diagnosis, or until death, whichever 
occurred first.  We further excluded women with end stage renal disease (ESRD) and 
women younger than 65.  In addition, women with additional cancer diagnoses within 12 
months of the index breast cancer diagnosis were excluded to avoid confusion in 
distinguishing adjuvant therapies targeting multiple cancers.  Finally, only cancer patients 
who had received primary surgery were eligible for inclusion.  Primary surgery was defined 
as receipt of breast-conserving surgery (including segmental mastectomy, lumpectomy, 
quadrantectomy, tylectomy, wedge resection, nipple resection, excisional biopsy, or partial 
mastectomy) or mastectomy (including total simple, modified radical, radical, extended 
radical, or subcutaneous mastectomy) as the first definitive cancer treatment. Figure 18 
summarizes these general inclusion/exclusion criteria and resulting effects on sample size.  
For regression models of the effect of timing of RT, analyses were further limited to women 
who first received breast conserving surgery.  For regression models of the effect of timing 
of adjuvant chemotherapy, analyses were limited to women with stage II-III disease who had 
not received neoadjuvant chemotherapy.   
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Figure 18: General inclusion/exclusion criteria and corresponding effects on sample size 
First or only primary breast cancer cases from SEER areas diagnosed in 1994+, female only, N=254,803
INCLUDED EXCLUDED
65 or older
White, black, or Hispanic
Invasive cancer (stage I-IV)
N= 128,895
Original reason for entitlement is 
ESRD; diagnosed at autopsy or 
death; stage is in situ or missing
N= 125,908
Enrolled in Medicare HMO or 
lapse in parts A & B Medicare 
coverage
N= 44,376
No current ESRD diagnosis
N= 84,242
Has current ESRD
N= 277
Continuous parts A & B Medicare 
coverage 12 mos pre/post 
diagnosis
N= 84,519
No surgery
N= 1,395
Diagnosed in 1994-2002
N= 54,524
Stage IV disease
N= 5,070
Received surgery
N= 53,129
Stage I-III disease only
N= 79,172
Diagnosed in 2003 or later
N= 24,648
Additional cancer diagnosis in 1yr
N= 2,524
Cancer treatments (claims) found 
before diagnosis
N= 1,776
No additional cancer in 1yr
N= 48,829
No cancer treatments (claims) 
found before diagnosis
N= 51,353
 
Notes: SEER: Surveillance, Epidemiology and End Results; ESRD: End Stage Renal Disease; HMO: 
Health Maintenance Organization 
 
Dependent Variable 
The primary outcomes of interest for this study were all-cause and breast cancer-
specific mortality at five years post-diagnosis.  Overall survival time was not examined in 
light of inherent problems with measurement, including possible lead-time bias, length-time 
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bias, and analytic difficulties in teasing out competing risks of death in hazard models, which 
have been discussed at length by other authors (Boyle et al., 2005; Earle et al., 2002; Ries 
et al., 2006; Sant et al., 2006; Schwartz, 1980).  Recurrence also was not the focus of the 
current study, given that nearly all previous analyses have demonstrated that delayed 
therapy leads to significantly greater risk of recurrence (Gold et al., 2008; Hartsell et al., 
1995; Hebert-Croteau et al., 2004; Wyatt et al., 2008); more importantly, breast cancer 
recurrence or relapse is not easily measured using SEER-Medicare data.  Five years post-
diagnosis was considered an appropriate time period of follow-up to observe long-term 
benefits (and risks) of cancer treatment and is consistent with follow-up time employed in the 
literature.   
 
Independent Variables of Interest 
Timing of initiation of radiation therapy after breast conserving surgery and initiation 
of adjuvant chemotherapy in months since diagnosis were independent variables of interest 
in separate regressions.  Follow-up time for receipt of radiation therapy and adjuvant 
chemotherapy in the Medicare claims was extended to 24 months post-diagnosis in an 
attempt to capture all relevant RT and chemotherapy claims.  The first claim on record for 
each of the treatments of interest was retained as the initial date of service and from it we 
subtracted the date of diagnosis to determine time in months between diagnosis and 
initiation of therapy.  Some imprecision in time elapsed may exist because SEER reports 
only month and year of diagnosis, not month/day/year; as such, a woman diagnosed and 
receiving surgery on the last day of one month and receiving RT on the first day of the next 
month is classified as having received RT one month post-diagnosis.  Specification of timing 
variables was considered continuously and categorically based upon cutoff times previously 
shown in the clinical literature to be meaningful (Gold et al., 2008; Hartsell et al., 1995; 
Hebert-Croteau et al., 2004; Hershman et al., 2006a; Hershman et al., 2006b; Hickey et al., 
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2006; Lohrisch et al., 2006; Tsoutsou et al., 2009); based upon individual Wald test statistics 
and comparisons of the overall log likelihoods, categorical versions of timing variables were 
retained in final models.   
Race/ethnicity was also an important independent variable of interest.  Race/ethnicity 
was taken from SEER-reported data instead of Medicare-reported race/ethnicity data, 
because of well-known measurement problems and inconsistencies over time in the Social 
Security Administration’s definition of racial and ethnic groups and the fact that SEER uses 
a Spanish-surname algorithm in addition to self-reported race information to ensure greater 
accuracy in reporting Hispanic ethnicity (Bach et al., 2002a).  For the purposes of this 
analysis, racial/ethnic classification was limited to non-Hispanic white, non-Hispanic black, 
and Hispanic. 
 
Control Variables 
Control variables included age; stage; histologic grade; hormone receptor (estrogen 
and progesterone receptor) status; axillary lymph node involvement; co-morbidity score; 
State-Buy-In months (a proxy for eligibility for state assistance and low income status); 
marital status at diagnosis; year of diagnosis; census-tract level income, education, and 
neighborhood racial composition; and distances to nearest radiation therapy and 
chemotherapy providers and distance traveled for surgery.  With the exception of the co-
morbidity score and distance to providers, all control variables were obtained directly from 
the SEER-Medicare data files.  Co-morbidity score was calculated using a breast cancer-
specific method described by Klabunde and colleagues (2007), which expands upon the 
Charlson co-morbidity index by adding breast cancer-specific weights to the overall score for 
co-morbid conditions identified in inpatient and/or physician claims during the 12 month 
period prior to cancer diagnosis.  The NCI combined index has been shown to be a better 
predictor of non-cancer mortality in the breast cancer population compared to other 
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commonly used co-morbidity indices (Klabunde et al., 2007).  Distance traveled for surgery 
was calculated by obtaining the geographic longitudinal/latitudinal distance between patient 
residence zip code centroid and provider zip code centroid for the facility where women 
received breast conserving surgery or mastectomy, in an approach similar to that used by 
other authors (Meden et al., 2002; Nattinger et al., 2001; Schroen et al., 2005; Shea et al., 
2008).  Distance to nearest radiation and chemotherapy providers was determined similarly 
by calculating the minimum possible distance between patient residence zip code centroid 
and the zip code centroid for the nearest radiation and chemotherapy providers (based upon 
Medicare-certified providers who filed any radiation therapy or chemotherapy claim for any 
breast cancer patient during the time since 1994).  Straight-line distance to care has been 
shown to be a reasonable proxy for relative travel time and geographic access to care 
(Phibbs and Luft, 1995).  Distance variables were measured in miles and specified in 
analytic models using indicators for non-zero distances and zero distances (i.e., when 
provider and patient zip code were identical). 
 
Statistical Analysis 
Bivariate descriptive statistics first assessed overall and breast cancer-specific 
mortality 5 years post-diagnosis by racial/ethnic group (Pagano and Gauvreau, 2000; 
Rothman et al., 2008).  Survival time and timing of receipt of RT and/or chemotherapy also 
were examined by race/ethnicity.  Bivariate analyses employed chi-squared and t-tests as 
appropriate to test differences by group (Chernoff and Lehmann, 1954; Pagano and 
Gauvreau, 2000).   
Among those women who met inclusion criteria and received BCS followed by RT, 
multivariate logistic regression was used to determine likelihood of all-cause and breast 
cancer-specific mortality five years post-diagnosis as a function of timing of initiation of RT 
and race/ethnicity, controlling for covariates (Berkson, 1944; Hosmer and Lemeshow, 2000; 
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Rothman et al., 2008).  Among those women who met inclusion criteria and received post-
operative adjuvant chemotherapy, multivariate logistic regression was used to determine the 
likelihood of 5-year all-cause and breast cancer specific mortality as a function of timing of 
initiation of chemotherapy and race/ethnicity, controlling for covariates.  All models of timing 
of therapy were limited to only those women who actually received the treatment of interest; 
as such, women who did not receive RT at all were not included in timing of RT models, and 
women who did not receive chemotherapy at all were not included in timing of 
chemotherapy models.  Interactions of race/ethnicity and timing of therapy were examined 
to determine whether the effect of timing varied by racial/ethnic group (i.e., to test sub-
population variations in treatment effect) (Rothman et al., 2008; Wooldridge, 2006); lack of 
evidence for effect modification in multiple models led us to exclude these interaction terms 
from final model specification.   
We theorized that model behavior would vary substantially by age group and receipt 
of another anticancer therapeutic regimen, leading to a need to stratify by age group 
(younger than 70 years versus 70 years and older) and by receipt of another anticancer 
treatment (Rothman et al., 2008).  Clinical trials and subsequent guidelines for many years 
omitted women 70 years and older, likely affecting physician practicing patterns and health 
outcomes.  In addition, the effect of timing of one anticancer treatment on mortality may be 
modified by receipt of another anticancer therapy (e.g., chemotherapy when timing of RT is 
of primary interest in the model) due to the nature of sequencing and treatment planning.  
We tested the need for stratum-specific models empirically by first interacting each variable 
in the models with binary indicators for age group, receipt of chemotherapy (in RT timing 
models), and receipt of RT (in models of chemotherapy timing).  We then ran unrestricted 
(with interactions) and restricted models and comparing likelihood ratio test statistics 
(Rothman et al., 2008).  We also examined Wald test statistics for the joint significance of 
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the age-specific, chemotherapy-specific, and RT-specific interaction terms, in a Chow-like 
test fashion for the nonlinear model (Rothman et al., 2008). 
Missing data were examined closely.  In general, missing data were rare in the 
SEER-Medicare dataset; however, we included dummy indicators for important clinical 
variables that were missing in higher numbers (such as grade and lymph node status) and 
used complete case analysis (CCA) for remaining missing variables. 
Wald tests were used to test significance of variable constructs (e.g., the group of 
dummy variables for year of diagnosis) (Wooldridge, 2006).  Huber-White robust standard 
errors were reported for all final regressions, and the 5% level of significance was to assess 
predictive power of each independent variable (Hosmer and Lemeshow, 2000; Wooldridge, 
2006).  The general form for the adjusted logistic regression model examining the effect of 
timing of radiation therapy is: 
 
Pr(Deathi) = f(β0 + β1TimingRTi + β2Race/Ethnicityi + β3Chemoi + γZi+ εi) 
Where “TimingRT” is timing of receipt of radiation therapy, “Race/Ethnicity” is non-
Hispanic white, non-Hispanic black, or Hispanic, “Chemo” is chemotherapy, “Z” is a 
vector of all other patient and community control variables, and “ε” is the error term. 
 
The general form of the adjusted logistic regression examining the effect of timing of 
adjuvant chemotherapy is: 
 
Pr(Deathi) = f(β0 + β1TimingCi + β2Race/Ethnicityi + β3RTi + γZi+ εi) 
Where “TimingC” is timing of receipt of chemotherapy, “Race/Ethnicity” is non-
Hispanic white, non-Hispanic black, or Hispanic, “RT” is radiation therapy, “Z” is a 
vector of all other patient and community control variables, and “ε” is the error term. 
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Results 
 Of the 48,829 women who met general inclusion/exclusion criteria, 38,574 women 
received breast conserving surgery as the first anticancer treatment post-diagnosis and 
were eligible for the sub-sample of women for whom timing of RT was assessed.  20,898 
women with stage II-III disease received surgery, had no claims for neoadjuvant 
chemotherapy, and thus were included in the sub-sample for women for whom timing of 
chemotherapy was assessed.  In bivariate analyses, across both RT and chemotherapy 
sub-samples (Tables 20 and 21), non-Hispanic black women died more often from breast 
cancer within 5 years (11% versus 5% in non-Hispanic white women and 7% in Hipanic 
women; p<0.001) and had higher all-cause mortality at 5 years (31% versus 22% in non-
Hispanic white women and 23% in Hispanic women; p<0.001).  Black women were also 
least likely to ever receive RT (51% versus 58% in white women and 58% in Hispanic 
women; p<0.001) (Table 20).  No statistically significant differences were observed in overall 
receipt of adjuvant chemotherapy by race/ethnicity (p=0.111).  Median time to initiation of 
RT was 2 months post-diagnosis, conditioned on not having received chemotherapy, 
whereas median time to initiation of RT was 5 months post-diagnosis, among women who 
received chemotherapy.  Timing of initiation of RT varied significantly by race/ethnicity; 
overall, approximately 40% of white women receiving RT within two months of diagnosis, 
compared to 26% of black women and 34% of Hispanic women (p<0.001), but black women 
and Hispanic women who received RT also were more likely to have received adjuvant 
chemotherapy (24% and 23% respectively, compared to 20% in white women, p<0.001)  
(Table 20).  Median time to initiation of adjuvant chemotherapy was 2 months post-
diagnosis; timing of initiation of chemotherapy also varied across racial/ethnic group, but to 
a lesser extent, with non-Hispanic black women being slightly more likely to commence 
chemotherapy beyond 2 months post-diagnosis (Table 21).   
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Table 20: Descriptive statistics of SEER-Medicare patient sample for timing of radiation 
therapy models (women with stage I-III cancer who received breast conserving surgery) 
Characteristic % or 
mean(SD) 
% or 
mean(SD) 
% or 
mean(SD) 
p-value 
 White 
(N=34,965) 
Black 
(N=2,273) 
Hispanic 
(N=1,336) 
 
Dependent variable     
Died within 5 yrs of diagnosis  22.22 30.53 22.75 <0.001 
Died of breast cancer in 5 yrs 5.33 10.07 6.89 <0.001 
Mean survival time (months) 59.9 (36.9) 
 
53.4 (36.2) 
 
56.7 (36.4) 
 
<0.001~ 
0.053# 
Key independent variable     
Ever received RT 58.18 51.37 58.35 <0.001 
Timing of initiation of RT, conditioned on 
having received RT (mean in months) 2.73 (2.93) 3.79 (3.51) 3.12 (3.00) 
<0.001~ 
<0.001# 
<=6 mos. 90.90 82.23 87.48 
<0.001 >6 and <=12 mos.  7.43 14.85 10.71 
>12 mos. 1.67 2.92 1.81 
Patient-level variables 
Age at diagnosis 75.7 (6.64) 
 
75.2 (6.79) 
 
74.4 (6.37) 
 
0.0013~ 
<0.001# 
Stage at diagnosis    
 
Stage I 64.47 52.35 56.44 
<0.001 Stage II 32.3 41.53 38.47 
Stage III 3.23 6.12 5.09 
Grade     
Well-differentiated 22.71 15.05 21.78 
<0.001 
Moderately-differentiated 40.58 34.49 36.75 
Poorly-differentiated 22.76 31.54 26.57 
Anaplastic 1.54 1.63 1.27 
Grade missing 12.41 17.29 13.62 
Hormone receptor status     
ER positive 71.8 56.8 66.24 
<0.001 ER unknown 16.51 24.55 21.11 PR positive 59.02 45.18 54.27 
PR unknown 17.81 25.60 22.16 
Node positive 18.51 23.8 22.83 
<0.001 Node status missing 24.14 26.88 21.33 
Co-morbidity index score 0.25 (0.46) 
 
0.41 (0.61) 
 
0.33 (0.53) 
 
<0.001~ 
<0.001# 
Received chemotherapy 19.91 24.34 23.16 <0.001 
Married 44.97 24.33 39.3 <0.001 
Low income (State-Buy-In) 13.47 44.57 49.4 <0.001 
Year of diagnosis     
1994 8.62 8.67 6.81 
0.444 
1995 8.76 8.93 9.06 
1996 8.54 8.62 8.38 
1997 8.78 8.32 9.13 
1998 8.49 8.71 7.71 
1999 8.93 7.88 8.98 
2000 15.81 17.69 16.77 
2001 16.26 15.66 16.62 
2002 15.82 15.53 16.54 
Notes: p-values derived from chi-squared tests or t-tests as appropriate; ER: estrogen receptor; PR: 
progesterone receptor; RT: radiation therapy; SD: standard deviation; ~ indicates two-sample t-tests 
between white and black groups; # indicates two-sample t-tests between white and Hispanic groups 
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Table 21: Descriptive statistics of SEER-Medicare patient sample for timing of adjuvant 
chemotherapy models (women with stage II-III cancers who received primary surgery) 
Characteristic % or 
mean(SD) 
% or 
mean(SD) 
% or 
mean(SD) 
p-value 
 White 
(N=18,462) 
Black 
(N=1,596) 
Hispanic 
(N=840) 
 
Dependent variable     
Died within 5 yrs of diagnosis  35.14 44.55 34.68 <0.001 
Died of breast cancer in 5 yrs 13.05 19.92 14.66 <0.001 
Mean survival time (months) 51.1 (34.9) 
 
44.8 (32.6) 
 
50.3 (34.5) 
 
<0.001~ 
0.69# 
Key independent variable     
Ever received chemotherapy 34.7 36.85 36.87 0.111 
Timing of chemotherapy initiation, 
conditioned on receiving chemotherapy 
(mean in months)  3.78 (5.22) 4.09 (5.16) 3.31 (4.25) 
 
0.117~ 
0.168# 
<=4 mos.  84.53 81.77 85.71 0.169 
>4 mos. 15.47 18.23 14.29 
Patient-level variables     
Age at diagnosis 76.7 (7.1) 
 
76.2 (7.17) 
 
75.6 (7.13) 
 
0.009~ 
<0.001# 
Stage at diagnosis    
 
Stage II 87.33 82.08 85.12 
<0.001 Stage III 12.67 17.92 14.88 
Grade     
Well-differentiated 12.1 7.96 9.29 
<0.001 
Moderately-differentiated 38.75 30.2 37.14 
Poorly-differentiated 34.84 45.55 39.52 
Anaplastic 2.28 1.69 1.9 
Grade missing 12.02 14.6 12.14 
Hormone receptor status     
ER positive 67.91 53.38 62.62 
<0.001 ER unknown 16.1 23.5 21.07 PR positive 54.78 41.54 52.14 
PR unknown 17.2 24.19 22.14 
Axillary lymph nodes     
Node positive 53.92 53.51 55.12 0.066 Node status missing 15.15 17.61 14.17 
Co-morbidity index score 0.29 (0.51) 
 
0.41 (0.62) 
 
0.35 (0.55) 
 
<0.001~ 
0.001# 
Married 40.01 23.31 34.17 <0.001 
Low income (State-Buy-In) 17.69 49.62 53.81 <0.001 
Year of diagnosis     
1994 9.14 8.65 8.57 
0.807 
1995 8.64 8.71 9.17 
1996 8.15 7.89 7.62 
1997 8.06 7.71 8.93 
1998 8.15 8.02 7.98 
1999 8.16 8.52 8.93 
2000 16.18 18.23 16.31 
2001 17.08 15.23 17.26 
2002 16.45 17.04 15.24 
Notes: p-values derived from chi-squared tests or t-tests as appropriate; ER: estrogen receptor; PR: 
progesterone receptor; RT: radiation therapy; SD: standard deviation; ~ indicates two-sample t-tests 
between white and black groups; # indicates two-sample t-tests between white and Hispanic groups 
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 In terms of the distribution of covariates across racial/ethnic group, black and 
Hispanic women were more likely to be diagnosed with more advanced stage disease 
(p<0.001) in both sub-samples (Tables 20 and 21).  Black women more often were classified 
as having poor histologic grade and less often had hormone receptor positive tumors 
(Tables 20 and 21).  Black women also suffered the highest burden of co-morbidities, 
followed by Hispanic women (Tables 20 and 21).  As well, black women and Hispanic 
women were less likely than white women to be married and more likely to be classified as 
low-income according to the State-Buy-In variable (Tables 20 and 21). 
 
Mortality:  Effect of Timing of RT 
 Results of multivariate analyses of the effects of timing of RT on all-cause and breast 
cancer-specific mortality are summarized in Tables 22 and 23, stratified by age group (65-69 
years versus 70 years and older) and receipt of chemotherapy.  Across all models, 
regardless of age group and receipt of chemotherapy, receiving RT more than 1 year after 
diagnosis corresponded to significantly higher odds of all-cause and breast-cancer specific 
mortality (ORs ranging from 3.88 to 13.04, p<0.01) (Tables 22 and 23).  Among women 
ages 65-69 who did not receive chemotherapy (Table 23), initiating RT between 4 and 5 
months corresponded to 2.95 higher odds of all-cause mortality (p<0.05), and initiation RT 
between 5 and 6 months corresponded to 4.85 higher odds of all-cause mortality (p<0.05), 
as compared with women initiating RT within 1 month of diagnosis.  Among women ages 70 
and older who did not receive adjuvant chemotherapy (Table 23), initiating RT more than 6 
months after diagnosis resulted in significantly higher odds of both all-cause mortality (Odds 
Ratio ([OR] 6-12mos: 2.80, p<0.01; OR1year+: 3.88, p<0.01) and breast cancer-specific 
mortality (OR6-12mos: 7.35, p<0.01; OR1year+: 6.31, p<0.01).   
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Table 22: Odds ratios for the effect of timing of RT on mortality, among breast cancer patients 
who received breast conserving surgery and adjuvant chemotherapy, stratified by age group 
Independent Variable 65-69 years old (N=1762) 70 years and older (N=3253) 
 
All-cause 
mortality 
BrCa 
mortality  
All-cause 
mortality 
BrCa  
mortality  
Timing of initiation of RT (<=1 month post-diagnosis is reference) 
>1 and <=2 mos. 1.73+ 1.56 1.21 0.97 
>2 and <=3 mos. 0.66 0.68 1.05 0.74 
>3 and <=4 mos. 0.53* 0.57 0.69+ 0.97 
>4 and <=5 mos. 0.61 0.70 0.73 0.95 
>5 and <=6 mos. 0.49** 0.64 0.95 1.07 
>6 and <=12 mos. 0.74 0.92 0.85 0.99 
>12 mos. 5.79** 6.58** 4.14** 5.04** 
Race/ethnicity (white is reference)    
Black 1.54 1.97* 1.24 1.38 
Hispanic     1.21 0.85 1.28 1.58 
Covariates 
Age (grouped in 5-year categories; 70-74 years is reference) 
75-79 years - - 1.49** 1.38* 
80-84 years - - 2.01** 1.54* 
85 years and older - - 2.43** 1.36 
Received surgery in diagnosis month 1.45* 2.40** 1.09 1.2 
Stage at diagnosis (stage I is reference) 
Stage II 1.83** 2.29** 1.73** 2.20** 
Stage III 5.32** 6.55** 4.35** 5.84** 
Grade (well-differentiated is reference)     
Moderately-differentiated 1.89* 3.04* 1.06 1.49 
Poorly-differentiated 3.02** 6.45** 1.51** 2.59** 
Anaplastic 2.63 5.73* 1.4 2.29* 
Grade missing 2.27* 5.72** 1.05 1.61 
Hormone receptor status (negative, borderline, or unknown is reference) 
ER positive 0.68+ 0.66 0.81+ 0.69* 
PR positive 0.75 0.58+ 0.77* 0.63** 
Node status (node negative is reference) 
Node positive 1.15 1.01 1.06 1.31 
Node status missing 1.86* 1.34 1.87** 1.16 
Co-morbidity index (score of 0 is reference) 
0.01-1 1.39+ 0.81 1.53** 1.16 
1.01-2 3.06** 2.50* 2.84** 1.35 
> 2 2.24 1.28 3.43** 0.63 
Married 0.8 1.02 0.91 0.87 
Low income proxy (State-Buy-In) 1.19 1.53 0.91 0.88 
Year of diagnosis (1994 is reference)     
1995 0.84 0.87 0.53* 0.54* 
1996 1.02 1.36 0.46** 0.49* 
1997 1.29 1.33 0.52* 0.53* 
1998 0.75 0.90 0.40** 0.30** 
1999 0.88 1.08 0.49** 0.37** 
2000 0.49+ 0.62 0.44** 0.31** 
2001 0.71 0.66 0.41** 0.24** 
2002  0.56 0.47 0.27** 0.19** 
Notes: + significant at 10%; * significant at 5%; ** significant at 1%; robust standard errors used; 
BrCa: breast cancer; ER: estrogen receptor; PR: progesterone receptor; RT: radiation therapy; 
regressions also control for distance traveled to surgery, distance to nearest RT provider, and zip 
code-level socioeconomic variables; 
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 Table 23: Odds ratios for the effect of timing of RT on mortality, in breast cancer patients who 
received breast conserving surgery with no adjuvant chemotherapy, stratified by age group  
Independent Variable 65-69 years old (N=3320) 70 years and older 
(N=12184) 
 
All-cause 
mortality 
BrCa 
mortality  
All-cause 
mortality 
BrCa 
mortality  
Timing of initiation of RT (<=1 month post-diagnosis is reference) 
>1 and <=2 mos. 1.19 1.36 0.99 0.98 
>2 and <=3 mos. 1.10 0.66 0.93 0.91 
>3 and <=4 mos 0.64 1.18 1.28+ 1.51 
>4 and <=5 mos. 2.95* 1.05 0.94 1.33 
>5 and <=6 mos. 4.85* # 1.22 1.52 
>6 and <=12 mos. 1.85 2.16 2.80** 7.35** 
>12 mos. 6.54** 13.04** 3.88** 6.31** 
Race/ethnicity (white is reference)    
Black 0.68 1.78 1.01 0.86 
Hispanic     0.63 2.39 0.87 1.09 
Covariates 
Age (grouped in 5-year categories; 70-74 years is reference) 
75-79 years - - 1.27** 1.05 
80-84 years - - 1.99** 1.41* 
85 years and older - - 3.35** 1.3 
Received surgery in diagnosis month 1.17 0.96 0.93 0.9 
Stage at diagnosis (stage I is reference) 
Stage II 1.67* 2.37* 1.50** 2.98** 
Stage III 3.89* 2.77 3.29** 6.32** 
Grade (well-differentiated is reference) 
Moderately-differentiated 1.14 2.15 1.26** 2.27** 
Poorly-differentiated 1.52+ 3.67** 1.66** 4.75** 
Anaplastic 4.02** 7.19* 1.25 5.10** 
Grade missing 0.9 0.84 1.25* 2.52** 
Hormone receptor status (negative, borderline, or unknown is reference) 
ER positive 0.99 0.67 0.88 0.61** 
PR positive 1.04 1.27 0.95 1.03 
Node status (node negative is reference) 
Node positive 1.60+ 1.83 1.27* 1.62** 
Node status missing 1.62* 0.95 1.58** 2.14** 
Co-morbidity index (score of 0 is reference) 
0.01-1 2.43** 1.44 2.02** 1.05 
1.01-2 5.94** 2.00 3.38** 1.36 
> 2 11.39** 4.70 10.06** 3.14** 
Married 0.97 0.88 0.87* 0.76* 
Low income proxy (State-Buy-In) 1.29 0.7 1.06 0.8 
Year of diagnosis (1994 is reference) 
1995 0.65 0.81 0.82 0.72 
1996 0.47* 0.39 0.70** 0.63* 
1997 0.71 1.05 0.76* 0.60* 
1998 1.0 0.79 0.81 0.81 
1999 0.64 0.95 0.74* 0.76 
2000 0.81 1.0 0.76* 0.78 
2001 0.61 1.01 0.81+ 0.59* 
2002 0.73 0.10+ 0.72* 0.50** 
Notes: + significant at 10%; * significant at 5%; ** significant at 1%; # this variable perfectly predicted 
the outcome, as a result, 17 observations were dropped; BrCa: breast cancer; ER: estrogen receptor; 
PR: progesterone receptor; RT: radiation therapy; regressions also control for distance traveled to 
surgery, distance to nearest RT provider, and zip code-level socioeconomic variables 
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In models omitting timing of RT variables (not shown), race/ethnicity as a construct 
was a significant predictor of all-cause and breast cancer-specific mortality; however, when 
timing of therapy was considered, the effects of black race and Hispanic ethnicity were no 
longer statistically significant.  The exception to this finding was the model examining breast 
cancer-specific mortality among women ages 65-69 years old conditioned on receiving 
chemotherapy (Table 21), in which black race was associated with nearly twice the odds of 
breast cancer-specific mortality, controlling for all other variables (p<0.05). 
Other covariates behaved in expected ways; specifically, increasing age, more 
advanced stage of disease, worse histologic grade, lymph node positivity and missing lymph 
node status, and higher co-morbidity all were generally associated with higher odds of both 
all-cause and breast cancer-specific mortality (Tables 22 and 23).  Odds of all-cause and 
breast-cancer specific mortality generally were generally lower with hormone receptor 
positivity and more recent year of diagnosis (Tables 22 and 23).  Low income status and 
distance to care (results not shown) were not predictive of mortality in this sub-sample 
(Tables 22 and 23).  Among younger women ages 65-69 who received chemotherapy in 
addition to RT (Table 22), receiving surgery in the same month as diagnosis corresponded 
to a higher likelihood of all-cause (OR: 1.45, p<0.05) and breast cancer-specific (OR: 2.40, 
p<0.01) mortality.  Among women ages 70 years and older who did not receive 
chemotherapy (Table 23), being married was associated with significantly lower odds of all-
cause (OR: 0.87, p<0.05) and breast cancer-specific (OR: 0.76, p<0.05) mortality.   
 
Mortality:  Effect of Timing of Chemotherapy 
Results of multivariate analyses of the effects of timing of adjuvant chemotherapy on 
all-cause and breast cancer-specific mortality are summarized in Tables 24 and 25, stratified 
by age group and receipt of RT.  In models conditioned on having received RT (Table 24), 
regardless of age group examined, initiating chemotherapy more than 4 months post-
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diagnosis was highly associated with increased odds of both all-cause and disease-specific 
mortality; however, in these models, initiation of chemotherapy from prior to 4 months post-
diagnosis was not significantly different from initiating chemotherapy within 1 month of 
diagnosis (the reference group).  Among women who did not receive RT in addition to 
chemotherapy (Table 25), commencing adjuvant chemotherapy more than 4 months post-
diagnosis generally was associated with higher mortality, regardless of age group, but in 
women ages 65-69, the odds of all-cause mortality increased substantially with increasing 
time to initiation of RT (OR2-3mos: 1.69; p<0.10; OR3-4mos: 2.91; p<0.05; OR4mos+: 2.34; 
p<0.05).  In terms of race/ethnicity, chemotherapy timing models conditioned on having 
received RT (Table 24) indicated that black race among younger women was highly 
associated with increased odds of all-cause mortality (ORblack: 1.97, p<0.01) and breast 
cancer-specific mortality (ORblack: 2.40, p<0.01), whereas Hispanic ethnicity was 
associated with higher odds of breast cancer-specific mortality among women 70 years and 
older.  In contrast, in multivariate chemotherapy models conditioned on not having received 
RT, race/ethnicity was not predictive of mortality (Table 25). 
In terms of covariates in these models, increasing age, more advanced stage, and 
poorly differentiated cell grade were highly correlated with increased odds of all-cause and 
breast cancer-specific mortality across models, regardless of age or RT receipt, whereas 
hormone receptor positivity and increasing year of diagnosis generally were associated with 
lower odds of mortality (Tables 24 and 25).  Important differences existed across strata and 
across the dependent variable specified.  For example, lymph node positivity and missing 
lymph node status were more important (and highly significant) predictors of all-cause and 
breast cancer specific mortality among women 70 years and older (Tables 24 and 25).  As 
well, the effect of low income status only appeared to matter among women younger than 
70 who did not receive RT (OR for all-cause mortality: 2.03, p<0.01; OR for breast cancer-
specific mortality: 2.01, p<0.01) (Table 25).  Finally, depending on the dependent variable 
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examined (all-cause mortality versus breast cancer-specific mortality), the effects of 
covariates varied; for example co-morbidity burden played a greater role in predicting all-
cause mortality than it did in predicting breast cancer-specific mortality (Tables 24 and 25).   
Table 24: Odds ratios for the effect of timing of adjuvant chemotherapy on mortality, among 
stage II-III breast cancer patients who received surgery and RT, stratified by age group  
Independent Variable 65-69 years old (N=1481) 70 years and older (N=2713) 
 
All-cause 
mortality 
BrCa 
mortality  
All-cause 
mortality 
BrCa 
mortality  
Timing of initiation of chemotherapy (<=1 month post-diagnosis is reference) 
>1 and <=2 mos. 0.87 0.98 1.07 1.12 
>2 and <=3 mos. 1.02 0.75 1.18 1.14 
>3 and <=4 mos 0.51 0.46 1.12 1.04 
>4 mos. 2.79** 3.89** 2.77** 2.64** 
Race/ethnicity (white is reference)    
Black 1.97** 2.40** 1.14 1.22 
Hispanic     1.33 1.4 1.53 1.79* 
Covariates 
Age (grouped in 5-year categories; 70-74 years is reference) 
75-79 years - - 1.64** 1.55** 
80-84 years - - 1.95** 1.48* 
85 years and older - - 2.59** 2.08** 
Received surgery in diagnosis month 1.52* 1.77** 1.09 1.02 
Stage at diagnosis (stage II is reference) 
Stage III 2.49** 2.74** 2.54** 2.62** 
Grade (well/moderately differentiated is reference) 
Poorly differentiated/anaplastic 2.00** 2.51** 1.74** 2.21** 
Grade missing 1.36 1.69 1.1 1.29 
Hormone receptor status (negative, borderline, or unknown is reference) 
ER positive 0.53** 0.47** 0.73* 0.63** 
PR positive 0.91 0.73 0.65** 0.62** 
Node status (node negative is reference) 
Node positive 1.21 1.33 1.26+ 1.45* 
Node status missing 1.90+ 1.9 1.53* 1.2 
Co-morbidity index (score of 0 is reference) 
0.01-1 1.52* 0.98 1.39** 0.96 
> 1 1.92 1.0 2.59** 1.14 
Married 0.74* 0.87 0.84+ 0.84 
Low income proxy (State-Buy-In) 0.97 1.05 1.08 1.03 
Year of diagnosis (1994 is reference) 
1995 0.71 0.63 0.64+ 0.59+ 
1996 0.91 1.14 0.58* 0.61+ 
1997 1.37 1.22 0.53* 0.48* 
1998 0.82 1.01 0.35** 0.29** 
1999 1.0 0.87 0.42** 0.35** 
2000 0.56+ 0.62 0.45** 0.31** 
2001 0.63 0.50+ 0.42** 0.29** 
2002 0.53+ 0.38* 0.29** 0.17** 
Notes: + significant at 10%; * significant at 5%; ** significant at 1%; robust standard errors used; 
BrCa: breast cancer; ER: estrogen receptor; PR: progesterone receptor; RT: radiation therapy; 
regressions also control for distance traveled to surgery, distance to nearest RT provider, and zip 
code-level socioeconomic variables 
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Table 25: Odds ratios for the effect of timing of adjuvant chemotherapy on mortality, in stage 
II-III breast cancer patients who received surgery and no RT, stratified by age group 
Independent Variable 65-69 years old (N=811) 70 years and older (N=1792) 
 
All-cause 
mortality 
BrCa 
mortality  
All-cause 
mortality 
BrCa 
mortality  
Timing of initiation of chemotherapy (<=1 month post-diagnosis is reference) 
>1 and <=2 mos. 0.77 0.82 1.15 0.79 
>2 and <=3 mos. 1.69+ 1.04 1.05 1.03 
>3 and <=4 mos 2.91* 1.08 1.42 1.30 
>4 mos. 2.34* 2.10 1.67** 1.69* 
Race/ethnicity (white is reference)    
Black 0.77 0.64 1.25 0.99 
Hispanic     1.35 0.52 0.68 0.82 
Covariates 
Age (grouped in 5-year categories; 70-74 years is reference) 
75-79 years - - 1.38* 1.05 
80-84 years - - 2.21** 1.25 
85 years and older - - 3.19** 1.12 
Received surgery in diagnosis month 1.59+ 1.48 1.11 0.95 
Stage at diagnosis (stage II is reference) 
Stage III 1.81+ 1.64 3.14** 4.96** 
Grade (well/moderately differentiated is reference) 
Poorly differentiated/anaplastic 3.28** 3.85** 1.60** 2.32** 
Grade missing 1.90+ 1.64 1.38+ 1.38 
Hormone receptor status (negative, borderline, or unknown is reference) 
ER positive 0.64 0.56 0.95 0.79 
PR positive 0.86 0.69 0.69* 0.54** 
Node status (node negative is reference) 
Node positive 1.00 1.78+ 1.52** 1.78** 
Node status missing 1.17 2.01 2.06** 2.44** 
Co-morbidity index (score of 0 is reference) 
0.01-1 1.44 0.72 1.36* 0.93 
> 1 5.06** 1.43 3.74** 1.75* 
Married 0.50** 0.91 0.75* 0.70* 
Low income proxy (State-Buy-In) 2.03** 2.01* 1.08 0.74 
Year of diagnosis (1994 is reference) 
1995 0.81 1.02 1.11 0.97 
1996 0.88 1.58 1.12 0.96 
1997 1.72 1.86 1.12 0.90 
1998 0.59 0.85 1.10 0.81 
1999 0.86 0.46 0.97 0.65 
2000 1.79 1.85 1.10 0.76 
2001 0.72 0.59 0.96 0.67 
2002 0.71 0.61 1.26 0.53* 
Notes: + significant at 10%; * significant at 5%; ** significant at 1%; robust standard errors used; 
BrCa: breast cancer; ER: estrogen receptor; PR: progesterone receptor; RT: radiation therapy; OR: 
odds ratio; regressions also control for distance traveled to surgery, distance to nearest RT provider, 
and zip code-level socioeconomic variables 
 
Discussion 
This study examined early versus late receipt of RT and chemotherapy and variation 
in treatment effects, in terms of the long-term effects of RT and chemotherapy in different 
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racial/ethnic and age groups over time.  Consistent with prior studies (Gorin et al., 2006; 
Lund et al., 2008; Shugarman et al., 2009), we have shown that significant differences exist 
by racial/ethnic group in timing of initiation of radiation therapy and to a lesser extent in 
timing of initiation of chemotherapy.  We also have demonstrated that differences in timing 
of therapy correlate with health outcomes, specifically, all-cause and breast cancer-specific 
mortality.  Our analyses indicate that initiation of RT beyond 1 year post-diagnosis, 
regardless of age and receipt of adjuvant chemotherapy, is associated with a greater 
likelihood of both all-cause and disease specific mortality.  Additionally, among women 70 
years and older who received RT in the absence of chemotherapy, initiation of RT more 
than 6 months post-diagnosis was associated with about three times the odds of all-cause 
mortality and seven times the odds of breast cancer-specific mortality.  As well, we observed 
that among women ages 65-69 who did not receive chemotherapy, initiating RT later than 4-
5 months post-diagnosis, relative to initiation within one month of diagnosis, was associated 
with significantly higher odds of all-cause mortality (Table 23).  These data imply that risk of 
local recurrence in this population may contribute to mortality and that RT generally should 
be initiated within six months of diagnosis, particularly if adjuvant chemotherapy is not part 
of the treatment plan.  This finding is similar to the conclusions reached by Tsoutsou and 
colleagues (2009) and Hickey and colleagues (2006) that RT should be initiated within 7 
months of surgery, but different studies have suggested that RT should be initiated within 3-
4 months to reduce the likelihood of poor health outcomes (Gold et al., 2008; Hartsell et al., 
1995; Hebert-Croteau et al., 2004; Hershman et al., 2006b).   
In terms of timing of adjuvant chemotherapy, initiation of chemotherapy more than 4 
months post-diagnosis was associated with significantly worse outcomes in terms of both 
all-cause and breast-cancer specific mortality.  This finding is somewhat similar to findings 
from Lohrisch and colleagues (2006) and Hershman and colleagues (2006a) whose studies 
suggested that adjuvant chemotherapy should be commenced within 12 weeks of surgery.  
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Particularly among younger women (65-69 years) who did not receive RT, early initiation of 
chemotherapy (within 2 months of diagnosis) appeared important, at least in terms of all-
cause mortality (Table 25).  Receipt of adjuvant chemotherapy earlier than 3 months post-
diagnosis was not significantly different from initiation of chemotherapy within one month of 
diagnosis across models, as seen in other observational studies cited above.  In models of 
women ages 65-69 who received RT in addition to chemotherapy, black race was 
associated with increased odds of all-cause and breast cancer specific mortality, controlling 
for all other variables; similarly, Hispanic ethnicity was associated with higher odds of breast 
cancer-specific mortality among women ages 70 and older who received RT (Table 24).  
The effects of race/ethnicity mattered less in models of women who received chemotherapy 
in the absence of RT, after controlling for covariates (Table 25).   
Delays in care occur for a number of reasons and may be related to poor provider-
patient communication, delays in referral, inadequate social support, lack of transportation, 
distance to oncology providers, opportunity costs involved in seeking care (e.g., missed 
work days or loss of employment), and/or ambiguity about the value of adjuvant therapy, 
given the side effect profile of many anticancer treatments (Carpenter and Peppercorn, 
2009; Gold et al., 2008; Hershman et al., 2006a, Hershman et al., 2006b).  The decision to 
undergo potentially difficult treatment regimens like chemotherapy is complex given the risks 
and benefits of adjuvant therapy and requires a more nuanced view of clinical decision 
making, including an understanding of the structural and organizational characteristics of 
health services that may impact decisions (Wheeler et al., unpublished data).  It is therefore 
important to further evaluate the potential for delays in receipt of RT among black women 
and Hispanic women with early stage breast cancer to contribute to disparities in breast 
cancer outcomes and if validated, to develop educational and structural interventions to 
address this issue.     
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This study has several strengths and limitations worth mention.  This study reflects 
the experiences of tens of thousands of women in the US diagnosed with breast cancer over 
a nine-year period and thus provides important information about the longitudinal effects of 
timing of radiation therapy and timing of chemotherapy on long term health outcomes.  
These data are a unique resource for examining patterns of care in cancer among Medicare 
beneficiaries, who represent 97% of the US population ages 65 and older, and can provide 
more treatment detail than registry-based data or claims data alone (Warren et al., 2002c).  
Additionally, we have attempted to control for endogeneity in treatment selection by limiting 
our analyses to women who received surgery plus the adjuvant treatment of interest and by 
stratifying on additional adjuvant treatments (excluding hormone therapy); thus, we were 
able to isolate the effect of timing and effects of race/ethnicity from potentially selection-
biased decisions about whether to undergo treatment at all.  Previous authors have 
demonstrated that black women with breast cancer may be less likely to receive certain 
anticancer treatments compared to white women (see, for example, Bhargava and Du, 
2009), and treatment selection may play a substantial role in determining heterogeneity in 
outcomes (Basu et al., 2007; Hadley et al., 2003). We have further attempted to limit 
possible endogeneity in the form of reverse causality (specifically in this case, higher 
likelihood of mortality and poor health status affecting timing of treatment) by including 
measures for co-morbidity and cancer severity.  Nevertheless, some bias may remain; 
unobservable variables such as physician practicing patterns and intent, health-seeking 
behavior, social support beyond marital status, and patient trust in the health care system 
may affect timing of care and long-term health outcomes.  Omission of such variables, if 
important, could have led to an incomplete picture of the effect of timing of therapy on 
mortality.   
We used complete case analysis (CCA) to deal with missing data and to avoid 
systematic bias potentially introduced by imputation (Rothman et al., 2008; Wooldridge, 
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2006).  CCA involves dropping observations for which data are incomplete and running the 
analyses only on observations with complete information.  The advantage to this approach 
is that it avoids the biases involved in using multiple imputation approaches, when data are 
missing at random (Rothman et al., 2008; Wooldridge, 2006).  When data are not missing at 
random, however, using CCA can compound problems because it essentially excludes 
whole groups of the sample that may be important (i.e., introducing selection bias) 
(Rothman et al., 2008; Wooldridge, 2006).  Alternatives to using CCA are imputing values 
for missing data and dropping variables for which there are significant missing numbers 
(Rothman et al., 2008; Wooldridge, 2006).  The latter would mean that we would no longer 
have effect estimates for the covariates missing data and moreover, there may be a 
confounding problem if the covariate is no longer in the model (Rothman et al., 2008).  The 
former may not make sense particularly with clinical data because treatment decisions are 
made based upon available clinical information, and imputation often involves random 
replacement, which is of course not clinically meaningful.  Based upon these considerations 
and after noting that missing data were rare in the SEER-Medicare dataset, we opted 
against imputation and rather checked for patterns/predictors of missing data (Rothman et 
al., 2008) and used dummy variables for missing data where appropriate (e.g., lymph node 
positivity and histological grade). 
Noting that racial/ethnic minority groups in this study were more likely to have 
clinically poorer prognosis based upon tumor features and clinical measures such as stage, 
histologic grade, hormone receptor status, and lymph node positivity and further noting that 
these factors were highly predictive of all-cause and breast cancer-specific mortality, it is 
critical that at-risk minority patients receive guideline-appropriate care as early as possible.  
Based on our findings and supported by prior studies as noted above, RT should be initiated 
within six months of diagnosis and adjuvant chemotherapy should be initiated within four 
months of diagnosis in appropriate patients.  Understandably, co-morbidity burden and 
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ability to withstand potentially invasive adjuvant treatments play a role in treatment planning, 
and evidence suggests that they vary with race/ethnicity and age (Barni et al., 2010; 
Bouchardy et al., 2007; Du and Goodwin, 2001; Tammemagi et al., 2005).  However, among 
healthy women, there is very little evidence to suggest that increasing age or ethnic/racial 
identification reduces the effectiveness of RT or chemotherapy (Barni et al., 2010; Smith et 
al., 2005).  Given that delay in initiation of adjuvant therapy may contribute to poor breast 
cancer outcomes among minority patients, research is needed to address the causes of 
delay, address barriers to care, and explore public health interventions that might address 
health disparities through improved and timely utilization of adjuvant therapies.     
CHAPTER 7:  POLICY IMPLICATIONS, LIMITATIONS, AND CONCLUSIONS 
 
Summary of findings, policy implications and limitations 
This study used population-based SEER-Medicare data to examine receipt of high 
quality care across vulnerable sub-population groups, focusing on structural/organizational 
features of health services and dispersion of these characteristics across diverse groups of 
people.  This study represents one of the first attempts to examine these issues interactively 
and comprehensively in breast cancer research.  Previous studies that have explored the 
relationships between race/ethnicity and health system factors primarily have focused upon 
different types of structural/organizational variables, such as surgical volume or hospital 
teaching status (Jerome D’Emilia and Begun, 2005). 
In chapter 4, we explored variation in receipt of RT after BCS over time and found 
that a substantial minority of breast cancer patients 65 years and older failed to receive 
guideline-recommended RT after BCS and that timing of initiation of RT varied significantly 
by age group and race/ethnicity.  We found evidence that characteristics of the health 
system play a role in determining receipt of RT and timing of initiation of RT and that these 
factors, when omitted, likely confound the effect of race/ethnicity.  For example, presence of 
on-site radiation services at the facility where women received surgery resulted in higher 
odds of RT at nearly every time period examined.  Among women 70 years and older, other 
structural and organizational characteristics, including surgical facility type/ownership, 
ACoSOG and Radiation Therapy Oncology Group (RTOG) affiliation, played significant roles 
in determining overall receipt of RT.  We also showed that increasing distance to the nearest 
radiation facility generally was associated with lower odds of ever receiving RT among 
women ages 65-69 and women ages 70 and older.  Finally, we demonstrated that delayed 
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initiation of RT after BCS is more common among non-Hispanic black women and Hispanic 
women younger than 70 years old, even after controlling for health services 
structural/organizational characteristics and multiple covariates, and racial/ethnic differences 
in ever receiving RT disappear after controlling for health system factors and other potential 
confounders.    
In chapter 5, we examined variation in receipt and timing of initiation of adjuvant 
chemotherapy among women diagnosed with breast cancer in 1994-2002 and found that 
although overall use of chemotherapy increased over time, less than half of women 
diagnosed with stage II or III breast cancer received chemotherapy at the last time period 
examined (i.e., 2002 diagnoses).  Not surprisingly, overall receipt of adjuvant chemotherapy 
and timing of initiation of adjuvant chemotherapy were closely related to age and hormone 
receptor status.  Generally, women with hormone receptor positive tumors were less likely to 
receive adjuvant chemotherapy, likely reflecting increased use of hormone therapy, 
consistent with changing evidence-based guidelines during the time period of interest.  In 
multivariate analyses, race/ethnicity was not significantly predictive of receipt of adjuvant 
chemotherapy at 4 months post-diagnosis, nor was it predictive of ever receiving adjuvant 
chemotherapy.  Contrary to expectations, structural and organizational characteristics of the 
surgical facility played a minor role in determining receipt and timing of initiation of 
chemotherapy; this finding could reflect the disconnect between structural/organizational 
characteristics measured at the surgical facility and care provided in the community post-
surgery.  Unfortunately, better institutional and provider data are not readily available at this 
time, and the need for better structural/organizational measures at oncology care facilities 
beyond the hospital is critical.  Distance to care was not predictive of chemotherapy use in 
women ages 65-69 years, but among women 70 years and older, increasing distance to the 
nearest chemotherapy provider generally was associated with lower odds of chemotherapy 
use at 4 months and ever, although this effect was not always statistically significant. 
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In chapter 6, we asked whether timing of initiation of RT and adjuvant chemotherapy 
affected health outcomes, specifically, 5-year all-cause and breast cancer specific mortality.   
In bivariate analyses, black women died more often from breast cancer and experienced 
greater overall mortality compared with white women; as well, significant differences in 
timing of initiation of RT, and to a lesser extent in timing of initiation of adjuvant 
chemotherapy, were observed by race/ethnicity.  In multivariate models examining timing of 
RT (stratified by age group and conditioned on receipt of chemotherapy), receipt of RT more 
than 1 year post-diagnosis was associated with significantly higher odds of all-cause and 
breast cancer specific mortality.  In RT timing models conditioned on not having received 
chemotherapy, among women 70 years and older receipt of RT more than 6 months after 
diagnosis corresponded to 6 to 8 times the odds of breast cancer specific mortality and 3 to 
4 times the odds of all-cause mortality.  Additionally, in RT timing models conditioned on not 
having received chemotherapy, among younger women ages 65-69 years, receipt of RT 
more than 4 months after diagnosis was associated with significantly higher odds of all-
cause mortality, relative to women who received RT within one month of diagnosis.  In 
multivariate models examining timing of chemotherapy (stratified by age group and 
conditioned on receipt of RT), receipt of chemotherapy more than 4 months post-diagnosis 
was associated with higher odds of both all-cause and breast cancer specific mortality, with 
odds ratios ranging from 1.7 to 3.9, regardless of receipt of RT; the odds ratios, however, 
were larger in magnitude generally among women who also received RT. The last point 
could reflect greater importance of earlier initiation of chemotherapy among women treated 
with both RT and chemotherapy or it could simply be related to differences in treatment 
selection (i.e., sicker women are treated more aggressively).  We have tried to account for 
the possibility of bias resulting from treatment selection by including multiple measures of 
cancer severity and co-morbidity, but use of another technique such as instrumental 
variables methods may be an important approach to use in future work, as discussed in the 
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next section.  With respect to racial/ethnic disparities in this third paper, among black women 
ages 65-69 who received both chemotherapy and RT, inclusion of multiple controls in 
addition to therapeutic timing variables did not eliminate the disparity in mortality between 
black women and white women; however, the racial/ethnic disparity in mortality in other 
models disappeared after inclusion of treatment timing variables and other covariates. 
This dissertation makes several important contributions to the literature.  Few 
previous analyses have examined racial/ethnic variation in receipt of RT and chemotherapy 
using specific time-sensitive endpoints.  Given the conflicting evidence about the effect of 
timing of therapy on health outcomes, particularly in older women (Gold et al., 2008; Hartsell 
et al., 1995; Hebert Croteau et al., 2004; Hershman et al., 2006a; Hershman et al., 2006b; 
Lorhisch et al., 2006), this study provides additional evidence on optimal timing of radiation 
therapy and chemotherapy.  Further, considering that black women are more likely to be 
diagnosed with aggressive, advanced stage cancers and that they are more likely to die 
from breast cancer, as we have shown, earlier initiation of treatment may help minimize 
racial disparities in breast cancer mortality.   
This study also documents the important role that health services characteristics may 
play in determining quality of care, in particular, receipt of guideline-recommended RT after 
BCS.  To our knowledge, no studies to date have examined how distance to care may affect 
timing of initiation of breast cancer treatment in elderly women.  Distance to care is often 
examined in terms of overall receipt of radiation therapy or chemotherapy, but timing of 
treatment as a function of distance to care is not well understood.  Among elderly women, 
distance to care may be especially problematic when transportation and/or family members 
are not available to help ensure patients make that first critical RT or chemotherapy 
appointment.  Disparities in the quality of care related to age and race/ethnicity have been 
well-documented in many diseases, including breast cancer.  Most previous studies have 
been cross-sectional in nature and only provide a descriptive picture of disparities; as such, 
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they are limited in their ability to provide insights as to how the design and functions of the 
health care system can narrow these differences.  In this study, we have shown that health 
care systems or policies can be designed in such a way to improve the quality of care for 
breast cancer patients.  The possibilities are numerous.  For example, interventions that 
may be inspired by this study include community-level programs designed to provide 
transportation to RT or chemotherapy treatments for the elderly and for racial/ethnic 
minorities without regular access to transportation; use of telemedicine collaboration 
between facilities that are RTOG or ACoSOG affiliated centers often treating complicated 
breast cancer cases and smaller community hospitals whose advanced breast cancer 
patients may benefit from inter-institutional tumor board meetings; and greater emphasis on 
the training and use of nurse navigators to encourage early initiation of adjuvant therapy and 
to limit underuse of adjuvant therapy in racial/ethnic minorities and elderly patients  
Furthermore, despite increased interest in innovation diffusion in health care, 
diffusion trends across sub-populations have not been examined in breast cancer with the 
exception of Freedman and colleagues (2009) and Jerome-D’Emilia and Begun (2005).  
Regional variation in health care cost, utilization, and quality of care has been well 
documented, but studies examining diffusion trends across racial/ethnic groups, age groups, 
socioeconomic classes, and organizations are limited in number.  This study thus fills an 
important gap in the diffusion of innovations and health disparities literature.   
In addition to the above contributions to the literature, this study has several 
additional strengths in its design.  First, the SEER-Medicare dataset itself allowed us to 
estimate population-level receipt of appropriate and timely breast cancer treatment across 
racial/ethnic groups and other sub-populations over time.  Medicare claims provide richer 
detail to treatments received by breast cancer patients than cancer registries alone and 
allow historic assessment of co-morbid conditions that may affect health care seeking 
behavior and overall health status.  Second, by controlling for a number of potential 
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confounders determined to be important in the literature, including marital status, 
neighborhood socioeconomic status, biological features of the tumor, and co-morbidities, 
this study was able to isolate the effect of structural/organizational variables on the 
relationships between race/ethnicity and receipt of guideline concordant care.  Finally, 
because this study was limited to Medicare beneficiaries and included State-Buy-In months 
as a covariate (a proxy for Medicaid enrollment and low income status), the important effect 
of insurance status on receipt of health care was effectively controlled.  Thus, we were able 
to examine quality of care among fully insured breast cancer patients. 
Several limitations exist in this dissertation.  First, this study may not be 
generalizable to the US general population.  Our data were limited to Medicare-eligible 
women ages 65 and older enrolled in parts A and B fee-for-service and living in SEER 
regions.  SEER regions were purposefully chosen to adequately represent minority sub-
populations, and studies have shown that the SEER population is very similar to the general 
population in terms of sex, race, and age distribution (Warren et al., 2002c).  Despite this 
fact, SEER-Medicare data generally represent more urban, affluent, and well-educated 
people (Warren et al., 2002c); in particular, the lack of information about the cancer 
experiences of racial/ethnic minorities living in rural areas is unfortunate. 
SEER-Medicare data are several years old before they can be used to ensure 
complete reporting, and late claims may still be a concern (Clegg et al., 2002).  More recent 
data cannot be obtained from NCI, so it is difficult to know whether quality of care has 
improved or declined in recent years.  Additionally, quality of reporting procedures, 
especially non-hospital-based outpatient chemotherapy and radiotherapy, may be variable 
or underreported (Clegg et al., 2002; Lamont et al., 2002; Virnig et al., 2002; Warren et al., 
2002c).  However, because claims are linked to payment, we believe the incidence of 
underreporting is low.  It is also unclear how validly or reliably ER and PR status are 
recorded in practice and whether variation in ER/PR testing exists by facility type.  An 
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additional limitation of the structural/organizational measures we used was that only 
information from hospital-affiliated surgical facilities was available.  Thus, we could not 
explore how structural/organizational characteristics of non-hospital affiliated facilities 
affected treatment planning.  We also could not say anything about the providers and 
facilities patients consulted after initial surgery; clearly, although the surgical facility plays a 
role in subsequent care, other providers outside of the surgical facility may be important.  
The lack of information about such facilities indicates a critical need for better data about the 
health systems providing care to cancer patients, including structural and organizational 
characteristics of individual facilities and providers.  Such information on a national scale is 
difficult, arguably impossible, for researchers to obtain currently. 
The patient information we have from the SEER-Medicare data is somewhat limited 
in that we did not have access to individual-level income, wealth, or education information 
(Bach et al., 2002a).  We also had no reliable information about supplemental private 
insurance coverage.  Medicaid dual coverage (proxied in this study by State-Buy-In months) 
is related to socioeconomic status and access to health care resources at the individual 
level.  Including aggregate measures of zip code median income and educational attainment 
also provided some insight into local resources and socioeconomic environment.  Other 
patient-level factors about which we know nothing include BMI, diet, parity/reproductive 
history, access to transportation, and burden of seeking care/traveling for appointments, all 
of which could affect receipt of therapy and/or health outcomes.   We also do not have 
access to the complete medical record, which would provide more detail about care 
administered and reasons why certain clinical decisions were made (or not made).  It may 
be unclear from the analysis conducted exactly why patients do not get high quality care or 
why initiation of therapy was delayed.  For example, if a woman with stage I disease who 
has had BCS does not receive RT, is it because the handoff/transition was poorly handled 
between providers, because the radiation therapist saw the patient but did not 
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recommend/administer radiation, or because the patient declined radiation?  If a woman 
receives BCS within the same month as diagnosis, but receipt of initial RT occurs 8 months 
afterwards, is it because the woman was too sick to withstand radiation, because she 
moved to another state and switched health care providers, or because chemotherapy 
administration delayed initiation of RT?  Such questions are not easily answered in a 
retrospective study of this nature; however, future studies involving qualitative methods or 
medical chart reviews may provide additional insight into understanding treatment decision 
making. 
Health care utilization is a complicated measure, in that unobserved variables, such 
as risk aversion, trust in the health care system, and having a primary “medical home” may 
affect whether or not a woman receives RT or chemotherapy in a timely manner.  Including 
known confounders from prior studies is one way we have attempted to reduce bias from 
omitted variables.  However, despite our best efforts, unobservable factors may have biased 
our estimates; most noteworthy is perhaps the absence of information about other breast 
cancer treatments beyond surgery, radiation therapy, and chemotherapy, such as hormone 
therapy use.  At this time, SEER-Medicare data do not include Part D claims; thus, we have 
no information about prescription drugs, including hormonal therapy (e.g., tamoxifen).  
Finally, this study was observational in nature, which precludes us making 
statements about causality.  However, an experimental study examining these issues, 
particularly in aim 3, would be ethically infeasible because we could not deny life-prolonging, 
systemic, breast cancer treatment to women in a control group.  Additionally, randomizing 
women to health facilities with certain structural/organizational characteristics would likely be 
difficult, and enrollment tricky.   
Despite these limitations, this study is a policy-relevant and timely contribution to 
research about breast cancer and health disparities.  From this study, it is clear that 
structural/organizational characteristics of the health system may independently influence 
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receipt of high quality care, and also may be correlated with racial/ethnic group.  It is further 
evident that racial/ethnic and age-related disparities in treatment may be minimized by the 
introduction of creative interventions targeted at the health system itself.   
 
Future research agenda 
Considering the possible issues with generalizability associated with using a Medicare 
fee-for-service population, it would be a natural extension of this work to examine specific 
aims 1, 2, and 3 in a younger population and in a Medicare managed care population.  
Information about breast cancer treatment in younger women (i.e., those younger than 65 
years old) could be obtained from employer-based, private insurance plan databases.  One 
possible source is private insurance claims data from the National Rural Electric 
Cooperative Association (NRECA).  The NRECA provides employer-based, private 
insurance to employees and dependents of national electric/utility cooperatives (NRECA, 
2009).  The NRECA has expressed an interest in improving quality of care among its 
beneficiaries and has a particular interest in cancer care quality.  These data contain 
personal health information from the medical record, as well as medical claims from 
inpatient and outpatient medical visits and services rendered (personal communication, Dr. 
Jeffrey Peppercorn, April 2009).  Health care information within this dataset has been 
relatively underutilized and is unique, in that it may allow targeted exploration of the cancer 
experiences of rural-dwelling women, who are overrepresented in NRECA membership.  
Information about breast cancer treatment within Medicare managed care plans could be 
obtained from private insurance providers who contract with Medicare to provide managed 
care and from the Medicare-linked Health Outcomes Survey.   
This study may benefit from use of instrumental variables (IV) estimation to further 
address the possibility of bias from treatment selection in aim 3 (Wooldridge, 2006).  As 
described above, despite our best efforts to control for factors that may have affected 
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treatment planning and timing – in particular, health status and prognosis, using the NCI 
combined co-morbidity index and tumor characteristics – endogeneity in the form of 
treatment selection may not have been adequately addressed.  We collected data on 
distance to oncology providers, which did not have an effect on the outcome of interest in 
aim 3, mortality, but which did to varying extents have an effect on RT and chemotherapy 
initiation.  Distance to care measures may be ideal and appropriate instruments in this case.  
According to Wooldridge (2006), the two criteria for a good instrument are (1) that it has no 
effect on the primary outcome of interest (i.e., all-cause and breast cancer specific 
mortality), and (2) that it is significantly predictive of the endogenous independent variable 
(in this case, timing of receipt of RT and chemotherapy).  These criteria can be tested 
empirically, and provided that distance measures are found to be appropriate instruments, 
another paper emerging from this dissertation could be to compare our current results 
against results from IV estimations.  
Additional innovations of interest for future diffusion and health disparities studies in 
breast cancer care include use of neoadjuvant chemotherapy, decision aids such as the 
Oncotype Dx® test, breast magnetic resonance imaging (MRI), and sentinel lymph node 
biopsy (Chen et al., 2008; Katipamula et al., 2009; Mamounas, 2006; Schegerin et al., 
2009).  These innovations would be excellent candidates for comparative effectiveness 
studies.  Furthermore, given rising health care costs, especially in cancer care, there is a 
need to evaluate the economic feasibility of using such innovations; as such, cost-
effectiveness models for these new detection and treatment modalities need to be 
developed and validated.  
Future studies of breast cancer treatment quality and disparities should include 
examinations of structural and organizational factors and race/ethnicity in receipt of post-
mastectomy RT for tumors greater than 5 centimeters or with four or more positive nodes 
and patterns of care in stage IV breast cancer.  Punglia and colleagues (2006a) and Smith 
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and colleagues (2008) examined receipt of radiation therapy after mastectomy in elderly 
women during the 1990s and found that adoption trends differed across practice settings, 
but more recent practice trends and more detailed structural/organizational factors have not 
been examined.  With respect to stage IV or advanced breast cancer, many treatment 
options exist (NCCN, 2008), and treatment options have rapidly changed over the years; as 
such, future studies should examine racial/ethnic, socioeconomic, geographic, and 
structural/organizational variation in treatment of advanced disease.   
Another interesting question related to health disparities in breast cancer is whether 
and to what degree the introduction of Federally Qualified Health Centers (FQHCs) 
increased access to and quality of breast cancer care within vulnerable populations.  Low-
income women with poor access to health care providers and limited financial resources to 
pay for cancer care may have benefited considerably from the introduction and expansion of 
this federal initiative, but to our knowledge, no study has explicitly examined the role of 
FQHCs on improving breast cancer care for at-risk women and eliminating disparities. 
Finally, systems thinking could be used to build, parameterize, and validate models 
to help coordinate breast cancer care across providers and facilities.  Recognizing that 
supply of oncologists and other cancer specialists is limited and that cancer prevalence may 
be increasing given the aging American population, optimal use of cancer resources is 
important.  For example, earlier stage, uncomplicated breast cancer patients may be treated 
sufficiently well at lower volume, community-based facilities, whereas advanced stage 
patients with significant clinical complications may benefit from being treated at higher 
volume medical facilities with ACoSOG or RTOG affiliations.  Because there are fewer of the 
latter, we should seek to optimize patient allocation in such a way that clinical expertise, 
technical resource capacity, transportation/travel, and case complexity can be taken into 
account to ensure the best outcomes for all patients, regardless of stage of disease, 
socioeconomic status, or race/ethnicity.  Use of telemedicine to conduct inter-institutional 
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tumor board meetings is one way to disseminate expertise across health facilities.  However, 
creative optimization models drawing upon the methods used in industrial engineering and 
operations research could be used to suggest ways to improve patient care at the health 
system level. 
 
Conclusions 
This dissertation revealed that differences in structure and organization of health 
services help explain a portion of the racial and ethnic disparities in breast cancer treatment 
patterns and that timing of adjuvant treatment is important in determining long term health 
outcomes, including breast cancer specific and all-cause mortality.  Further, given that non-
Hispanic black women are more often than non-Hispanic white women diagnosed with 
advanced stage disease with clinical characteristics commonly associated with poorer 
prognosis, it may be vitally important that they initiate adjuvant treatment earlier to improve 
chances of survival.  This study is a truly unique contribution to the health services and 
breast cancer literatures in that it helps identify system-level factors that may contribute to 
persistent disparities in breast cancer.  Findings should help policymakers and stakeholders 
better target efforts to equalize health care access and quality across diverse user 
populations and to ensure that patients and their health care providers have access to the 
most comprehensive clinical information possible to make informed health care decisions. 
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APPENDIX A.  VARIABLE CODING SCHEMES AND DEFINITIONS 
 
Variable Name Source Description Coding 
Identification variables (for purposes of identifying the sample within the SEER-Medicare dataset) 
regcase PEDSF- 
Master file 
Patient unique ID number Numeric string (10 
characters) 
cssch1-cssch10 PEDSF-
SEER 
Collaborative Stage (CS) schema 
grouping based on primary site and 
histology 
Numeric string (2 
characters) 
  Breast:  58 
siter1-siter10 PEDSF-
SEER 
Site group in which the primary tumor 
originated, based on International 
Classification of Disease (ICD) codes 
Numeric string (2 
characters) 
  Breast:46 
med_dod PEDSF-
EDB 
Medicare date of death, reported by 
Social Security Administration 
Numeric: 
MMDDYYYY 
dod_flg PEDSF-
IMS 
Level of agreement between SEER and 
Medicare on patient’s death and date of 
death 
Categorical 
  0-not dead 
  1-dead, files agree 
  2-dead, off by 1-3  
  months 
  3-dead, off by 4-6  
  months 
4-dead Medicare  
only 
  5-dead SEER only 
  6-dead, months  
  missing 
codpub PEDSF-
SEER 
Cause of death recode (accounts for 
newly valid International Classification 
of Disease codes and includes cancer 
and non-cancer causes of death) 
Numeric string (4 
characters) 
Breast cancer- 
specific    
  death: 046 
m_sex PEDSF-
EDB 
Patient’s sex according to Medicare Categorical 
  1-male 
  2-female 
rsncd1 PEDSF-
EDB 
Original reason for entitlement for 
Medicare (age, disability, or end stage 
renal disease [ESRD]) 
Categorical 
  0-age 
  1-disability 
  2-ESRD 
  3-disability/ESRD 
cur_ent PEDSF-
EDB 
Current reason for entitlement for 
Medicare (age, disability, or end stage 
renal disease [ESRD]) 
Categorical 
  0-age 
  1-disability 
  2-ESRD 
  3-disability/ESRD 
chr_esrd PEDSF-
EDB 
End stage renal disease (ESRD) status Categorical 
  0-no ESRD 
  Y-has ESRD 
MDCRSTAT MEDPAR Beneficiary Medicare status code; 
reason for beneficiary’s entitlement as 
of the reference date (age, disability, or 
end stage renal disease [ESRD]) 
Categorical 
  10-aged without  
  ESRD 
  11-aged with ESRD 
  20-disabled without  
  ESRD 
  21-disabled with  
  ESRD 
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  31-ESRD only 
ptacnt1986-
ptacnt2007 
PEDSF-
EDB 
Number of months covered for Part A in 
each year from 1986-2007 
Categorical 
  0-not covered 
  01-12-months  
  covered 
ptbcnt1986-
ptbcnt2007 
PEDSF-
EDB 
Number of months covered for Part B in 
each year from 1986-2007 
Categorical 
  0-not covered 
  01-12-months 
hmocnt1986-
hmocnt2007 
PEDSF-
EDB 
Number of months as a health 
maintenance organization (HMO) 
member in each year from 1986-2007 
Categorical 
  0-not covered 
  01-12-months  
  covered 
numprims PEDSF-
SEER 
Number of primary tumors ever 
recorded for the patient 
Continuous 
seq1-seq10 PEDSF-
SEER 
Number and sequence of all reportable 
malignant, in situ, benign, and 
borderline primary tumors over patient’s 
lifetime 
Numeric string (2 
characters) 
lat1-lat10 PEDSF-
SEER 
Laterality:  side of a paired organ of 
side of the body on which the 
reportable tumor emerged 
Categorical 
  0-not paired site 
  1-right; origin of  
  primary 
2-left; origin of  
primary 
  3-only one side, but  
  unspecified 
  4-bilateral  
  involvement 
  9-paired site, no info  
  on laterality 
src1-src10 PEDSF-
EDB 
Type of reporting source Categorical 
  1-hospital/outpatient 
  3-lab only 
  4-physician’s office 
  5-nursing home or    
  hospice 
  6-autopsy 
  7-death certificate   
Patient-level socio-demographic variables 
rac_recb PEDSF-
SEER 
Recoded race/ethnicity from SEER 
(more accurate than Medicare) 
Categorical 
  1-non-Hispanic white 
  2-black 
  3-8,12-other 
  9-unknown 
  11-Hispanic 
birthm PEDSF-
EDB 
Medicare month of birth Numeric string (2 
characters) 
birthyr PEDSF-
EDB 
Medicare year of birth Numeric string (4 
characters) 
modx1-modx10 PEDSF-
SEER 
Month of diagnosis by a recognized 
medical practitioner 
Categorical 
  01-12-valid month 
  13,99-unknown 
yrdx1-yrdx10 PEDSF-
SEER 
Year of diagnosis by a recognized 
medical practitioner 
Categorical 
  1973-2005-valid 
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Variable Name Source Description Coding 
year 
age1dx PEDSF-
SEER 
Age at first ever cancer diagnosis Continuous 
age_dx PEDSF-
SEER 
Age at diagnosis  Continuous 
ager1-ager10 PEDSF-
SEER 
Age at diagnosis recode to 5-year 
intervals 
Categorical 
dx65m, dx65y PEDSF-
SEER 
Diagnosis date at age 65 or older Numeric: 
MMDDYYYY 
seq1ov65 PEDSF-
SEER 
Shows whether patient was 65 or older 
at first cancer diagnosis 
Categorical 
  Y=yes 
  N=no 
stbuy1986-
stbuy2007 
PEDSF-
EDB 
Medicaid dual enrollment; number of 
months with state buy-in (Medicaid) 
coverage in each year from 1986-2007 
Categorical 
  0-not covered 
  01-12-months 
zip1986-zip2007 PEDSF-
EDB 
Patient zip code; assigned as last zip 
code of patient residence in that year 
Numeric string (9 
characters) 
county PEDSF-
SEER 
Patient county See FIPS county 
codes 
state PEDSF-
SEER 
Patient state See FIPS state codes 
hsa PEDSF-
ARF 
Health Service Area, taken from Area 
Resource File (ARF) 
Numeric string (3 
characters) 
reg1-reg10 PEDSF-
SEER 
SEER registry code at diagnosis Categorical 
  01-San Francisco 
  02-Connecticut 
  20-Detroit 
  21-Hawaii 
  22-Iowa 
  23-New Mexico 
  25-Seattle 
  26-Utah 
  27-Atlanta 
  31-San Jose 
  35-Los Angeles 
  37-rural Georgia 
  41-greater California 
  42-Kentucky 
  43-Louisiana 
  44-New Jersey 
marst1-marst10 PEDSF-
SEER 
Patient’s marital status at the time of 
diagnosis of the reportable tumor 
Categorical 
  1-single 
  2-married 
  3-separated 
  4-divorced 
  5-widowed 
  9-unknown 
urbrur PEDSF-
ARF 
Urban/rural recode for patient residence Categorical 
  1-large metro 
  2-metro 
  3-urban 
  4-less urban 
  5-rural 
  9-unknown 
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Variable Name Source Description Coding 
Area/aggregate socio-demographic variables 
ctmed00 and 
ctmed90 
PEDSF-
Census 
Median household income for census 
tract  
Continuous 
medag00 and 
medag90 
PEDSF-
Census 
Median household income by age for 
census tract 
Continuous 
medrc00 and 
medrc90 
PEDSF-
Census 
Median household income by race for 
census tract 
Continuous 
zpmed00 and 
zpmed90 
PEDSF-
Census 
Median household income for zip code Continuous 
ctnon00 and 
ctnon90 
PEDSF-
Census 
Percent of persons aged 25+ with < 
high school education within the census 
tract 
Continuous (0-1) 
zpnon00 and 
zpnon90 
PEDSF-
Census 
Percent of persons aged 25+ with < 
high school education within the zip 
code 
Continuous (0-1) 
ctblk00 and ctblk90 PEDSF-
Census 
Ratio of black population to total 
population within the census tract 
Continuous (0-1) 
ctwht00 and 
ctwht90 
PEDSF-
Census 
Ratio of white population to total 
population within the census tract 
Continuous (0-1) 
cthsp00 and 
cthsp90 
PEDSF-
Census 
Ratio of Hispanic population to total 
population within the census tract 
Continuous (0-1) 
zpblk00 and 
zpblk90 
PEDSF-
Census 
Ratio of black population to total 
population within the zip code 
Continuous (0-1) 
zpwht00 and 
zpwht90 
PEDSF-
Census 
Ratio of white population to total 
population within the zip code 
Continuous (0-1) 
zphsp00 and 
zphsp90 
PEDSF-
Census 
Ratio of Hispanic population to total 
population within the zip code 
Continuous (0-1) 
Clinical variables 
numprims PEDSF-
IMS 
Total number of primaries based on the 
number of tumors ever recorded in 
SEER 
Continuous (1-10) 
multprim1-
multprim10 
PEDSF-
SEER 
Multiple primary indicator based on all 
tumors in SEER 
Categorical 
  0-first in situ, no  
  malignant cancers 
  1-first malignant 
  9-second or  
  subsequent 
tumor1_1-
tumor1_10 (1990-
2003) OR cs1st1-
cs1st10 (2004+) 
PEDSF-
SEER 
Prognostic indicator for estrogen 
receptor status for breast cases (ERA 
for 1990-2003 and CS Site-specific 
factor for 2004+) 
Categorical 
  0-no test performed 
  1-positive 
  2-negative 
  3-borderline 
  8-ordered, but  
  unavailable 
  9-unknown 
tumor2_1-
tumor2_10 (1990-
2003) OR cs2st1-
cs2st10 (2004+) 
PEDSF-
SEER 
Prognostic indicator for progesterone 
receptor status for breast cases (ERA 
for 1990-2003 and CS Site-specific 
factor for 2004+) 
Categorical 
  0-no test performed 
  1-positive 
  2-negative 
  3-borderline 
  8-ordered, but  
  unavailable 
  9-unknown 
grade1-grade10 PEDSF- Histologic grading and differentiation, Categorical 
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SEER based on International Classification of 
Disease codes 
  1-well differentiated 
  2-moderately  
  differentiated 
3-poorly  
differentiated 
  4-undifferentiated,  
  anaplastic 
  5-T-cell/precursor 
  6-B-cell/B-precursor 
  7-null ; non T, non B 
  8-natural killer cell 
  9-unknown 
aj3sr1-aj3sr10 PEDSF-
SEER 
Modified American Joint Committee on 
Cancer (AJCC) stage (for diagnosis 
years 1988-2003)  
Categorical 
dajccstg1-
dajccstg10 
PEDSF-
SEER 
Derived American Joint Committee on 
Cancer (AJCC)  stage group, 6th edition 
(for diagnosis years 2004+) 
Categorical 
ajccstg1-ajccstg10 PEDSF-
SEER 
Derived American Joint Committee on 
Cancer (AJCC)  stage 3rd edition, 
1988+ 
Categorical 
e10sz1-e10sz10 
(1988-2003) OR 
cstum1-cstum10 
(2004+) 
PEDSF-
SEER 
Primary tumor size in mm (1988-2003), 
from 10-digit extent of disease; 
diameter of primary tumor in mm 
(2004+) 
Continuous 
  999-unknown size 
e10pn1-e10pn10 PEDSF-
SEER 
Number of positive nodes; exact 
number of regional lymph nodes 
examined by pathologist that were 
found to contain metastasis 
Categorical 
  00-all nodes 
negative 
01-89-#positive  
nodes 
97-positive nodes,  
number unspecified 
98-nodes  
unexamined 
  99-unknown 
survt1-survt10 PEDSF-
SEER 
Total survival time count in months of 
patient survival from time of diagnosis 
Continuous 
survy1-survy10 PEDSF-
SEER 
Survival time recode in years, 
calculated from date of diagnosis to one 
of the following:  date of death, date last 
known alive, or follow-up cutoff (censor) 
date 
Continuous 
  YY-#full years  
  survived 
  99-unknown 
survm1-survm10 PEDSF-
SEER 
Survival time recode in months, 
calculated from date of diagnosis to one 
of the following:  date of death, date last 
known alive, or censor date 
Continuous 
  MM-#full months  
  survived 
  99-unknown 
Treatment variables in SEER 
sssurg1-sssurg10 PEDSF-
SEER 
Site specific surgery performed (1983-
1997) 
Categorical (see 
PEDSF) 
nosrg1-nosrg10 PEDSF-
SEER 
Was cancer-directed surgery 
performed? 
Categorical 
  0-surgery performed 
  1-not recommended 
2-contraindicated;  
not  
 177 
Variable Name Source Description Coding 
  recommended 
  5-not performed;  
  patient died 
  6-recommended; not  
  performed, unknown  
  reason 
  7-recommended; not  
  received, patient  
  refused 
  8-recommended;  
unknown if  
performed 
  9-unknown 
sxprif1-sxprif10 PEDFSF-
SEER 
Surgery of primary site (1998+); 
describes surgical procedure that 
removes or destroys tissue as part of 
initial work-up or first course of therapy 
Categorical (see 
PEDSF) 
recstr1-recstr10 PEDSF-
SEER 
First course of reconstruction surgery 
(1998-2002) 
Categorical (see 
PEDSF) 
rad1-rad10 PEDSF-
SEER 
Receipt of radiation therapy and type 
received 
Categorical 
  0-none 
  1-beam 
2-radioactive  
implants 
  3-radioisotopes 
  4-combination (beam  
  with implants or  
  isotopes) 
  5-radiation received,  
  unspecified 
  7-refused 
  8-recommended,  
  receipt unknown 
  9-unknown 
other_tx1-
other_tx10 
PEDSF-
SEER 
Other cancer-directed therapy received Categorical (see 
PEDSF) 
radsurg1-
radsurg10 
PEDSF-
SEER 
Radiation sequence with surgery Categorical (see 
PEDSF) 
Health system structure and organization (provider- and facility-level variables) 
prov3230 and 
prov2700 and F71 
NCI 
Hospital 
file 
State code Character string (see  
NCI Hospital file) 
prov2885 NCI 
Hospital 
file 
Indicates the nature (profit status/type) 
of the organization that operates as the 
provider of services 
Categorical 
  01-voluntary non- 
  profit, church 
  02-voluntary non- 
  profit, private 
  03-voluntary non- 
  profit, other 
04- 
proprietary/private 
  05-government,  
  federal 
  06-government, 
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stage 
  07-government, local 
  08-government,  
  hospital dist. or  
  authority 
F25 NCI 
Hospital 
file 
Type of control (nonprofit, proprietary, 
government, etc.) 
Categorical (see NCI 
hospital file) 
F26 NCI 
Hospital 
file 
Type of facility Categorical (see NCI 
hospital file; 3=cancer 
facility) 
prov0740 OR F85 NCI 
Hospital 
file 
Total number of beds in hospital facility Continuous 
prov2445 NCI 
Hospital 
file 
Indicates how/whether therapeutic 
radiology services are offered by the 
hospital 
Categorical 
  0-not provided 
  1-provided by staff 
  2-provided under  
  arrangement 
  3-provided by staff  
  and arrangement 
F47 NCI 
Hospital 
file 
Does hospital qualify as a rural primary 
hospital? 
Categorical 
  Y-yes 
F29 NCI 
Hospital 
file 
Urban/rural location of hospital Categorical 
  1-urban 
  2-rural 
F38 NCI 
Hospital 
file 
Teaching hospital or affiliated with 
teaching hospital 
Categorical 
  Y-yes 
prov0645 NCI 
Hospital 
file 
Type of affiliation the hospital may have 
with a medical school 
Categorical 
  1-major 
  2-limited 
  3-graduate 
  4-no affiliation 
seer_area NCI 
Hospital 
file 
Indicates if the provider is in a SEER 
area or not 
Categorical 
  0-not a SEER area 
  1-SEER area 
nci_cen_02 and 
nci_cen_05 
NCI 
Hospital 
file 
NCI-designated center as of 2002 and 
as of 2005 
Categorical 
  0-no 
  1-clinical 
  2-comprehensive 
ACOSOG_02 and 
ACOSOG_05 
NCI 
Hospital 
file 
American College of Surgeons (ACoS) 
Oncology group affiliation as of 2002 
and as of 2005 
Categorical 
  0-not a member 
  1-member 
CTSU_02 and 
CTSU_05 
NCI 
Hospital 
file 
Cancer trials support unit (NCI) Categorical 
  0-not a member 
  1-member 
NSABP_02 and 
NSABP_05 
NCI 
Hospital 
file 
National Surgical Adjuvant Breast and 
Bowel Project 
Categorical 
  0-not a member 
  1-member 
RTOG_02 and 
RTOG_05 
NCI 
Hospital 
file 
Radiation Therapy Oncology Group Categorical 
  0-not a member 
  1-member 
 179 
Variable Name Source Description Coding 
Zip NCI 
Hospital 
file 
Hospital zip code Numeric string (5 
characters) 
Other (Related to procedures, services, dates of claims, and charges/payments found in Medicare 
claims data 
ONCLGIND MEDPAR Indicates whether the beneficiary 
received radiation oncology services 
during the stay (linked to revenue code 
028x) 
Categorical 
  0-No rad/oncology 
  1-Yes rad/oncology 
RADTHIND MEDPAR Indicates whether the beneficiary 
received therapeutic radiology services 
during the stay (linked to revenue code 
033x) 
Categorical 
  0-No rad/therapeutic 
  1-Yes 
rad/therapeutic 
ADM_M, ADM_D, 
ADM_Y and 
DIS_M, DIS_D, 
DIS_Y, LOS 
MEDPAR Admission date and discharge date and 
length of stay 
Numeric: 
MMDDYYYY and 
continuous days 
count 
PROVNUMB MEDPAR Provider number Numeric string (6 
characters) 
DIAGCD1-
DIAGCD10 
MEDPAR Diagnosis code:  the ICD-9-CM code 
identifying the primary condition or 
other existing conditions shown in 
medical records as affecting services 
provided 
Numeric string (5 
characters) 
SRGCDE1-
SRGCDE6 
MEDPAR Surgical Procedure Code:  the ICD-9-
CM surgical procedure that was 
performed 
Numeric string (4 
characters) 
SG1_M, SG1_D, 
SG1_Y 
MEDPAR Surgical procedure date performed Numeric: 
MMDDYYYY 
DRGCODE MEDPAR Code indicating the diagnostic related 
group (DRG) to which the claims that 
comprise the stay belong 
Numeric string (3 
characters) 
ADMDXCDE MEDPAR Primary diagnosis code at time of 
admission 
Categorical (see 
MEDPAR) 
hcpcs Carrier 
claims 
Health Care Financing Administration 
Common Procedure Coding System 
(HCPCS) code for procedure, supplies, 
products, or services 
Numeric string (5 
characters) 
linediag Carrier 
claims 
ICD-9-CM code indicating diagnosis 
supporting this procedure or service 
Numeric string (5 
characters) 
pdgns_cd Carrier 
claims 
Beneficiary’s principle diagnosis code Numeric string (5 
characters) 
dgn_cd1-dgn_cd8 Carrier 
claims 
Up to 8 ICD-9-CM diagnosis codes 
allowed per claim 
Numeric string (5 
characters) 
Betos Carrier 
claims 
Berenson-Eggers type of service 
procedure code 
See Carrier claims 
appendix 
hcfaspec Carrier 
claims 
Provider’s specialty code for service 
(HCFA) 
See Carrier claims 
appendix 
hcfatype Carrier 
claims 
Carrier’s type of service code (HCFA) See carrier claims 
appendix 
frexpenm, 
frexpend, frexpeny 
Carrier 
claims 
Beginning date of service Numeric: 
MMDDYYYY 
lsexpenm, 
lsexpend, 
Carrier 
claims 
Ending date of service Numeric: 
MMDDYYYY 
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lsdexpeny 
from_dtm, 
from_dtd, from_dty 
Carrier 
claims 
Claim from date (first day of 
provider’s/physician’s billing statement) 
Numeric: 
MMDDYYYY 
thru_dtm, thru_dtd, 
thru_dty 
Carrier 
claims 
Claim thru date (last day of 
provider’s/physician’s billing statement 
Numeric: 
MMDDYYYY 
prv_type Carrier 
claims 
Code identifying type of provider 
furnishing the services for the line item 
on Part B claim 
Categorical (see 
Carrier claims) 
prozip Carrier 
claims 
Zip code of physician/supplier who 
performed the Part B service for this 
line item 
Numeric string (9 
characters) 
plcsrvc Carrier 
claims 
Carrier’s place of service for this 
procedure code 
Numeric string (2 
characters) 
perupin Carrier 
claims 
Unique carrier line performing UPIN 
number for procedure specified by 
HCPCS code (encrypted) 
Numeric string (6 
characters) 
fac_type Outpatient 
claims 
Claim facility type code of the facility 
providing care 
Categorical 
  1-hospital 
  2-skilled nursing  
  facility 
  3-Home Health  
  Association 
  4-Religious hospital 
  5-religious extended  
  care 
  6-intermediate care 
  7-clinic 
  8-special facility 
  9-reserved 
typesrvc Outpatient 
claims 
Classification of type of claims service 
provided to the beneficiary 
Categorical (see 
Outpatient claims) 
from_dtm, 
from_dtd, from_dty 
Outpatient 
claims 
Claim from date (first day of 
provider’s/physician’s billing statement) 
Numeric: 
MMDDYYYY 
thru_dtm, thru_dtd, 
thru_dty 
Outpatient 
claims 
Claim thru date (last day of 
provider’s/physician’s billing statement 
Numeric: 
MMDDYYYY 
hcpcs Outpatient 
claims 
Health Care Financing Administration 
Common Procedure Coding System 
(HCPCS) code; procedures, supplies, 
products, or services provided to 
Medicare beneficiaries 
Numeric string (5 
characters) 
dgn_cd1-dgn_cd10 Outpatient 
claims 
ICD-9-CM diagnosis codes; coexisting 
conditions that affect services provided 
Numeric string (5 
characters) 
pr_cd1-pr_cd6 Outpatient 
claims 
ICD-9-CM code that indicates primary 
or other procedure performed during 
the period covered by the institutional 
claim 
Numeric string (5 
characters) 
prdtm1-prdtm6, 
prdtd1-prdtd6, 
prdty1-prdty6 
Outpatient 
claims 
Procedure performed dates; on an 
institutional claim, the date on which the 
principle or other procedure was 
performed 
Numeric: 
MMDDYYYY 
provider Outpatient 
claims 
Medicare certified provider number Numeric string (6 
characters) 
hcpcs DME 
claims 
Health Care Financing Administration 
Common Procedure Coding System 
Numeric string (5 
characters) 
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(HCPCS) code; procedures, supplies, 
products, or services provided 
hcfatype DME 
claims 
HCFA carrier’s type of service code 
used for pricing services 
Categorical (see DME 
claims) 
plcsrvc DME 
claims 
Place of service for procedure code Categorical (see DME 
claims) 
frexpenm, 
frexpend, frexpeny 
DME 
claims 
Beginning date of service Numeric: 
MMDDYYYY 
linediag DME 
claims 
ICD-9-CM code indicating diagnosis 
supporting this procedure/service 
Numeric string (5 
characters) 
betos DME 
claims 
Berenson-Eggers type of service for the 
procedure code based on clinically 
meaningful groupings of procedures 
and services 
Numeric string (3 
characters) 
ndc_cd DME 
claims 
National Drug Code identifies oral anti-
cancer drugs 
Numeric string (11 
characters) 
dgnscd1-dgnscd8 DME 
claims 
ICD-9-CM diagnosis codes Numeric string (5 
characters) 
 
 
 
 
 
Notes: AJCC: American Joint Committee on Cancer; ARF: area resource file; ASC: ambulatory surgical 
center; DME: durable medical equipment file; EDB: Medicare Entitlement Database; HCFA: Health Care 
Financing Administration; ICD-9-CM: International Classification of Diseases, Modification 9; MEDPAR: 
Medical Provider Analysis and Review file; NCI: National Cancer Institute; PEDSF: Patient Entitlement 
and Diagnosis Summary file; RT: radiation therapy; SEER: Surveillance Epidemiology and End Results; 
SNF: skilled nursing facility; UPIN: unique provider identification number 
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